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ABSTRACT 
 
Deepa Viswanathan (Ajit) . University of Missouri-Saint Louis, September 2009. Role of 
Amyloid Beta Assembly State in the Human Immune Response. 
  
 
Major Professor: Michael R. Nichols 
 
Alzheimer‟s disease (AD) is a slowly progressing neurodegenerative disease that leads to 
dementia. Histopathological hallmarks that characterize AD are senile plaques formed by 
extracellular deposition of Amyloid beta (Aβ) peptide and intracellular aggregates of 
hyperphosphorylated tau protein. The plaques, which are found in the brain parenchyma, 
comprise both 40 and 42 residue Aβ. Aggregation of Aβ is an established pathogenic 
mechanism in AD, but little is known about the initiation of this process in vivo. Several 
studies have revealed significant inflammatory markers such as activated microglia and 
cytokines surrounding the plaques. Plaques are a hallmark of AD, but they are only part 
of an array of Aβ aggregate morphologies observed in vivo. Structural polymorphism is a 
prominent feature of Aβ aggregation both in vitro and in vivo. The molecular relationship 
between the different forms of Aβ remains to be determined. Inflammatory processes are 
believed to contribute to AD pathophysiology, and may play an important role in the 
disease progression. Not all Aβ deposits evoke a proinflammatory response, making it all 
the more important to probe into structural details of the Aβ aggregation pathway. This 
research was aimed at investigating what Aβ morphology or aggregation species induce 
the strongest proinflammatory response in human THP-1 monocytes as a model system. 
Our results indicate that an intermediate fibrillar aggregation species formed when Aβ(1-
42) is reconstituted in water (100 M, pH 3.6) and incubated at 4C under quiescent 
conditions was capable of stimulating maximum tumor necrosis factor alpha (TNF). 
Modulating conditions that accelerated or increased Aβ(1-42) fibril formation such as 
temperature, peptide concentration, or pH diminished the ability to activate the cells. 
Immunodepletion of Aβ(1-42) solution with fibril specific antibody (OC immune serum) 
reduced the ability to induce TNF production. Characterization by SEC showed an 
included peak that appeared immediately after the void volume and stimulated the 
maximum proinflammatory response.  We have also shown that the shorter peptide Aβ(1-
40) could not stimulate a proinflammatory response under similar aggregation conditions. 
Overall, the data suggest that an intermediate Aβ(1-42) fibrillar precursor species is 
optimal for inducing maximum proinflammatory activity in THP-1 monocytes. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Protein Misfolding and Amyloid Formation 
 
  Proteins are involved in virtually every biological process in the living system. 
The amino acids in the protein must fold into the native three-dimensional structures, and 
these structures are characteristic of individual proteins (Voet, 1995).  The folding of a 
protein is influenced by its amino acid sequence, and the cellular environment around the 
amino acid chain (Anfinsen, 1973, Horwich et al., 1999). The folding and unfolding of 
proteins is associated with a wide range of cellular processes from the trafficking of 
molecules to specific organelles to the regulation of the cell cycle and the immune 
response (Radford and Dobson, 1999, Stefani and Dobson, 2003). These observations led 
to the conclusion that the failure to fold correctly, or to remain folded correctly, leads to 
many different types of biological malfunctions and hence to many different forms of 
diseases (Radford and Dobson, 1999). In the case of incompletely folded proteins, some 
regions of the structure that are actually buried in the native state will be exposed to the 
solvent.  Hence, these proteins are prone to inappropriate interaction with other molecules 
within the crowded environment of the cell (Ellis, 2001). Therefore living systems have 
evolved strategies to prevent unwanted interactions.  The cell has evolved the chaperone 
 2 
system, and some chaperones interact with the nascent proteins as they emerge out of the 
ribosomes, while others are involved in guiding later stages of the folding process (Bukau 
and Horwich, 1998, Hartl and Hayer-Hartl, 2002), and hence prevent aggregation. 
Furthermore, unfolded proteins that escape the chaperone system are degraded by the 
proteasome.  However, there is a gradual decrease in the efficiency of the system with 
age that could lead to late onset disorders. 
  Failure of a specific peptide or protein to adopt, or remain in, its native functional 
conformational state results in a broad range of human diseases termed as protein folding 
disorders (Chiti and Dobson, 2006). Abnormal physiological concentrations and 
mutations are believed to destabilize the native three-dimensional state, thereby deviating 
the protein from its normal folding pathway (Dobson, 1999, Hetz and Soto, 2003).  The 
largest group of misfolding diseases is associated with the conversion of specific peptides 
or proteins from their soluble functional states ultimately into highly organized fibrillar 
aggregates (Lansbury, 1999).  The fact that only select groups of proteins are found in the 
disease-associated fibrils suggest that these proteins are subject to abnormally high 
expression to such an extent that the chaperone and the proteosome system are 
temporarily overwhelmed (Lansbury, 1999).  These structures are generally described as 
amyloid fibrils or plaques when they accumulate extracellularly.  The term “intracellular 
inclusions” has been suggested when fibrils that are morphologically and structurally 
related to extracellular amyloid form inside the cell (Westermark et al., 2005).  Current 
focus in studying the structural aspects of amyloid aggregation states is due to their 
crucial role in disorders such as Alzheimer‟s disease, Parkinson‟s disease, Huntington‟s 
disease (Table 1), and diverse systemic amyloidosis (Walker and LeVine, 2000, Selkoe 
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and Podlisny, 2002, Selkoe, 2003).  Despite the ability of many proteins to form amyloid 
fibrils, not much is known about their structures or the factors that govern their 
formation.  A principal unanswered question about these disorders is the nature in which 
the natively soluble proteins of different primary structures undergo partial unfolding and 
aberrant refolding to produce highly stable oligomers and polymers.  The partially folded 
forms have exposed hydrophobic regions and are therefore prone to self-aggregation 
(Selkoe, 2003).  An understanding of how this aggregation process happens and how the 
resultant aggregates initiate cell dysfunction will offer valuable information that is 
essential in the development of new therapeutic strategies for specific molecular 
interventions, and treatment modalities for these disorders. 
 
1.2 Alzheimer‟s Disease (AD) 
 
AD is the most common cause of dementia in the elderly, and is a progressive 
neurodegenerative disorder that gradually destroys cognitive function and eventually 
causes death.  AD currently affects nearly 2% of the population in industrialized 
countries (Mattson, 2004).  As the life expectancy of  individuals has extended 
considerably, these diseases are of a major concern (Glenner, 1989), and it is estimated 
that about 22 million people will be afflicted globally by 2025 [St George- Hyslop 2000]. 
This statistics emphasizes the need for novel and effective treatments.  During the last 
decade there has been expansive research in the field of AD.  Microscopic studies have 
revealed a loss of neurons in hippocampus, a center for memory, and the cerebral cortex, 
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Table1.1 Some human brain diseases characterized by protein misfolding and 
aggregation Figure adapted from Selkoe. D.J., (2003) Nature, 426: 900-904  
 
 
 
Disease Protein Locus 
Alzheimer‟s disease 
Amyloid beta protein  
 
Tau 
 
Extracellular plaques 
 
Tangles in neuronal 
cytoplasm 
Frontotemporal dementia with 
parkinsonism 
Tau 
Tangles in  
neuronal cytoplasm 
Parkinson‟s disease; dementia 
with Lewy bodies 
α-synuclein Neuronal cytoplasm 
Creutzfeldt-Jakob disease: 
 Mad cow disease 
Prion protein PrP
SC
 
Extracellular plaques 
Oligomers inside and 
outside neurons 
Polyglutamine disease; 
Huntigton‟s disease, spino 
cerebellar ataxias 
Long glutamine stretches 
within certain proteins 
Neuronal nuclei and 
cytoplasm 
Amyotrophic lateral sclerosis Superoxide dismutase Nueronal cytoplasm 
 5 
which is the center for reasoning memory and other thought processes. Hallmark lesions  
of AD include amyloid deposits neurofibrillary tangles (NFTs) and dystrophic neuritis 
(Glenner, 1989, Ballatore et al., 2007). 
Immunocytochemsitry revealed that one of the earliest pathological changes 
include a population of neurons packed with swollen lysosomal granules (Nixon et al., 
1992).  These lysosomes or granules also stain with antibodies against Aβ (Gouras et al., 
2000, D'Andrea et al., 2001).  Extracellular heparan sulfate (Perry et al., 1991, Cummings 
et al., 1993) immunoreactivity, advanced glycation end products (Smith et al., 1994, 
Vitek et al., 1994), racemic amino acids and isopeptide bonds (Shapira et al., 1988, Roher 
et al., 1993) are found associated with senile plaques, NFTs, and dystrophic neurites. 
Activated microglia are found along the margins of senile plaques (Wisniewski et al., 
1989). Key markers of inflammation are also associated with amyloid deposits 
(Rozemuller et al., 1989, Dickson et al., 1993).  A broad spectrum of pathological events 
are associated with AD, and recent studies have indicated the possibility of AD 
representing a spectrum of diseases (Hyman, 1996).  These studies have also revealed 
genetic causes of the disease in addition to cellular and molecular mechanisms that are 
linked to AD.  Until recently post mortem analysis of the brain tissue was the only way to 
study the pathological features of AD.  This limitation prompted research on biochemical 
markers of AD in serum and cerebrospinal fluid that will be able to complement clinical 
approaches and help in early diagnosis (Khachaturian, 2002).  It was initially assumed 
that extracellular amyloid fibrils were responsible for exerting cytotoxic effects.  Over the 
past decade data from cell culture models, β-amyloid precursor transgenic mice, and 
studies on the human brain suggest that prefibrillar, diffusible assemblies of amyloid beta 
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was also deleterious.  This has opened up a wide avenue for further probing the 
mechanisms of AD. 
 
1.3 AD Pathology 
 
The characteristic neuropathology of AD was first described by a German 
psychiatrist, Alois Alzheimer, in 1907.  Two hallmark pathological findings in the brains 
of AD patients are extracellular amyloid plaques, and intracellular neurofibrillary tangles 
(NFTs).  However, there is evidence that suggests that apart from the plaques and the 
neurofibrillary tangles, a third of the AD patients will exhibit significant cerebrovascular 
pathology.  Cerebral amyloid angiopathy, micro vascular degeneration that affects the 
cerebral endothelium and smooth muscle cells, hyalinosis and fibrosis are also seen in 
AD (Vinters et al., 1996, Attems, 2005, Thal et al., 2008).  
 
1.3.1 Extracellular Plaques 
 
Extracellular amyloid plaques mainly constitute diffuse and neuritic plaques.  The 
neuritic plaques are intimately surrounded by dystrophic axons and dendrites, reactive 
astrocytes and activated microglia (Selkoe, 2001).  Neuritic plaques are brain lesions that 
are generally found in large numbers in limbic and association cortices (Dickson, 1997).  
The main protein constituent of plaques is amyloid beta (A) peptide.  A peptide is a 
39-43 amino acid proteolytic product of amyloid precursor protein (APP) and forms long 
insoluble amyloid fibrils which accumulate as spherical microscopic deposits known as 
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senile plaques.  These plaques consist of a central amorphous core which can be 
identified by histological amyloid stains such as Congo red (Klunk et al., 1989) and  
Thioflavin T or S (Sage et al., 1983).  Plaques are surrounded by dystrophic neurites 
(Glenner, 1989, Dickson, 1997) reactive astrocytes (Pike et al., 1995) and microglia  
(Perlmutter et al., 1990) that are thought to release complement factors and cytokines 
(McGeer and McGeer, 2001) and cause inflammatory reactions around the plaques.  
Studies have established that much of the fibrillar Aβ found in neuritic plaques is 
the 42 amino acid peptide Aβ(1-42).  This peptide is more hydrophobic, and more prone 
to aggregation than the shorter Aβ(1-40) peptide (Jarrett et al., 1993a).  In the late 1980s 
experimental data confirmed the presence of diffuse amyloid plaques in the same brain 
region that contained many neuritic plaques (Tagliavini et al., 1988, Joachim et al., 
1989).  However, further research on the diffuse plaques showed that they were the sole 
form found in brain regions that lacked neuritic dystrophy, glial changes, and 
neurofibrillary tangles.  In the case of healthy aged human, free of AD or other 
dementing processes, studies have shown the presence of solely diffuse plaques in the 
limbic and association cortices.  AD patients on the other hand showed mixtures of 
diffuse and neuritic plaques (Fig 1.1).  It was therefore hypothesized that these diffuse 
plaques represent precursor lesions of neuritic plaques (Selkoe, 2001).  This hypothesis is 
best illustrated by studies on Down's syndrome.  Patients with Down‟s syndrome have 
little or no Aβ deposition in the first decade of life, but by around 12 years of age one 
begins to see diffuse plaques containing Aβ(1-42) and not Aβ(1-40).  More and more 
Down's subjects develop such plaques during the second and third decade of life (Lemere 
et al., 1996).  After the age of 30, amyloid fibril formation is seen and there is associated  
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Figure 1.1.Types of Plaques Diagram showing the relationship between the subsets of 
senile plaques based on the morphology of the amyloid and whether or not they are 
associated with PHF type or dystrophic neurites. (Figure adapted from Dickson W D, 
1997, J Neuropathol Exp Neurol, 56:321-339) 
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 microgliosis, astrocytosis and some neuritic dystrophy.  These neuritic plaques then 
become more prevalent over the next 2 decades of life. 
 
1.3.2 Neurofibrillary Tangles 
 
The healthy neurons in the brain are connected by axons.  Microtubules are 
support structures present inside the axons that aid in the transport of molecules and 
nutrients into and out of the cell.  Tau is a microtubule-associated protein and the 
hyperphosphorylation of this protein leads to detachment of tau from the microtubules, 
which results in the formation of neurofibrillary tangles and neurophil threads.  The three 
main types of neurofibrillary lesions (NFLs) based on their localizations in nerve cells 
are: (i) neurofibrillary tangles (NFTs) in the cell body and apical dendrites of neurons, (ii) 
neurophil threads (NTs) in distal dendrites and (iii) dystrophic neurites associated with 
neuritic plaques (Tolnay and Probst, 1999).  NFLs contain bundles of abnormal fibers 
that consist of pairs of ~10 nm filaments wound into helices (paired helical filaments or 
PHFs) as a major fibrous component, and straight 10 nm to 15 nm filaments (SFs) as a 
minor component (Selkoe, 2001).  Most of these filaments are highly insoluble and 
resistant to detergent such as sodium dodecyl sulfate (Selkoe et al., 1982).  In AD, the 
hyperphosphorylated tau decreases the ability to promote the microtubule assembly and 
instead aggregates into paired helical filaments (PHFs) in the cytoplasm of the 
degenerating neurons (Buee et al., 2000).  Neurofibrillary pathology is also found in other 
neurodegenerative disorders like FTDP-17 (fronto temporal dementia and Parkinsonism 
linked to chromosome 17) (Lewis et al., 2001). 
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1.3.3 Relationship Between Aβ and Tau 
 
Pathophysiological mechanisms underlying AD have been controversial. The 
most dominant theory of AD etiology and pathogenesis is amyloid cascade hypothesis. 
The hypothesis states that overproduction of A, or defect in the peptide clearance, leads 
to amyloid deposition, which produces tangles that may lead to cell death, resulting in 
memory impairment in AD (Hardy and Gwinn-Hardy, 1998, Selkoe, 2001).  There is 
strong evidence suggesting that A is critically involved at an early stage in the 
pathogenesis of AD (Vassar, 2004), and that A accumulation precedes and promotes tau 
pathology.  PHF formation in AD is not due to mutations in the tau gene but is due to 
cellular cascade triggered by A, which causes the abnormal phosphorylation of tau 
proteins, and their assembly to filaments (Gouras et al., 2000, Greenfield et al., 2000, 
Gotz et al., 2001, Lewis et al., 2001).  This statement has been supported by data that 
showed presence of A in the vicinity of the neurons enhanced tau phophorylation in 
vitro and in vivo (Busciglio et al., 1995).  Double transgenic mice expressing mutant 
human tau gene (P301L) and mutant APP developed neurofibrillary tangles and 
degeneration in cortical and subcortical brain regions (Lewis et al., 2001).  Further 
studies on 3xTg-AD mouse harboring mutations in APP, Tau and presenilin showed that 
intraneural A accumulation in cell bodies preceded tau hyperphosphorylation (Oddo et 
al., 2003, Billings et al., 2005).  Injection of A(1-42) into the brains of P30IL mutant tau 
transgenic mice resulted in an increase in the number of NFTs by a factor of five.  The 
increase in the numbers were seen in the amygdale from where the neurons project into 
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the injection sites (Gotz et al., 2001).  These data support the fact that A is the primary 
cause for the disease. 
 
1.4 Overview of Amyloid Beta (Aβ) Peptide 
 
1.4.1 Aβ Generation from Amyloid Precursor Protein (APP) 
 
Amyloid beta is derived from a larger precursor protein, amyloid precursor 
protein (APP), a type-I integral transmembrane glycoprotein.  APP contains an 
extracellular N-terminus and a short C-terminal region that lies in the cytoplasm  APP is 
present in a variety of tissues but predominantly in the brain (Mattson, 1997).  It is 
encoded by a gene located on chromosome 21 (Masters et al., 1985).  Splicing of the APP 
gene gives rise to at least three transcripts that encode proteins of 695, 751 and 770 
amino acids (Hardy, 1997, Selkoe, 1999).  All of the APP isoforms contain the 39/43 
amino acids long Aβ domain.  The 695 amino acids are the main isoform expressed in 
neurons (Golde et al., 1990).  At present the physiological function of APP in the brain 
remains unclear, although it has been proposed to have functions in transmembrane 
signal transduction (Nishimoto et al., 1993), calcium regulation (Mattson et al., 1993) and 
cell proliferation and adhesion (Saitoh et al., 1989).  A characteristic feature of APP is its 
proteolytic cleavage by group of enzymes or enzyme complexes,  the α-, β- and γ-
secretases (Selkoe, 2001).  The differential actions of these secretases lead either to the 
non-amyloidogenic or amyloidogenic pathway.  Three enzymes, ADAM 9, ADAM 10 
and ADAM 17 (also known as tumor necrosis factor converting enzyme), all with α-
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secretase activity, have been identified.  These belong to the ADAM family, a 
disintergrin and metalloproteinase enzyme (Allinson et al., 2003).  The α-secretase 
cleaves APP within the Aβ region to produce the large amino N-terminal ectodomain, the 
soluble sAPP that is subsequently secreted into the extracellular medium (Kojro and 
Fahrenholz, 2005), and the 83-residue COOH-terminal fragment C83 (Sisodia et al., 
1990).  The C83 fragment is retained in the membrane, and subsequently cleaved by γ-
secretase to form the short segment p3 (Sisodia et al., 1990).  The α-cleavage pathway is 
considered as default, non-amyloidogenic pathway, since the cleavage occurs in the Aβ 
region, thereby precluding formation of Aβ.  In the amyloidogenic pathway, initial 
proteolysis is mediated by β-secretase, a type I integral membrane protein of the pepsin 
family of aspartyl proteases (Vassar et al., 1999). The β-secretase cleavage produces a 
99-residue COOH-terminal fragment C99 within the membrane and soluble β-APPs, in 
the extracellular space (Vassar, 2004).  These fragments are processed by γ-secretase to 
produce p3 from C83 or Aβ from C99 (Fig 1.2).  γ-secretase cleavage is not sequence 
specific resulting in Aβ peptides of varying length ranging from 39-43 amino acids. 
(Selkoe, 2001). 
 
1.4.2 Aβ Fibrillogenesis 
 
Monomeric A formed from APP cleavage is unstructured (Suzuki et al., 1994), 
and can self- assemble via non-covalent nucleation dependent polymerization process 
(Jarrett and Lansbury, 1993, Lomakin et al., 1996).  Aβ is thought to start accumulating 
in vivo as low molecular weight species (LMW Aβ) that consists primarily of monomers  
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Figure 1.2 Schematic representation of formation of Aβ from APP by the action of 
secretases. EC: extracellular; TM: transmembrane; IC: intracellular. Aβ domain is 
highlighted in red. Only one cleavage site is shown for each enzyme. Figure adapted from 
Zheng.H and Koo H.E, 2006, Mol Neurodegen, 1:5.  
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that are constitutively secreted from the brain cells (Hartley et al., 1999).  Formation of 
Aβ consists of a change from random coil or α-helix into a β-strand.  The conformational 
change of β-amyloid is in part due to the hydrophobic collapse of the very hydrophobic 
C-terminal region of Aβ. This limits the rate of nucleation, and the hydrophobic 
interaction is further maximized by β-sheet conformation (Tycko, 2003).  Although 
Aβ(1-40) residue is present in higher concentrations in the human body, elevated levels 
of Aβ(1-42) residue with additional hydrophobic I41 and A42 are found to be associated 
with familial forms of AD.  Furthermore, it has been reported that Aβ(1-42) is the major 
component of the immature senile plaques and cerebrovascular amyloid deposits (Roher 
et al., 1993, Iwatsubo et al., 1994).  In vitro, Aβ(1-42) forms fibrils rapidly even at much 
lower concentration than Aβ(1-40) (Jarrett et al., 1993b, Harper et al., 1997a).  Hence, 
identification of the slowest or rate-determining step in the overall process is the key to 
understanding the rate of amyloid formation. 
 
1.4.3 Nucleation-Dependent Polymerization of Aβ 
 
In vitro, Aβ fibrillogenesis is proposed to occur via nucleation-dependent 
polymerization process.  This model consists of a nucleation or lag phase and an 
extension phase.  Monomers undergo a slow nucleation phase or lag phase, which 
comprise a series of association steps to form an oligomeric nucleus.  This step is 
thermodynamically unfavorable, representing the rate-limiting step in amyloid fibril 
formation.  Once the nucleus has been formed, further addition of monomers becomes 
 15 
thermodynamically favorable, resulting in a growth phase in which the nucleus grows 
rapidly to form large polymers.  This is followed by a steady state phase, in which the 
aggregate and the monomer appear to be at equilibrium (Fig 1.3A) (Jarrett and Lansbury, 
1993, Harper and Lansbury, 1997).  In nucleation dependent polymerization, polymer 
formation is observed only if the monomer exceeds a certain level known as the critical 
concentration.  Beyond the critical concentration, the polymer concentration increases but 
the monomer concentration remains the same (Harper and Lansbury, 1997).  The in vivo 
concentration of Aβ in the CSF is in the low nanomolar range (Nitsch et al., 1995, van 
Gool et al., 1995).  However, the critical concentration of Aβ measured in vitro is 3-4 
orders of magnitude greater than the average brain concentration, thereby suggesting a 
local super saturation mechanism for Aβ nucleus formation and growth (Harper and 
Lansbury, 1997, Klunk et al., 1994).  The proposed mechanism suggests that the Aβ gets 
supersaturated transiently in a cellular compartment.  During this period a slight increase 
in the concentration results in intracellular aggregation.  Also, the length of time that Aβ 
is locally supersaturated is very critical.  If Aβ is released from the supersaturated state 
before nucleus is formed, there will be no amyloid formation as in normal conditions.  In 
AD, it is hypothesized that the duration of supersaturated state is lengthened thereby 
leading to nucleation and amyloid fibril formation (Harper and Lansbury, 1997, Jarrett 
and Lansbury, 1993, Lomakin et al., 1996), Lomakin et al., 1997).  In a typical 
nucleation-dependent polymerization oligomerization is not observed until the monomer 
concentration exceeds the critical concentration.  During the lag phase protein associates 
in a supersaturated solution to form ordered soluble oligomeric nuclei, and during this 
period there are no detectable fibers.  Addition of preformed protein nuclei during the lag  
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Figure 1.3. Schematic representation of nucleation dependent polymerization  
(A) Monomers undergo slow nucleation to form the nucleus (lag phase). Once the 
nucleus is formed there is rapid aggregation to form fibrils. The lag phase can be 
overcome by the addition of preformed seeds, or by manipulating the aggregation 
conditions like peptide concentration, temperature, pH and ionic strength. (B) Once 
critical concentration is achieved, monomers undergo nucleation to form nucleus, and 
this proceeds to form the protobrils and then the mature fibrils. (Fig 1.3A adapted from 
Harper. J.D., and Lansbury, P.T. Jr., 1997, Ann Rev Biochem, 66:387-407. 1.3 B adapted 
from Walsh, D.M., et al 1997, J Biol Chem, 272:22364-22372). 
B
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time results in immediate polymerization, a process known as seeding (Harper et al., 
1997a).  Once the oligomeric nuclei are formed, the aggregates grow rapidly (elongation 
phase) until a thermodynamic equilibrium between the aggregate and monomer is 
reached (Harper et al., 1997a, Walsh et al., 1997).  Studies have shown that small 
elongated oligomers appear early in the fibril formation pathway, and measure 2.7 to 4.2 
nm in diameter and < 200 nm in length. These structures disappeared with longer 
incubation time, and were replaced by full length fibrils (Kowalewski and Holtzman, 
1999).  Radiochemical immunological assays have shown the existence of short lived 
species prior to the formation of protofibrils, that progress to form the mature fibrils 
(Walsh et al., 1997).  Intermediate protofibril structures were about ~40% the height of 
the mature fibril, and are believed to appear very early in the process and disapears as the 
fibrils appear (Koo et al., 1999).  These findings support the idea that protofibrils acts as 
a center for the formation of mature fibril. Several models exist that shows the proposed 
coversion of protofibrils to mature fibrils. One is the end to end association of protofibrils 
but,this was considered unlikely due to the kinetic barriers associated with proper 
allignment of protofibril ends (Walsh et al., 1997).  Alternatively, protofibrils could also 
associate laterally followed by an end-end annealing to form mature fibrils (Nichols et 
al., 2002).   
The longer peptide Aβ(1-42) was shown to nucleate faster than Aβ(1-40) (Harper 
and Lansbury, 1997).  Transgenic mice that secrete high levels of Aβ(1-42) in the 
absence of APP over expression, show greater extent of amyloid pathology in contrast to 
 18 
transgenic Aβ(1-40) mice (McGowan et al., 2005).  These experiments highlighted the 
importance of Aβ(1-42) in amyloid deposition, and it was suggested that Aβ(1-42) is 
required for the nucleation in vivo.  The exact nature of the nucleation seed in vivo is not 
known.  It is hypothesized that in the crowded environment inside neurons or in the brain 
parenchyma, Aβ binds to other proteins or lipids and contributes to seeding (Hoozemans 
et al., 2006).  One such example that supports this hypothesis is the binding of Aβ to 
ganglioside GM1, leading to a conformation change that likely acts as a seed for 
aggregation, thereby increasing the fibril formation (Hayashi et al., 2004). 
1.5 Fibril Structural Assembly 
 
Amyloid fibrils are noncrystalline and insoluble making it difficult for structural 
studies by the two principal experimental approaches to structure determination – X-ray 
crystallography and solution-state nuclear magnetic resonance (NMR).  However, X-ray 
fiber diffraction studies indicate a cross β‟ orientation in amyloid fibrils.  Intense 
synchrotron X-ray beams were used to obtain high-resolution diffraction patterns from a 
range of different ex vivo and synthetic amyloid fibrils. Amyloid fibrils were isolated 
from patients with monoclonal λ immunoglobulin light chain amyloidosis, reactive 
systemic amyloid A protein amyloidosis and Val30Met transthyretin amyloid, synthetic 
fibrils were isolated from residues 10-19 of transthyretin, and peptide was isolated from 
residues 20-29 of islet–associated polypeptide (1APP) (Inouye et al., 1993, Sunde et al., 
1997).  High resolution patterns from these samples were dominated by cross beta 
reflections, and the diffraction patterns showed similarities in spite of the fact that the 
samples were from different peptides.  This suggested the presence of a common core 
 19 
molecular structure at least at the level of protofilament.  Extensive biophysical studies 
were done on transthyretin, a tetrameric protein that is the backup transporter of 
thyroxine and the main transporter of retinol binding protein (Blake et al., 1978).  One 
model that was extensively studied was the Val30Met transthyretin amyloid (Blake and 
Serpell, 1996), and this model represented the basic structural elements of the other 
amyloid fibrils that were studied in Sunde et al, (1997).  Structure prediction studies have 
indicated that C –terminal 10 residues and residues 17-21 are highly hydrophobic. 
Residues 28 onwards had high probability for β-sheet structure (Kirschner et al., 1987) 
The fiber diffraction studies cannot determine the chemical details required to 
understand the fibrillogenesis, especially details regarding parts of the sequence that form 
β-strands, and the specific amino acid residues that interact.  Solid state NMR studies 
(Petkova et al., 2002) have revealed that the cross-β motif in full length Aβ fibrils is 
comprised of in-register parallel –β sheets.  These studies have shown that the first 10 
residues of Aβ(1-40) are structurally disordered in the fibrils. Further probe into the 
structural aspects revealed that the residues 12-24 and 30-40 (Fig 1.4B) form two β -
strand segments that are separated by a “bend” segment with non-β -strand conformation 
at G25, S26 and G29.  The bend enables the two strands to form parallel β-sheets that are  
in contact via the side chains.  The resulting structure is a parallel, in register, cross β 
structure with a hydrophobic core and one hydrophobic face.  Fibrillization of amyloid is 
generally considered to driven by hydrophobic rather than electrostatic interactions 
(Halverson et al., 1990, Hilbich et al., 1991, Hilbich et al., 1992).  All full-length Aβ and 
Aβ fragment fibrils studied so far have been found to possess structures that maximize 
hydrophobic contacts within a β -sheet.  Thus, hydrophobic interactions appear to play a. 
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Structure predictions of Aβ 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
Figure 1.4 (A) Structural prediction showing the region with a high propensity for 
β-sheet (shown in black). The hydrophobic clusters are shown in pink. Figure adapted 
from Serpell (2000) Biochim Biophys Acta 1502:16-30.  (B) Structural model of Aβ(1-
40) schematic representation of a single molecular layer, or cross-β unit.  The yellow 
arrow indicates the direction of the long axis of the fibril, which coincides with the 
direction of intermolecular backbone hydrogen bonds. The cross-β unit is double-layered 
structure, with in-register parallel β-sheets formed by residues 12–24 (red ribbons) and 
30–40 (blue ribbons). Figure adapted from Petkova.et al (2002) Proc.Natl.Acad.Sci.USA, 
99:16742-16747. 
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large role in stabilizing amyloid fibril structures (Halverson et al., 1990, Hilbich et al., 
1991, Hilbich et al., 1992, Harper et al., 1999) 
 
1.6 Classification of AD 
 
Although AD is predominantly a disease of late life, there are two broad types of 
AD – the familial AD (FAD) and the sporadic AD (SAD).  About 5% of AD cases are 
„familial‟ and occur due to mutations in the APP or in the presenilin genes.  Sporadic AD 
cases are thought to be chiefly associated with lack of Aβ clearance from the brain, unlike 
familial AD that shows increased Aβ production (Winklhofer et al., 2008).  In FAD, the 
disease segregates in families, following an autosomal dominant inheritance pattern.  In 
SAD, no clear family history is indicated and the disease usually occurs above 60 years 
of age (Price and Sisodia, 1998).  Because of the variation in age at onset, AD is also 
categorized into early onset and late onset forms.  Both the early-onset (familial) and the 
late-onset (mostly sporadic) forms of the disease have similar neurological and 
histopathological changes, suggesting that the different forms of the disease have a 
common pathophysiology and shared etiology (Pimplikar, 2009). 
 
1.6.1 Genetic Mutations Linked with Early Onset AD 
 
Three different genes have been implicated in the pathology of familial 
Alzheimer‟s disease.  They are: APP (mAPP) gene on chromosome 21 (Goate et al., 
1989, Levy et al., 1990), mutations in the presenilin 1 (PS1) gene on chromosome 14 and 
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mutations in the presenilin 2 (PS2) gene on chromosome 1 (St George-Hyslop, 2000, 
Tanzi and Bertram, 2001).  Mutation in the APP gene was the first mutation associated 
with FAD.  Involvement of APP in FAD was suspected due to the fact that the genes 
resided on chromosome 21, and people with Down‟s syndrome developed the symptoms 
of AD by the age of 40 (Selkoe and Podlisny, 2002).  Presenilins are transmembrane 
proteins localized mainly in the endoplasmic reticulum and Golgi membranes of neuronal 
and non-neuronal cells (De Strooper et al., 1998).  Precise functions of presenilins are 
unclear.  Several studies indicate that PS1 and PS2 are catalytic components of γ- 
secretases (Haass and De Strooper, 1999, Sisodia et al., 1999).  In vitro studies 
demonstrated that the pathogenic mutations in the APP and presenilin genes are 
associated with abnormal processing of APP.  The processing sites are either located 
adjacent to the Aβ domain in APP at the β- and γ- secretase cleavage sites (Nilsberth et 
al., 2001) or within the Aβ sequence at the α-secretase cleavage site.  Either of these lead 
to increased production and elevated plasma levels of Aβ, especially Aβ(1-42) or 
increased ratio between Aβ(1-42) and Aβ(1-40) (Mullan et al., 1992, Citron et al., 1994, 
Suzuki et al., 1994).  The only known mutation near to the β-secretase cleavage site is the 
Swedish double mutation KM → NL.  This mutation increases the level of total Aβ by 
increasing Aβ(1-40) and the levels of Aβ(1-42), though the increase is less in the case of 
the latter.  Mutations near the γ- secretase cleavage site results in an increased production 
of Aβ(1-42) (Scheuner et al., 1996).  However, the V715M mutation (French) results in 
reduction of Aβ(1-40) levels without affecting the Aβ(1-42)  levels (Ancolio et al., 1999), 
suggesting that the increase in Aβ(1-42) : Aβ(1-40) ratio is important rather than the 
absolute amount of Aβ(1-42).  
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Intra-Aβ mutations are associated with amyloid accumulation in the cerebral 
blood vessels in addition to the amyloid plaque formation.  E693Q (Dutch) mutations are 
associated with intracerebral hemorrhages (Levy et al., 1990).  A692G (Flemish) 
mutation manifest with intracerebral hemorrhages but these patients may survive to 
develop a progressive AD-like dementia (Hendriks et al., 1992).  The E693G (Arctic) 
mutation is associated with a decrease in Aβ(1-42) concentration in media from cells that 
were transfected with APPE693G.  Also, the plasma levels of both Aβ(1-42) and Aβ(1-40) 
were low in mutation carriers compared to healthy family members.  In vitro studies have 
shown that the carriers of E693G (Arctic) mutation have a high propensity to form 
protofibrils (Nilsberth et al., 2001). 
Transgenic (Tg) animals carrying mutations in amyloid precursor protein and 
presenilin genes displayed enhanced production and progressive aggregation of Aβ.  
Mouse models have shown that  Aβ(1-42) is essential for Aβ deposition not only in 
parenchyma but also in vessels (Borchelt et al., 1997, Holcomb et al., 1998).  These 
models have established that when APP/Sw mice (producing both Aβ(1-40) and Aβ(1-
42) are bred with mice expressing mutant PS1 (that increases brain Aβ(1-42)/Aβ(1-40) 
ratio), the crossbred mice have drastically increased amyloid deposition in parenchyma 
and vessels compared to single transgenic controls.  However, no significant tau 
pathology or extensive neuron loss, as found in AD brain, was detected in these 
transgenic animals (Games et al., 1995, Hsiao et al., 1996).  Studies on mutations in APP, 
PS1 and PS2 genes have provided important insights for understanding some of the key 
underlying biological mechanisms of AD.  All these genetic mutations lead to  
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Table 1.2 Three genes implicated in the pathology of early onset AD 
 
 
 
 
  
 
Gene (and protein) 
Chromosomal 
location 
Relevance to AD pathogenesis 
Amyloid Precursor 
Protein (APP) 
21q21.3 
Increase in Aβ production or Aβ(1-
42)/Aβ(1-40) ratio; mutations in the  
Aβ sequence or close to the β and γ-
secretase site of APP [need beta 
symbols for Abeta] 
Presenilin 1 PSEN1 14q24.3 
Increase in Aβ(1-42)/Aβ(1-40) ratio; 
mutations throughout molecule; 
enzymatic role in γ-secretase complex 
Presenilin 2 PSEN2 1q31–42 
Increase in Aβ(1-42)/Aβ(1-40) ratio; 
mutations throughout molecule; 
enzymatic role in γ-secretase complex 
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Intra Aβ mutations 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 1.5 Intra Aβ mutations. Schematic representation of APP molecule illustrating 
the sites of cleavage by α-, β-, γ-secretases. Localization of Aβ and p3 proteins containing 
the intra Aβ mutations. [Figure adapted from Nilsberth C, et al, 2001, Nat Neurosci, 
4:887-893.] 
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 overproduction of Aβ(1-42) in the brain before AD symptoms arise, indicating 
accumulation of Aβ(1-42) as initiating factor in the pathogenesis of Alzheimer‟s disease.  
APP or presenilin mutations  cause chronic increase in the Aβ(1-42) levels in the brain 
extracellular fluid, and inside neurons that slowly leads to the oligomerization and, 
eventually, forms fibrils that deposit and later forms the mature plaques (Selkoe and 
Podlisny, 2002).  FAD genetics and other mouse studies have been very useful in 
research on early onset AD.  However, vast majority of AD cases occur late in life, and 
are influenced by both genetic and environmental factors (Bertram and Tanzi, 2008, Bu, 
2009).  These include the ε4 allele of the apolipoprotein E (ApoE) gene (Blacker et al., 
1998, Bu, 2009).  ApoE was identified as a risk factor or a susceptibility gene for AD in 
1993 (Strittmatter et al., 1993).  ApoE plays a major role in lipoprotein metabolism and 
cholesterol homeostasis, in the brain (Mahley, 1988).  The other genetic factors are, 
proteinase inhibitor α2-macroglobulin gene on chromosome 12 (Pericak-Vance et al., 
1997, Blacker et al., 1998), insulin degrading enzyme on chromosome 10 (Olson, 1998, 
Vekrellis et al., 2000), low density lipoprotein receptor related protein and angiotensin 
converting enzyme (Olson, 1998, Kehoe et al., 1999).  So far, 20 mutations in the APP 
gene, 124 mutations in the PS1gene and 8 mutaions in PS2 gene have been described 
worldwide. Therefore gene-targeting strategies will help clarify the in vivo functions of 
genes linked to AD.  The transgenic mouse model studies will offer new opportunities to 
study the evolution and character of AD-type cellular dysfunction in addition to 
biochemical and cellular mechanisms of the disease.  These models will also be very 
useful to test the various treatment strategies for the disease. 
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1.7 Amyloid Cascade Hypothesis 
 
The amyloid cascade hypothesis was formulated more than a decade ago and 
states that the neurodegenerative process comprises of series of events triggered by the 
abnormal processing of the amyloid precursor protein.  The main tenet of the hypothesis 
is that the increased production or decreased clearance of Aβ peptides causes the disease 
(Hardy and Higgins, 1992, Hardy and Selkoe, 2002).  In either case there is accumulation 
of Aβ(1-40) and Aβ(1-42) peptides that result in aggregation and formation of insoluble 
plaques, triggering a series of deleterious changes that results in death of the neuronal 
cells.  Since Aβ(1-42) levels are found to be higher in AD patients, it was proposed that 
increased levels of Aβ(1-42) triggered the cascade of events resulting in AD (Younkin, 
1995).  Over the years the hypothesis has changed with regards to the type of pathogenic 
Aβ species that initiates deleterious events resulting in AD.  Two primary reasons led to 
this alteration in the hypothesis.  First, the plaque load does not correlate with the degree 
of dementia in humans (Terry et al., 1991).  Also, many mouse models of AD show 
memory deficits long before appearance of plaques in the brain (Lesne et al., 2008).  
Second, in vivo neuroimaging techniques have shown the presence of plaques in 
cognitively normal people (Nordberg, 2008, Villemagne et al., 2008).  It is possible that 
these people may have high risk of AD.  These observations suggest that insoluble 
plaques are not responsible for the pathologic cascade of events, and may in fact be 
benign or even protective in nature (Caughey and Lansbury, 2003).  
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1.8 Modified Amyloid Cascade Hypothesis 
Intracellular Aβ is assumed to be an early event in AD pathogenesis (Fig 1.6) 
prior to extracellular Aβ deposition (Wirths et al., 2004).  There is evidence for 
intracellular accumulation of Aβ, in both mouse models and human AD brains, that could 
contribute to disease progression (Gouras et al., 2000).  The focal point is mainly on the 
soluble aggregates of Aβ termed oligomers.  Oligomers were observed to occur 
intracellularly (Walsh et al., 2000).  Furthermore, Aβ(1-42) oligomers were found to be 
potent neurotoxins in neuronal cultures at nanomolar concentrations (Lambert et al., 
1998).  These oligomers were termed as Aβ derived diffusible ligands (ADDLs), and 
were found to be capable of inhibiting hippocampal long term potentiation thereby 
disrupting synaptic plasticity (Lambert et al., 1998, Walsh et al., 2002b). Primary 
neuronal cultures from APP transgenic mice have shown that oligomeric Aβ(1-42) 
redistributes from the outer membrane of the multivesicular bodies (MVB) to the inner 
membranes of the abnormal endosomal organelles and microtubules, and oligomeric 
forms have been observed in abnormal processes and synaptic components in the human 
AD brain (Takahashi et al., 2002, Takahashi et al., 2004).  Sodium dodecyl sulfate (SDS) 
soluble dimeric Aβ was found to accumulate in lipid rafts in the brain tissue of APP 
transgenic mice.  These dimers were found to appear early on as memory impairments 
become obvious, and provide a further link to the assumption that Aβ oligomers are 
tightly linked to memory dysfunction in AD (Kawarabayashi et al., 2004).  Dimeric 
oligomeric species have been isolated from human AD brains even in the absence of 
protofibrils, or fibrils (Walsh et al., 2002a, Shankar et al., 2008), and the dimers were 
found to inhibit long–term potentiation. A number of other poorly characterized but  
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Modified β-Amyloid Cascade 
 
Risk Factors: Aging, Trisomy 21, APP-, PS1- and PS2- mutations 
                                                                                           
          Accumulation of intracellular cellular                    Soluble extracellular  
Aβ(1-42)/ Aβ(1-40)                                                  Aβ(1-42)/ Aβ(1-40)                
                                                                                      
Synapse and neuron dysfunction                             Plaque formation 
                 
Synapse and neuron loss 
                 
Atrophy of distinct brain areas 
                
Dementia and other clinical symptoms 
 
 
 
Figure 1.6. Scheme showing the modified Aβ amyloid hypothesis. Ageing, Down 
syndrome and mutant APP, PS-1 or PS-2 causes an increase in intraneuronal Aβ(1-42) 
levels causing it to accumulate, leading to synaptic and neuronal dysfunction and 
degeneration in brain areas responsible for distinct memory functions. In parallel, 
increased secretion and deposition of Aβ(1-42) leads to extracellular plaque formation.  
Aβ(1-42) plaques are dynamic structures, and can also be internalized again, thereby 
increasing the intraneuronal pool of Aβ(1-42), which in turn increases the neurotoxic 
intracellular events. (Adapted from Wirths.O 2004, J Neuchem, 91: 513-520) 
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biochemically distinct forms of Aβ oligomers have been identified. These aggregation 
species have demonstrated toxicity effects in vivo and in vitro model systems (Klein et 
al., 2001, Walsh and Selkoe, 2004, Glabe, 2005, Walsh and Selkoe, 2007).  Fibrillar and 
pre-fibrillar oligomer species formation have been reported by (Kayed et al., 2007).  The 
new hypothesis suggests that Aβ formation activates the microglial cells which in turn 
release neurotoxic substances such as nitric oxide, proinflammatory cytokines, 
complement proteins and other inflammatory mediators leading to tau phosphorylation 
and neurodegenerative changes (Akiyama et al., 2000, McGeer and McGeer, 2001). 
 
1.9 Microglia 
 
Microglia represent the macrophage-derived cells in the nervous system that are 
capable of responding rapidly to various types of insults (Davalos et al., 2005, 
Nimmerjahn et al., 2005).  They are derived from a myeloid lineage and are the immune 
effector cells in the brain.  Microglia represent approximately 5-10% of all the glia found 
in the brain and are distributed throughout the gray and white matter of the nervous 
system.  At rest, they are believed to play supportive roles for neurons.  An inflammatory 
stimulus will activate the microglia causing them to migrate to sites of injury and 
subsequently transform into a macrophage-like phenotype (Bamberger and Landreth, 
2001). Transformation of microglia into activated form is accompanied by the up 
regulation of cell surface molecules that are involved in immune responses, secretion of 
cytokines and acute phase proteins (Kalaria, 1999).  Deposition of fibrillar amyloid 
deposits leads to activation of microglia, and this has been supported by a number of 
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animal studies.  Transgenic (Tg2576) mice overexpressing APP were generated and they 
developed extensive amyloid plaques, mostly in the hippocampus and in the cortex.  
Analyses of these animals revealed the presence of activated microglia surrounding the 
plaques (Benzing et al., 1999, Mehlhorn et al., 2000).  Aβ accumulation leads to a site-
specific activation of glia resulting in the secretion of pro-inflammatory cytokines 
(Akiyama et al., 2000, Cooper et al., 2000).  The inflammatory response can be 
considered as an attempt to clear the Aβ, however, an overwhelming accumulation of Aβ 
will lead to a chronic proinflammatory response (Blasko et al., 2004) which causes the 
defect in neuronal function. 
A „microglia dysfunction‟ theory (Streit, 2004) has been proposed recently. The 
theory states that many of the microglia in the AD brains are dystrophic and apoptotic 
due to presence of Aβ and cellular debris, and are unable to carry out their normal 
function of phagocytosis and neuroprotection.  The activation of microglia in AD reflects 
the ongoing pathology.  Experimental data have shown that reactive microglia occur 
within Aβ deposits that are associated with tissue injury and dementia ( neuritic plaques), 
and not with diffuse plaques (clinically benign Aβ deposits) (Perlmutter et al., 1992, 
Giulian et al., 1995, Giulian, 1999).  Selectivity in the distribution of reactive microglia 
suggests that a specific signal within the neuritic and core plaques triggers the brain 
inflammation.  Moreover the pattern of microglia distribution in AD is unique to the 
disease, suggesting a very crucial role for brain inflammatory responses in the etiology of 
the disease.  In AD, it is believed that plaques serve as stable irritants that sets the CNS in 
a chronic state of inflammation, promoting the activation and recruitment of microglia, 
which in turn secretes neurotoxins (Giulian, 1999).  Two in vitro models support this 
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hypothesis.  First, plaque fragments are engulfed within few minutes after they were 
placed in cultures of human microglia (Giulian et al., 1995).  The morphology changes 
from resting ramified forms to reactive, amoeboid shapes.  Data also suggest that plaque 
activated, and not resting microglia, secrete neurotoxic substances.  Second, plaque 
fragments do not show direct toxic effects on microglia depleted neuron cultures.  About 
50-µl to 100-µl spots of highly aggregated Aβ are placed on the floor of a cell culture 
well to mimic the Aβ deposits of AD.  Cultured microglia from rapid brain autopsies of 
subjects with or without AD are then seeded into the well.  Within days, there is a 
pronounced activation of the microglia as well as clear chemotaxis to the Aβ spots. The 
activated microglia, within weeks, completely cover the Aβ deposits and begin to 
phagocytose them, a process that can be measured quantitatively (Rogers and Lue, 2001).  
These findings support the fact that immune cells of the brain are necessary to mediate 
the plaque related injury to the neurons.  Activated glia contributes to neurotoxicity 
through the induction of inflammatory mediators such as interleukin (IL)-1and tumor 
necrosis factor-alpha (TNF α).  In addition, these cytokines also mediate the expression 
of the inflammatory enzyme-inducible nitric-oxide synthase (iNOS) (Akama and Van 
Eldik, 2000). 
 
1.10 Aβ Induced Inflammatory Response 
 
The brain was believed to be immunologically privileged by virtue of two factors.  
One is the blood-brain barrier, which hinders entry of humoral immune elements into the 
brain.  Second, it was assumed that the nervous system was unable to mount an intrinsic 
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inflammatory response.  However, it is now widely recognized that brain immunologic 
privilege may be limited since antibodies and humoral immune cells do penetrate the 
brain, (Wekerle, 2002).  Innate, intrinsic, microlocalized, chronic inflammatory responses 
are clearly evident in multiple neurologic disorders, especially AD (Akiyama et al., 2000, 
Griffin, 2006).  In vitro models have facilitated elucidation of mechanisms underlying 
microglial migration, colocalization, and scavenging of Aβ deposits (Rogers and Lue, 
2001).  Several groups have identified a number of inflammation-related receptors 
expressed on microglia.  Among the many receptors that have been identified, 
macrophage scavenger receptors (El Khoury et al., 2003),  Formyl chemotactic receptors  
(Lorton et al., 2000), receptor of advanced glycation end products ( RAGE) (Yan et al., 
1996), are probable important ones since they can have Aβ as a ligand.  Studies have also 
confirmed that Aβ induces glial activation in vivo (Weldon et al., 1998, Ishii et al., 2000).  
The fibrillar conformation of Aβ seems to be a crucial feature for such cell activating 
effects (Ishii et al., 2000).  Alternative and classical complement pathways have been 
implicated in AD pathogenesis (Rogers et al., 2002b), Akiyama et al., 2000).  Fibrillar 
Aβ can bind C1q, the first classical pathway component.  This leads to sequential 
activation of other components of the classic pathway with the release of anaphylatoxin 
(C4a and C3a) and opsonizing (C3b and iC3b) fragments (Rogers, 2008) that enhance 
inflammatory mechanisms.  Another mechanism of complement-mediated inflammatory 
responses is the formation of C5b-9, the membrane attack complex (MAC), targeted at 
cellular membranes.  This assembly creates a transmembrane channel that facilitates the 
diffusion of ions to and from the cytoplasm, leading to disruption of cell homeostasis.  
Sufficient assembling of MAC complexes on the cell surface leads to cell lysis.  
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Immunohistochemical staining of C1q was shown to be colocalized with aggregated Aβ 
deposits in the AD brain, but is absent in the non demented brain  (Rogers et al., 1992).  
A certain degree of aggregation is required for the activation of the complement system.  
The amino acids 14-26 of the antibody- independent binding site of C1q contain five 
cationic side chains that are likely to become charge-coupled to four anionic side chains 
within residues 1 to 16 of N-terminus of Aβ peptide (Jiang et al., 1994). Along with this 
charge coupling, the hexameric structure of C1q appears to align well with adjacent C1q 
binding sites when Aβ is in its aggregated cross-β-pleated sheet configuration, the 
configuration that is predominant in the aggregated Aβ deposit.  Once C1q has been 
activated by Aβ, subsequent activation of the full classic cascade may ensue, and this has 
been widely reported in Aβ -rich areas of the AD brain (Webster et al., 1995). CD14, the 
receptor for lipopolysaccharide (LPS) interacts with fibrillar Aβ (Fassbender et al., 2004) 
and microglia kill the Aβ(1-42) damaged neuron by a CD14 dependent process (Bate et 
al., 2004).  The involvement of CD14 in Aβ induced microglia activation strongly 
supports the hypothesis that innate immunity is linked with AD pathology (Fassbender et 
al., 2004, Eikelenboom et al., 2006). 
  
1.10.1 Neuroinflammation and AD Pathogenesis 
 
One of the mechanisms underlying neurodegeneration in AD is a significant 
inflammatory response to Aβ plaques. Inflammatory response to Aβ plaques are observed 
in the brains of human patients (McGeer et al., 1987), and in AD transgenic mouse 
models (Meyer-Luehmann et al., 2008).  Neuropathological studies in human brains have 
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demonstrated activation of microglial cells (McGeer et al., 1996), and these results have 
been corroborated by in vitro studies  in which microglial cells exposed to aggregated Aβ 
have shown an overproduction of proinflamamtory cytokines that trigger the 
neurodegenerative cascade in the neurons (Quintanilla et al., 2004, Orellana et al., 2005).  
Further support for this concept came from data showing that individuals consuming 
nonsteroidal anti-inflammatory drugs (NSAIDS) have a lower risk of AD (McGeer et al., 
2006). NSAIDS have also shown protective mechanism in animal models of AD (Yan et 
al., 2003).  Patients receiving systemic NSAIDS developed significantly less symptoms 
of AD, suggesting that controlling inflammation in the brain helps prevent or slow down 
the onset of AD (McGeer et al., 1996, Rojo et al., 2008).  However, this effect is 
restricted to only certain (NSAIDS) drugs (Maccioni et al., 2009).  Neuroinflammation is 
characterized by generation of proinflammatory mediators that are locally produced by 
the host cells, thereby indicating the involvement of the innate immune system. 
Inflammation associated with the brain (neuroinflammation) is different from the 
peripheral inflammation.  AD can be thought to be autotoxic disease in which an innate 
immune system uses local phagocytes, microglia, as an effector (Maccioni et al., 2009).  
In vitro studies have shown that Aβ fibrils result in microglial activation (Giulian et al., 
1996, McDonald et al., 1997).  The plaque-associated  microglia have dilated intracellular 
channels of smooth endoplasmic reticulum containing amyloid fibrils (Wisniewski et al., 
1989, Wisniewski et al., 1992).  These findings indicate the role of microglia in clearing 
the Aβ by phagocytosis, which normally takes place in health (Wisniewski et al., 1991).  
In AD, the microglia, found clustered around the amyloid deposits, become dysfunctional 
and unable to clear the amyloid deposits (Rogers et al., 2002a), (Meyer-Luehmann et al., 
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2008).  While the activated microglia fail to clear Aβ, their presence results in neuronal 
damage and cognitive decline due to release of cytokines (Edison et al., 2008).  Infusion 
of anti-Aβ antibodies stimulates the plaque-associated activated microglia to clear the 
deposits (Bacskai et al., 2001). 
 
1.11 Modeling of Alzheimer‟s Disease 
 
Several in vivo models have been developed that were aimed at being a replica to 
the AD symptoms, and to model certain aspects of neurodegeneration, or amyloid 
deposition.  Mouse models that express wild type APP, APP fragments, Aβ and FAD-
linked mutant APP and PS1 were produced.  Mice expressing both mutant PS1 and 
mutant APP were shown to develop Aβ amyloidosis in the central nervous system.  Co-
expression of the human A246E mutant PS1 and APPswe have displayed elevated levels 
of Aβ in the brain, and these mice developed several amyloid deposits, dystrophic 
neurites and glial responses in the hippocampus and cortex (Borchelt et al., 1997).  
Further, these studies have demonstrated that APP, PS1 and BACE1 are colocalized in 
the neurites immediately proximal to the sites of Aβ formation in the brain.  These 
findings strengthen the concept of a neuronal origin for Aβ (Wong et al., 2002).  The 
triple transgenic model (3xTg-AD) (Oddo et al., 2003), harbors PS1M146V, APP (Swe) and 
tauP301L transgenes, and exhibit deficits in synaptic plasticity, long term potentiation, and 
deficits in long-term synaptic plasticity correlate with the accumulation of intraneuronal 
Aβ. Besides, data from 3xTg-AD model suggest that Aβ pathology precedes tau 
pathology by several months.  In vitro models have been very useful since they constitute 
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models that are able to serve as approximations of a disease.  In vitro models allow 
detailed study of pathological factors, and make characterization possible at a cellular 
level.  Rat primary septal cultures (Zheng et al., 2002) and human neuroblastoma cells  
(Misonou et al., 2000) have been used to study the pathophysiological mechanisms that 
are hypothesized to contribute to AD.  Non transfected cell lines like differentiated PC-12 
cells have been treated with Aβ(1-42) to study Aβ neurotoxicity (Bergamaschini et al., 
2002).  Human SH-SY5Y cells exposed to aggregated synthetic beta-amyloid peptide 
Aβ(1-42), caused a decreased solubility of tau along with the generation of PHF-like tau-
containing filaments that correlates with amyloid cascade (Ferrari et al., 2003). 
 
1.11.1  In vitro and In vivo Studies on Inflammation and AD 
 
The in vivo inflammatory response to Aβ has been mirrored in numerous in vitro 
cell model systems including both microglial and monocytic cells (Klegeris et al., 1997, 
Misonou et al., 2000, Yates et al., 2000, Combs et al., 2001). Aβ is deposited in the 
cerebral cortex in the AD brains, and studies have shown the presence of fibrillar Aβ 
(fAβ) associated with the dystrophic neuritis (Mirra et al., 1991).  Geula et al have shown 
that injection of plaque equivalent concentrations (200pg) of fAβ to the cerebral cortex of 
aged Rhesus or marmoset monkeys resulted in a significant neuronal loss, and induced 
hyperphosphorylation of tau.  Further, it was also reported that injections of fAβ in the 
aged primates also resulted in the recruitment and activation of large population of 
microglia (Geula et al., 1998).  Recent studies have shown that low concentrations of fAβ 
induced massive activation of microglia in aged rhesus cortex in addition to neuronal loss 
 38 
(Leung et al., 2009).  Fibrillar Aβ serves as a ligand for both the scavenger receptor class 
A (El Khoury et al. 1996; Paresce et al. 1996) and receptor for advanced glycation end 
products (Yan et al. 1996).  
 
1.12 Human Immune Response 
 
The mammalian immune system is comprised of two branches: innate (cellular), 
and adaptive immune systems.  Innate immune system is the first line of host defense 
against the pathogens, and is mediated by phagocytes, including the macrophages and the 
dendritic cells.  Innate immunity does not require prior exposure to foreign antigens to 
get stimulated.  Adaptive immunity is dependent upon the signals provided by the innate 
immune system, which in turn facilitates expansion of antigen specific T and B 
lymphocytes that can recognize infinite number of potential antigens (Kielian, 2006).  
Host-defense has been based on the ability to recognize pathogen structures (Akira et al., 
2006).  The innate immune system recognizes pathogens via a predetermined subset of 
germ line encoded receptors, thereby limiting the ability to recognize every possible 
antigen.  The innate immune system focuses on few highly conserved structures that are 
unique and expressed by a large group of microorganisms (Kielian, 2006).  The 
conserved structural motifs are called pathogen-associated molecular patterns (PAMPS). 
These bind via a limited number of germ-line encoded pattern recognition receptors 
(PRRs) (Akira et al., 2006, Danilova, 2006).  This attribute enables the immune system to 
distinguish between self and nonself (Medzhitov and Janeway, 1997).  Further, PAMPS 
are essential for the microbial survival, and any mutaion or loss of pattern can be very 
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lethal.  Hence, these patterns are less likely to be subjected to high mutation rates 
(Medzhitov and Janeway, 1997).  Among the various PAMPS available, (Fig 1.7) the 
TLR-family members are pattern recognition receptors (PRRs) that collectively recognize 
lipid, carbohydrate, peptide and nucleic acid structures expressed by different 
microorganisms.  
 
1.12.1 Toll Like Receptors (TLRs) as Pattern Recognition Receptors 
 
Toll-like receptors (TLRs) are evolutionarily conserved from the worm 
Caenorhabditis elegans to mammals (Hoffmann, 2003, Akira and Takeda, 2004, Beutler, 
2004).  TLRs are the primary mediators of the innate immune response and belong to a 
class of type-1 integral membrane glycoproteins.  Depending on the primary sequences, 
TLRs are further divided into subfamilies. TLR1, TLR2 and TLR6 recognize lipids, 
while TLR7, TLR8 and TLR9 recognize nucleic acids.  TLR4 is known to recognize a 
collection of different ligands, each having a different structure, such as, 
lipopolysaccharides (LPS), plant diterpene pactlitaxel, fusion protein of respiratory 
synctytial virus (RSV), fibronectin and heat shock protein (Akira et al., 2006).  TLRs are 
expressed on various immune cells, including macrophages, dendritic cells (DCs), B 
cells, specific types of T cells, and even on nonimmune cells such as fibroblasts and 
epithelial cells.  Expressions of TLRs are modulated rapidly in response to a variety of 
cytokines and environmental stresses.  Certain TLRs (TLRs 1, 2, 4, 5, and 6) are 
expressed on the cell surface, others (TLRs 3, 7, 8, and 9) are found almost exclusively in 
intracellular compartments such as endosomes.  The most extensively studied PAMP is  
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Figure 1.7 Pattern Recognition Receptors (PRRs) Pattern recognition receptors 
involved in the innate immunity mediated host defence against amyloid-beta oligomers 
and fibrils in brain. Figure adapted from Salminen A et al, 2009, Pro Neubiol, 87:187-
194 
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the bacterial lipopolysaccahride (LPS), an outer membrane component of Gram-negative 
bacteria.  LPS is an endotoxin and the most potent immunostimulant.  The lipid portion 
of LPS termed “lipid A” is the portion associated with the Gram-negative bacterial 
infection such as the endotoxic shock.  The LPS released from the gram-negative bacteria 
associates with LPS binding protein (LBP), an acute phase protein present in the blood 
stream.  The LPS-LBP complex binds to CD14; a glycosylphosphatidylinositol (GPI) 
linked protein.  CD14 is expressed on the cell surface of the phagocytes.  The LPS is then 
transferred to MD-2, which is associated with the extracellular portion of TLR4.  These 
steps are followed by the oligomerization of TLR4, a key component in LPS signaling 
(Poltorak et al., 1998, Shimazu et al., 1999).   
Aβ, is one among the several growing number of endogenous human molecules to 
activate the human immune response (Kielian, 2006).  There is increasing evidence that 
suggests the involvement of aggregated Aβ in triggering the human innate immune 
response.  Interaction between fibrillar Aβ(1-42) and CD14 resulted in the release of 
inflammatory products in primary murine microglial cells and human peripheral blood.  
Also, recent data shows that aggregated Aβ(1-42) induces cytokine production via TLR2 
and TLR4, in a human monocytic cell line (Udan et al., 2008).  It has been reported 
earlier that activated microglial cells are typically found clustered around the dense core 
plaques and not around the diffuse Aβ deposits (Selkoe, 2004).  These findings suggest 
that the activation of the microglial cells is selective to a particular Aβ morphology. 
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Figure 1.8 Potential roles of TLRs in the CNS response to infection and injury. 
Microglia and astrocytes respond to numerous PAMPs, including peptidoglycan (PGN; 
TLR2 agonist), double-stranded RNA (dsRNA; TLR3 agonist), lipopolysaccharide (LPS; 
TLR4 agonist), and unmethylated CpG oligodeoxynucleotides and/or bacterial DNA 
(CpG DNA; TLR9 agonist).  The stimulation leads to the release of wide array of 
proinflammatory cytokines (including TNF-α, IL-1β, and IL-12), chemokines [including 
macrophage inflammatory protein-2 (MIP-2/CXCL2) and monocyte chemoattractant 
protein-1 (MCP-1)], and reactive oxygen/nitrogen species [ROI/RNI; including 
superoxide and nitric oxide (NO)].  There is a resultant enhancement of blood–brain 
barrier (BBB) permeability.  Endogenous TLR ligands may be released from injured cells 
within the CNS parenchyma that may serve to augment neuroinflammation. (Figure 
adapted from Kielian, T (2004 a) J Neuroinflamm 1:16.) 
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1.12.2 Proinflammatory Cytokine Markers 
 
Ultra structural studies indicate microglia to be closely apposed to extracellular 
fibrils, and are likely to be involved in a phagocytic response (Wisniewski et al., 1992).  
Monocytes or macroglia have receptors for Aβ ( scavenger type and RAGE) (El Khoury 
et al., 1996, Yan et al., 1996).  In culture conditions the macrophages readily engulf Aβ 
aggregates, and this interaction is often associated with the release of proinflammatory 
cytokines, reactive oxygen species, proteases (eg.matrix metalloproteases) (Giulian et al., 
1995, Lorton, 1997). 
AD brain display immunoreactivity for proinflammatory cytokines IL-1β, TNF-α, 
IL-6 (Dickson et al., 1993) and IL-1α (Giulian et al., 1995, Mrak et al., 1995).  In vitro 
studies have demonstrated that fibrillar Aβ stimulation increases microglial/monocytic  
TNF-α production (Klegeris et al., 1997, Combs et al., 2000).  Increased levels of TNF-α 
have been reported in the brain and plasma of AD patients (Bruunsgaard et al., 1999, 
Tarkowski et al., 1999).  Transgenic mouse models have shown evidence that 
inflammation and TNF-α contribute to disease progression.  Three month old mice 
carrying three familial mutations (APPSwe, TauP301L, and PS1M146V) have shown 
accumulation of intraneuronal amyloid immunoreactivity in regions that include 
entorhinal cortex.  These studies have also reported the presence of elevated TNF-α 
mRNA levels in the same regions, and correlated with onset of cognitive deficits in these 
mice models (Billings et al., 2005, Janelsins et al., 2005).  These findings suggest the 
importance of TNF-α as a valuable proinflammatory marker. 
 44 
 
1.13 Therapeutic Approach: Vaccination in AD 
 
Immunotherapy is a very promising approach to target the disease causing Aβ 
aggregation species.  This therapy has been approached in two ways.  One is by active Aβ 
peptide vaccination (Schenk et al., 1999, Bard et al., 2000), and the other is passive 
infusion of anti-Aβ monoclonal antibodies (Bard et al., 2000).  Nasal vaccination with 
synthetic copolymer used to treat MS was found to decrease senile plaques in mouse 
model of AD (Frenkel et al., 2005).  T-cell based vaccination with glatiramer acetate 
resulted in decreased plaque formation and induction of neurogenesis in APP mice 
(Butovsky et al., 2006).  There is strong evidence that immune therapy of AD is able to 
remove Aβ from the CNS, leading to an improvement in the cognitive decline that is 
associated with AD (Glezer et al., 2007).  These data justified the first clinical trial with 
the active immunization in patients with mild to moderate AD.  During the Phase 2 trial 
of active immunization with Aβ(1-42) in patients with AD, it was observed that about 6 
% of the patients developed a T-cell mediated, autoimmune meningoencephalitis, and the 
treatment had to be stopped (Orgogozo et al., 2003).  Autopsy investigations of a few 
participants showed clearance of parenchymal plaques.  Amyloid clearance in these cases 
was associated with microglia that showed Aβ immunoreactivity, thereby suggesting 
phagocytosis.  A general cognitive-status test revealed a slowing of cognitive decline in 
these patients (Hock et al., 2003).  The passive infusions of anti-Aβ monoclonal 
antibodies target specific epitopes within the Aβ(1-42) peptide, avoiding a possible 
harmful binding to normal APP.  Since immunotherapy requires repeated infusion of 
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antibodies over a long period, AD patients will be able to tolerate such antibodies 
provided they are of human origin (Steinitz, 2008).  Immunotherapy has been successful 
in affecting the Aβ oligomerization and plaque formation.  The striking feature was the 
clearance of early hyperphosphorylated tau in the neurons of mouse models (Oddo et al., 
2004).  While trials are ongoing, the current hope is that one or more of these approaches 
can slow down the progression of AD and cognitive impairment.  
 
1.14 Aβ Polymorphism and AD Pathogenic Cascade 
 
Post mortem data suggest that different conformations of Aβ aggregated species, and not 
one particular Aβ aggregated intermediate, contribute to the disease mechanisms 
involved in the pathogenic cascade of AD (Hoozemans et al., 2006).  Studies have shown 
that the AD brain has a wide array of polymorphic aggregated Aβ species.  
Immunocytochemistry studies have shown the presence of diffuse plaques in the limbic 
and association cortices, and even in the striatum and cerebellum.  These diffuse deposits 
appear loose and granular by light microscopy, and they lack dystrophic neuritis, altered 
astrocytes and microglia.  Abundant diffuse plaques also occur in the brains of 
neurologically normal elderly humans, and in children with Down‟s syndrome, leading to 
the hypothesis that these are precursor lesions to the neuritic plaques.  These parenchymal 
deposits exist as range of species from dense core neuritic plaques containing fibrillar 
structures to wispy, loose, and granular deposits (Selkoe, 2004).  In vitro aggregation 
studies have provided detailed understanding of the fibrillogenesis mechanisms.  Many 
types of Aβ assembly forms have been reported from studies using synthetic Aβ.  
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Protofibrils (Harper et al., 1997b, Walsh et al., 1997, Hartley et al., 1999, Walsh et al., 
1999), annular structures, paranuclei, amyloid derived diffusible ligands (ADDLs) 
(Lambert et al., 1998, Gong et al., 2003), Aβ*56 (Lesne et al., 2006), secreted soluble Aβ 
dimers and trimers (Podlisny et al., 1995, Walsh et al., 2000, Walsh et al., 2002a), and 
amyloid fibrils are the different aggregation species that have been reported. Soluble 
oligomers are aggregation species that cannot be separated/pelleted from physiological 
fluids by high speed centrifugation (Dahlgren et al., 2002, Haass and Selkoe, 2007).  The 
conditions that produce these different structures are not well understood.  Also, these 
diverse morphologies have distinct toxic and biologic activity and not do provoke the 
same in vivo response (Dahlgren et al., 2002, Walsh et al., 2002a, Deshpande et al., 2006, 
Salminen et al., 2009).  Significant amount of data suggest that induction of an 
inflammatory response appeared to favor a fibrillar conformation.  The local acidic 
environment in the brain (endosomes and lysosomes) are believed to promote Aβ fibril 
formation (McLaurin and Chakrabartty, 1996), thereby inducing the nerurotoxic effects. 
The objective of this study was to characterize the different Aβ aggregation 
species and identify the optimal Aβ aggregation state required for the stimulation of 
maximal TNF-α response in a human monocytic cell line.  It is possible that in the near 
future the early molecular diagnosis of AD will be based on the correlation of Aβ 
structural polymorphisms and levels of proinflammatory cytokines.  The results of this 
study will provide further clues to unraveling the complexities of AD, and help find a 
solution for early diagnosis and treatment of this disorder. 
 
 
 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 Schematic representation of various aggregation species in Aβ(1-42) 
assembly. The different species reported are annular structures, paranuclei, Amyloid 
derived diffusible ligands (generally categorized as oligomers). Protofibril formation 
involves structural rearrangement. The final step is the formation of the mature fibrils. 
U (unstructured) α- (alpha helical structure) β (beta sheet). Figure adapted from Bitan et 
al (2003) PNAS,100: 330-335 
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CHAPTER 2 
METHODS 
 
2.1 Disaggregation of Aβ peptides 
The main focus of our study was to determine the assembly state of Aβ 
aggregation species and correlate structure with biological activity.  In order to have 
reproducibility in experimental trials, it was important to start the experiment with a 
homogenous monomeric solution of Aβ.  Commercially purchased peptides may be 
contaminated with certain levels of preexisting aggregates.  These aggregates act as seeds 
to accelerate the aggregation of monomeric peptides (Evans et al., 1995).  Any aggregate 
seed present in the solution will self assemble and alter the structure of the aggregate 
being investigated.  Studies indicate formation of different conformers of Aβ assemblies 
from the same peptide sequence (Petkova et al., 2005).  Small amounts of preformed 
aggregates can compromise the experiment. Therefore, protocols that ensure a uniform 
starting material are very useful when working with synthetic peptides (Chen and Wetzel, 
2001).  
Aβ(1-42), Aβ(1-40) was purchased from r-Peptide (Bogarth, GA, USA).  Aβ(1-
42) WT and Aβ(1-42) (L34P) were gifts from Dr Ron Wetzel, University of Pittsburgh.  
The peptide powder was resuspended in 100% hexafluoroisopropanol (HFIP) to a 
concentration of 1 mM for one hour to solubilize any preformed aggregates, and also 
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make smaller aliquots for storage purposes.  Further, this treatment allows 
“normalization” of the properties of different commercial Aβ preparations and also 
avoids need for subsequent filtration steps. (Wood et al., 1996, Zagorski et al., 1999).  
The peptide solutions were speed vacuum centrifuged to remove the HFIP.  It was 
important to remove traces of HFIP, since low percentages of it can alter the aggregation 
pathway (Nichols et al 2005). The speed vacuum centrifuged samples were stored at -
20C. 
An alternative method of pretreatment utilized a combination of trifluoroacetic 
acid (TFA) and HFIP.  TFA is known to dissolve the H-bonded protein aggregates and is 
relatively volatile making its removal from solution easier.  Further treatment with HFIP 
will remove any traces of TFA and ensuring disaggregation of any aggregated material 
left behind (Zagorski et al., 1999).  This protocol was used on crude peptides Aβ(1-42), 
Aβ(1-40) WT Aβ(1-40) (F4W) and Aβ(1-40) (F19W), synthesized by Dr. Fabio Gallazzi, 
University of Missouri- Columbia.  The peptides were resuspended in 100% TFA to a 
concentration of 1mM and bath sonicated for 10 minutes, and speed vacuum centrifuged 
to remove TFA.  This was followed by addition of an equal volume of 100% HFIP, 
followed by incubation in water bath (37C) for 1 hour, and speed vacuum centrifuged to 
remove HFIP.  The speed vacuum centrifuged peptide samples were stored at -20C. 
 
2.2 Preparation of Aβ Aggregation Solutions. 
 
Lyophilized peptides were stored as 0.25 mg aliquots.  The vials were 
resuspended in sterile water, phosphate buffered saline (PBS), or Hams F12 medium with 
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phenol red, as required in the experiment protocol to a final concentration of 100 µM.  A 
more concentrated Aβ aggregation solution of 1.2mM was made in some experiments.  
For preparations in water, aliquots (0.25 mg) were resuspended in 555 µl sterile water to 
a final concentration of 100 µM Aβ in a cell culture hood to maintain sterile conditions.  
The aggregation reactions were initiated, and stored at appropriate temperature conditions 
as required by the experiment protocol.  For a more concentrated Aβ preparation the 0.25 
mg vial was resuspended in 46 µl sterile water to a final concentration of 1.2 mM. For 
preparations in phosphate-buffered saline (PBS), lyophilized Aβ(1-42) peptide (0.25 mg) 
was resuspended in 500 µl water to a final concentration of 110 µM.  The preparation 
was divided into two aliquots of 250 µl each, and one was supplemented with 25 µl of 
10x PBS (Hyclone) to a final Aβ concentration of 100 µM.  The pH of the resulting 
solution was measured using a micro pH electrode (7.1).  Alternatively, aggregation 
reactions in PBS were initiated by resuspending the lyophilized peptide in 100 mM 
NaOH, (Aβ conc 2 mM, pH 10.2) followed by dilution into PBS (Hyclone,1X) to final 
Aβ concentration of 100 µM. The measured pH after dilution into PBS was 7.4. 
 
2.3 Preparation of Aβ-Derived Diffusible Ligands (ADDLs) 
 
Lyophilized Aβ(1-42) r-Peptide (0.25 mg) was resuspended in 11µl dimethyl 
sulfoxide (DMSO,Sigma) to a concentration of 5mM as described in (Dahlgren et al., 
2002).  Ice cold Ham‟s F12 medium with phenol red (Hyclone) was added to a final Aβ 
concentration of 100 µM.  The peptide solution was incubated at 4C for 24 hours, 
followed by centrifugation at 14,000 x g for 10 minutes.  The supernatant after 
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centrifugation was labeled ADDLs.  The only modification made in the protocol was the 
use of Hams F 12 medium with phenol red. 
 
2.4 Determination of pH of Aggregation Solutions. 
 
The pH of aggregation solutions was measured using a micro pH electrode 
(Thermo Scientific) connected to pH meter (Accumet
R 
Fisher Scientific).  This setup 
allows pH measurements in microliter volumes.  The aggregation studies were done with 
samples less than 1 ml and volumes as low as 5 μl was sufficient for making pH 
measurements. 
 
2.5 SDS PAGE / Western Blotting 
2.5.1 SDS/PAGE 
Aβ samples (100 µM) are prepared and diluted into Laemmli sample buffer 
(Biorad) 1:1 in the presence of reducing agent β-mercaptoethanol.  The samples were 
boiled for five minutes and 15 L loaded onto precast 18% Tris- glycine SDS 
polyacrylamide gels (Biorad).  Protein standards (10 L) (Biorad, Dual color, 10-250 kD) 
were loaded as control.  Aβ aggregation species were separated by electrophoresis in 
Mini-cell (Mini-Protean, Biorad) using running buffer (25mM Tris, 192 mM glycine, 
0.1% SDS, pH 8.3).  Electrophoresis was carried out at 200 volts for 40 minutes.  After 
electrophoresis, protein gels were either visualized by Coomassie staining or blotted to 
membranes for immunoreactivity detection. 
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2.5.2 Western Blotting 
 
The SDS-PAGE resolved proteins were transferred onto polyvinylidene difluoride 
(PVDF) membranes (Hybond
TM
-P, Amersham Biosciences) by electroblotting using the 
tank system (OWL, Bandit
TM
 VEP-2).  The PVDF membrane must be prewetted with 
methanol in order to enable macromolecules in the aqueous phase to bind to the 
hydrophobic surface of the membrane (Wetzel, 1999).  Electroblotting was carried out at 
200 -400 mA for 2 hours in transfer buffer (25mM Tris, 192 mM glycine, 10% methanol, 
pH 8.3).  The nonspecific binding sites on the membranes were blocked by incubating the 
blots in 5% non-fat dry milk in PBS/T (Phosphate buffer saline; 6.7 mM phosphate, 
140mM NaCl, and 0.1% Tween-20, pH 7.5) at 4ºC for at least an hour.  In some 
experiments the blocking was done overnight at 4ºC.  The membrane was treated with 
primary antibody, Ab 9 (gift from Mayo Clinic, Jacksonville) diluted in 5% fat free 
powdered milk in PBS/T for one hour, followed by wash (three times), each for five 
minutes with PBS/T.  The blots were then incubated with HRP-conjugated secondary 
antibody, IgG anti-mouse (R&D systems) diluted (1:1000) in 5% fat free powdered milk 
in PBS/T for one hour, followed by three five minute washes in PBS/T.  All incubations 
and washes were done with rocking.  Immunoreactive bands were detected using 
enhanced chemiluminescence reagent (ECL, Pierce), prepared 5-10 mintes prior to the 
treating the film. Exposure to (Kodak) was used to measure chemiluminescence, and 
exposure time depended on strength of the signal. 
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2.6 Dot Blot Assay 
2.6.1 Dot-Blot Procedures 
Nitrocellulose membrane was wetted with water and set on a filter paper for 5 
minutes.  Prior to spotting the sample the surface of the membrane was checked to see if 
there were any droplets of water.  Aβ (1-42) 5 μl (100 µM) was spotted allowed to stand 
for 20 minutes.  The membrane was blocked with 10% milk in PBS-0.2% Tween 20 
(PBST) for experiments with OC immune serum and Ab 9.  The concentration of Tween 
was reduced to 0.01% for A11 antibody probing based on recommendations in protocol 
in (Kayed et al., 2003).  The blocking step was done for one hour at 4ºC.  The membrane 
was washed with PBST twice (each 5 minutes), and incubated with OC immune serum 
(1:5000), Ab 9 antibody (1:5000), or A11 antibody (1:2000) for 1 hr with gentle shaking.  
Wash procedure was done as mentioned above, and followed by incubation for one hour 
with secondary antibody which is a 1:1000 dilution of an anti-rabbit IgG [HAF008, R&D 
systems] for OC immune serum and A11 antibody or anti-mouse IgG [HAF007, R&D 
systems] for Ab 9.  Washed the membrane twice, and incubated with ECL substrate and 
exposed to film for 30 seconds.  All steps were done at 25C and slight modifications 
were made to the protocols in (Akiyama et al., 2000, Kayed et al., 2003, Parvathy et al., 
2008). 
 
2.6.2 Preparation of Controls for Dot Blot 
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2.6.2.1 OC Positive Control 
0.1 mg of lyophilized Aβ(1-42) was dissolved in 50 µl 100 % HFIP  for 10–20 
minutes at room temperature.  The solution was transferred to a siliconized eppendorf 
tube and diluted to a concentration of 80 µM in sterile water followed by 10-15 minutes 
incubation at room temperature.  The samples were centrifuged for 15 mins at 14,000 x g.  
The supernatant was transferred to a new siliconized tube and subjected to a gentle 
stream of nitrogen for 10 minutes to remove the HFIP.  OC positive fibrillar oligomers 
were generated by stirring sample at ~ 500 RPM using Teflon coated microstir bar for 24 
hours at room temperature (Kayed et al., 2007). However, this preparation did not show 
positive reaction with OC immune serum in the experiments we conducted. 
 
2.6. 2.2 A11 Positive Control 
Soluble oligomers were prepared by dissolving 0.1 mg Aβ in 40 µl 100 % HFIP 
for 10-20 minutes at room temperature as mentioned above. The only difference from 
above being the final concentration of Aβ (55 µM). 10 μL of monomeric Aβ solution was 
added to 90 μL sterile water in a siliconized eppendorf tube to a final concentration of 55 
µM, and incubated for 10-20 min incubation at room temperature.  Following incubation 
samples were centrifuged for 15 minutes at 14,000 x g and the supernatant fraction 
(measured pH 3.3) was transferred to a new siliconized tube and subjected to a gentle 
stream of N2 for 5-10 minutes to evaporate the HFIP.  An aliquot was flash frozen after 
this step.  The samples were stirred at low speed (~ 500 RPM) using a Teflon coated 
micro stir bar for 24-48 hours at 22 °C (Kayed et al., 2003).  An aliquot was taken out 
and flash frozen after 24 and 48 hours.  The flash frozen samples were probed with A11 
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antibody to test for presence of oligomers. This preparation showed reactivity to A11.  
Prefibrillar oligomers have also reportedly been prepared by resuspension of Aβ(1-42) in 
100 mM NaOH (Aβ conc. 2 mM), followed by bath sonication for 30 seconds.  The 
aggregation reaction was initiated by diluting the solution in phosphate buffered saline 
(PBS) pH 7.4 and 0.02% sodium azide (Aβ final concentration 45 µM) and incubated at 
room temperature for up to 96 hours.  This method is a slightly modified version of 
protocol from (Kayed et al., 2007). This preparation was tried as positive control for A11 
antibody, but did not show reactivity. However, this preparation showed reactivity when 
probed with  OC immune serum inspite of being a control for oligomers. 
 
2.7 Immunoprecipitation 
Aβ aggregation solutions were resuspended to a concentration of 100 μM.  
Aliquots of 60 µl was incubated with 2 µl (1:10 dilution) OC antisera (2 mg/ml) resulting 
in ~1:300 dilution.  The incubation was done without agitation for 1 hr at 4°C.  Protein 
G-sepharose beads (10 µl) in 20% ethanol suspension (fast flow, Sigma P 3296) was 
added to the aggregation solution.  Protein G beads were tap spun to remove ethanol, and 
resuspended in same volume of water prior to treatment with aggregation solution.  The 
incubation with Protein-G beads was done with slow mixing for an additional 1 hr at 4°C.  
Protein G is a cell wall protein isolated from Type G streptococci, and has high binding 
affinity to the Fc region of immunoglobulin G (IgG) (Akerstrom and Bjorck, 1986).  The 
solution was centrifuged for 15 min at 18,000 x g and the supernatant (45 µl) was used to 
treat THP-1 monocytes for 6 hours or 24 hours depending on the experiment protocol.  
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After the incubation period the cells were spun and supernatants tested for TNF- levels.  
Another aliquot (5µl) of the 18,000 x g supernatant was used to test for OC immune 
reactivity by dot blot analysis.  AFM image analysis was done with the spin supernatant 
after dilution to a concentration of 1µM.  
 
2.8 Atomic Force Microscopy (AFM) 
An atomic force microscope is optimized for measuring surface features that are 
extremely small.  A Nanoscope III multimode atomic force microscope (Digital 
Instruments) was used in Tapping Mode.  The images were obtained using noncontact 
high frequency cantilevers (Ted Pella).   
 
2.8.1 Preparation of sample grids for AFM 
Aβ(1-42), Aβ(1-40) aggregation solutions (100 µM) were diluted to a 
concentration of 1 µM.  In our earlier trials we used higher concentrations (50 µM) of Aβ 
and we encountered frequent damage of the cantilever.  Samples were allowed to adsorb 
onto mica which is known to be anatomically flat surface with hydrophilic property.  
Grade VI mica (Ted Pella, Inc, Redding, CA) was cut into 11mm circles and affixed to 
12 mm metal discs.  Before application of sample, layers of mica was cleaved by placing 
a section of one-sided scotch tape on the surface.  The tape was then gently pressed and 
pulled up to reveal a smooth and clean surface.  Aliquots (50 µl) were applied to the 
freshly cleaved mica and allowed to adsorb for 15 minutes.  The solution was wicked off 
from the mica surface with tissue wipe, washed with deionized water twice to remove 
any unadsorbed sample, and air dried.  The prepared mica grids were stored in a 
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container with desiccant.  Images were obtained with a Nanoscope III multimode atomic 
microscope (Digital Instruments, Santa Barbara, CA) in Tapping Mode 
TM
.  Height 
analysis was performed using the Nanoscope III software on flattened height modes.  
Alternatively the grids were also prepared by pretreatment with 3 Aminopropyl triethoxy 
silane (APTES) 99% (Sigma Aldrich).  Layers of mica were cleaved as described above 
and the grids were treated with APTES diluted to 100 fold in 1 mM acetic acid for 10 
minutes.  The APTES treated grids were washed with water and air dried.  The APTES 
solution is prepared fresh for each treatment.  Treated mica grids were placed in disc 
container overnight and 50 µl Aβ sample was applied the following day and allowed to 
adsorb for 15 minutes and followed the same steps described above.  For SEC fractions, 
10 µl from the fractions were applied on APTES treated grids without sample dilution. A 
small mark was made with a marker adjacent to the sample drop so that the grid could be 
mounted appropriately for AFM imaging. 
 
2.9 Transmission Electron Microscopy (TEM) 
2.9.1 Preparation of Sample Grids for TEM. 
 Aβ aggregation solutions (100 µM) were diluted to 20 µM in water.  
Aliquots (10 µl) were applied to 200-mesh formvar-coated copper grids (Ted Pella, Inc.).  
The coating on the grid gives a shiny surface and hence can be easily identified.  Samples 
are applied on the shiny surface and allowed to adsorb for 10 minutes at room 
temperature.  Excess sample was wicked away with a tissue wipe.  The samples grids 
were washed three times by placing the sample side down on a droplet of water.  Heavy 
metal staining of the samples was done in a similar manner by incubation on a droplet of 
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2% uranyl acetate (Electron microscopy Sciences, Hatfield, PA) for 5-10 minutes.  The 
excess stain solution was removed and the grids were air dried and stored in desiccated 
containers.  The affixed samples were visualized with a JEOL JEM-2000 FX 
transmission electron microscope operated at 100 – 200 k eV.  The width measurements 
of aggregation species were done manually.  
 
2.9.2 Preparation of Sample Grids for Immunogold Label Studies. 
 
Aβ aggregation solutions (100 µM) were diluted to 20 µM in water.  Aliquots (10 
µl) were applied to 200-mesh formvar-coated copper grids with face up (Ted Pella, Inc.).  
Samples were allowed to adsorb for 10 minutes at room temperature, followed by 
removal of excess sample solution with a tissue wipe.  The samples grids were washed 
three times by placing the sample side down on a droplet of water.  The grids were 
treated with primary antibody Ab9 which recognizes the amino acids 1-16 in the Aβ 
peptide.  Ab9 was diluted (1:1000) into sample diluent [20 mM Tris pH 7.3, 150mM 
NaCl, 0.1% BSA, 0.05% Tween 20].  The grids were treated with the diluted Ab 9 
preparation with the sample side down and incubated for 1 hour at room temperature, 
followed by wash with water thrice.  This was followed by treatment with secondary 
antibody which is a solution of goat-anti mouse IgG conjugated to gold particles [Aurion 
Cat #25129] diluted 1:1000 into sample diluent.  Incubation with conjugated gold 
particles was also done at room temperature with the sample side down.  The grids were 
washed thrice with water and treated with 2% uranyl acetate solution for 5-10 minutes, 
excess solution removed and the grids were air dried. The affixed samples were 
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visualized with a JEOL JEM-2000 FX transmission electron microscope operated at 100 
– 200 k eV (Yagi et al., 2005, Vicente et al., 2006)  
 
2.10 Cell Culture 
 
2.10.1 THP-1 Monocytes 
 
THP-1 cells are cultured from the blood of patient with acute monocytic 
leukemia, and have distinct monocytic markers.  During culture these cells can maintain 
the monocytic characteristics for over 14 months (Tsuchiya et al., 1980).  THP-1 cells 
were obtained from ATCC (Manassas, VA) and stored as 1 ml aliquots in liquid nitrogen 
until they are required for culturing.  The cells were maintained in RPMI-1640 culture 
medium (HyClone, Logan, UT) containing 2 mM L-glutamine, 25 mM HEPES, 1.5 g/L 
sodium bicarbonate, 10% fetal bovine serum (HyClone), 50 U/ml penicillin, 50 g/ml 
streptomycin (HyClone), and 50 M -mercaptoethanol at 37oC in 5% CO2.  Prior to 
experiments, THP-1 monocytes were centrifuged, and the pellet was resuspended in 
reduced FBS (2%) growth medium (assay medium) followed by centrifugation as 
mentioned above.  Once again pellet was resuspended in assay medium, and cell 
concentrations were adjusted to 1.0 x 10
6
 cells/ml.  The cell concentrations were adjusted 
by counting using a hemocytometer.  Depending on the protocol the THP-1 cells (0.255 
ml) was added to individual wells of a 48-well sterile culture plate the final volume in the 
well was 0.3 ml.  The Aβ sample (45 µl) and other effectors were added to the wells and 
incubated at 37C for 6 or 24 hours as per experiment protocol.  For 96-well sterile 
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culture plate 12 µl Aβ sample was added to individual wells containing 0.068ml cells.  
The contents of each well were removed, centrifuged at 2500g for 10 min, and the 
supernatant was frozen at −20°C for subsequent TNF-α measurements by ELISA 
(Enzyme Linked Immunosorbant Assay). 
 
2.10.2 Determination of TNF levels by ELISA 
 
TNF levels were measured by using a sandwich enzyme linked immunosorbant 
assay as described previously in (Udan et al., 2008).  Prior to the experiment, 100 l of 4 
g/ml monoclonal anti-human TNF/TNFSF1A capture antibody (R&D Systems, 
Minneapolis, MN) was added to 96-well plates and incubated overnight at room 
temperature.  Wells were washed with PBS (HyClone) containing 0.05% Tween-20 and 
blocked with 300 l PBS containing 1% BSA, 5% Sucrose and 0.05% NaN3 for an hour 
at room temperature.  After washing, 50 l of sample diluent (20 mM Tris containing 
150mM NaCl, 0.1% BSA and 0.05% Tween 20) was added to the wells.  This was 
followed by addition of 50 l samples, human TNF-α standards, and incubated at room 
temperature for 2 hours.  Following the incubation plates were washed three times, and 
the wells were next treated with 100 l biotinylated polyclonal anti-human TNF-
/TNFSF1A detection antibody (R&D Systems) in 20mM Tris with 150 mM NaCl and 
0.1% BSA (2 hours at room temperature).  In the next step, 100 L streptavidin-HRP 
(R&D Systems) diluted 200 times with PBS containing 1% BSA was added and 
incubated for 20 minutes at room temperature.  The wells were washed as described 
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above followed by addition of substrate which was 100 l of equal volumes of 3,3',5,5'-
tetramethylbenzidine and hydrogen peroxide (KPL, Gaithersburg, MD) for 30 minutes.  
The reaction was stopped by the addition of 1% H2SO4 solution.  The optical density of 
each sample was analyzed at 450nm with a reference reading at 540 nm using a 
SpectraMax 340 absorbance plate reader (Molecular Devices, Union City, CA).  A 
standard curve was constructed by sequential dilution of a TNF- standard from 15-2000 
pg/ml.  The concentration of TNF- in the experimental samples were calculated from a 
TNF- standard curve and the TNF- levels were normalized by dividing it with the 
number of cells plated. 
 
 
2.10.3 Test for Contamination by Lipopolysaccharide (LPS) 
  
Contamination of samples with bacterial lipopolysaccharide (LPS), can give rise 
to increased signals from the cells.  In order to rule out any contamination, and confirm 
that the proinflammatory signal was not due to LPS contamination, we added polymyxin 
B sulfate PMX-B (Sigma) to the samples.  PMX-B is known to neutralize the 
pathogenecity of LPS and can be used to detect any trace levels of contaminating LPS in 
the Aβ(1-42) aggregation preparations (Pristovsek and Kidric, 1999).  THP-1 cells were 
prepared as described above, and plated on 48-well culture plate or 96 well plate.  Cells 
were pretreated with 0.1 µg/ml PMX-B and incubated for 30 minutes at 37C, 5% CO2.  
Following incubation with PMX-B, the cells were treated with 10 ng/ml ultra pure LPS 
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or Aβ(1-42) (final concentration 15 µM) and incubated for 6 hours at 37C.  The cell 
supernatants were collected, and stored at −20°C and analysed for TNFα levels. 
 
2.10.4 Monocyte Adhesion Studies 
 
2.10.4.1 Cell adhesion assay 
THP-1 monocytes were prepared in reduced FBS growth medium prior to the start 
of the experiment. THP-1 cells were centrifuged and resuspended in reduced FBS (2%) 
growth medium, and 0.204 ml was added to individual wells of a 48-well sterile culture 
plate.  Cell adhesion was induced as described in (Crouse et al., 2009), by direct addition 
of 10 ng/ml phorbol 12-myristate 13-acetate (PMA) (Sigma) or 15 μM Aβ peptides to 
THP-1 cells.  Controls were 0.0005% DMSO for PMA and sterile water for Aβ 
respectively.  Cells were treated with the effectors and incubated at 37°C for 6 hours.  
After the incubation period, the medium that contains non-adherent cells were removed 
from the wells.  The wells were washed with 200 µl of phosphate buffered saline (PBS) 
and wash was collected.  The cells that adhered to the plate were washed with phosphate 
buffered saline (PBS, Hyclone).  The adherent cells were then removed with 0.25% 
trypsin-EDTA (HyClone), and counted under a microscope using a standard 
hemocytometer.  Percent adhesion was determined by the adherent cell number divided 
by the plated cell number.  We also coated the surface of 48-well cell culture plates with 
human fibronectin (Fn) (Sigma).  Surface coating was done by addition of 0.1 ml per well 
of 50 μg/mL Fn in sterile PBS and incubation for 1 hr at 25°C.  The plate was covered 
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and stored at 4°C until needed for an experiment.  Before the addition of cells, the excess 
Fn solution was aspirated from the wells. 
 
2.10.5 XTT Cell Viability Assay 
 Cell viability was monitored using an XTT (2, 3-bis (2-methoxy-4-nitro-5-
sulfophenyl) -2H-tetrazolium-5-carboxanilide) cell assay.  XTT is a tetrazolium salt, and 
is used to measure the cell metabolism of viable cells (Braeckman et al., 2002).  The 
assay is based on the reduction of the colorless XTT tetrazolium salt within the 
mitochondria of living cells by the enzyme succinate dehydrogenase to form an orange-
colored water-soluble formazan.  A stock solution of XTT (Sigma) 1mg/ml was prepared 
in RPMI 1640 without phenol red (Hyclone) supplemented with 2 mM L-glutamine and 
stored at -20°C.  Cells were treated with Aβ for 6 hours or 24 hours followed by further 
incubation with final concentrations of 0.33 mg/ml XTT and 8.3 µM phenazine 
methosulfate (PMS) (Acros, Morris Plains, NJ) for 3 hours at 37C.  Cell supernatants 
were removed from individual wells after incubation and centrifuged at 5000 rpm for 10 
minutes.  Supernatants were transferred to a fresh 96 well plate.  The XTT reduction by 
viable cells was determined by absorbance measurements of the reduced form of XTT at 
467 nm. 
 
2.11 Fast Pressure Liquid Chromatography (FPLC) 
 The AKTA FPLC is a type of liquid chromatography where the solvent velocity is 
controlled by pumps to control the constant flow rate of solvents.  The standard FPLC 
consist of one or two high-precision pumps, a control unit, a column, a detection system 
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(UV spectrophotometer) and a fraction collector.  AKTA FPLC is controlled through 
UNICORN software, which actually controls the run and offers a number of options such 
as automatic detection and collection of peak fractions.  The Superdex 75 HR column 
was pretreated with 2 mg/ml BSA in running buffer to block non specific binding of A 
aggregation species to the resin.  The column was equilibrated with running buffer.  The 
A preparation was loaded and eluted from a Superdex 75 HR 10/30 column (GE 
Healthcare) in 50 mM Tris-HCl (pH 8.0) at a flow rate of 0.5 ml/min.  Monomeric 
fractions were isolated by size-exclusion chromatography (SEC).  Concentrations of 
monomeric Aβ isolated from the SEC elution fractions were determined by absorbance 
using an extinction coefficient of 1450 cm
-1
 M
-1
 at 276 nm for Aβ(1-40) as previously 
described (Nichols et al., 2002).  The percentage recovery of the monomer concentration 
from the column can be calculated by dividing it by the preload concentration of Aβ.  The 
purified monomer fractions were used to initiate aggregation the aggregation reactions.  
At the appropriate aggregation time point THP-1 cells were treated with the aggregated 
fractions for 6 hours and the cell supernatants were tested for TNF-α production.  SEC 
was also used to separate Aβ(1-42) aggregation species.  Aβ(1-42) solutions (100 µM) 
were allowed to aggregate at 4C for 96 hours, centrifuged for 10 minutes at 18,000 x g, 
and supernatants were loaded on the column.  The fractions were treated with THP-1 
monocytes to test for TNF α level.  Morphology studies were done using AFM and TEM. 
 
2.12 Thioflavin-T Fluorescence Assay 
Thioflavin-T (ThT) is a benzothiazole salt obtained by the methylation of 
dehydrothiotoluidine with methanol in the presence of hydrochloric acid.  ThT  
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Fig 2.1 Structure of Thioflavin T. 
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 fluorescence intensity is enhanced when bound to enriched β-sheet structure found in 
amyloid fibrils.  This provides a simple fluorometric method for following Aβ  
aggregation in prepared samples.  The dye undergoes a characteristic 120 nm red shift of 
its excitation spectrum that may be selectively excited at 450 nm, resulting in a 
fluorescence maximum at 482 nm.  The excitation and emission slits of 10 nm were used 
and all measuremensts were made at room temperature.  The fluorescence intensity was 
monitored by excitation at 450nm and emission scan from 460-520nm using a Cary 
Eclipse fluorescence spectrophotometer (Naiki et al., 1989, LeVine, 1993).  Aβ 
aggregation solutions were monitored by thioflavin T (ThT) fluorescence as described in 
(Nichols et al., 2005).  Aβ aliquots were removed and diluted 10 fold into water, PBS 
(pH 7.4), or 50 mM Tris (pH 8.0), or 150mM glycine buffer (pH 8.0) containing 5 µM 
ThT.  The scans were integrated from 470-500 nm to obtain ThT fluorescence values. 
 
2.13 Centrifugation of Aβ Aggregation Solutions to Test Solubility  
of Aggregation Species 
 
2.13.1 Centrifugation at 18k, 50k, 100 k and 150 k x g 
Microfuge
R 
18 centrifuge, Beckman Coulter
TM 
was moved to 4C prior to 
spinning the samples.  Aβ(1-42) aggregation solutions were spun for 15 minutes at 
18,000 g or 14,000 g as per the experiment protocol.  The spun supernatants were treated 
with THP-1 cells to test for TNFα secretion.  Aliquots were removed for AFM and dot 
blot as per the experiment protocol. The solubility of Aβ(1-42) aggregation species were 
also tested by high speed ultracentrifugation.  Initial centrifugation at 50,000 x g was 
 90 
done in Sorvall RC 5B plus refrigerated centrifuge using SS-34 rotor.  Since we were 
working with small sample volumes (100 µl), adaptors were used.  Aβ(1-42) aggregation 
solutions were placed in 1.5 ml eppendorf tubes which were in turn placed in adaptors 
that fit into the SS-34 rotor.  The samples were spun for an hour at 50,000 x g, 
supernatants were collected,and treated with THP-1 cells to measure the proinflammatory 
response.  Simultaneously, samples were diluted to 1µM and applied to mica grids for 
AFM image analysis.  For centrifugation at higher speeds, a refrigerated Beckman 
Coulter Optima Max ultracentrifuge with TLA-120 rotor was used.  The samples were 
placed in polycarbonate Beckman centrifuge tubes and centrifuged for an hour at 50 k, 
100 k, or 150 k x g as per the experiment protocol.  The centrifugation supernatants were 
collected and treated with THP-1 monocytes as described above and the supernatants 
were tested for TNF-α secretion. 
 
2.13.2 Centrifugation with Centrifugation Filter Devices  
 
Two types of microcentrifugal devices , YM-50 with a nominal molecular weight 
limit (NMWL) of 50,000 Daltons, and YM-100 with a NMWL of  100,000 Daltons were 
used.  The filter device has a sample reservoir that fits into a vial.  The membranes used 
in the micron filters are anisotrophic, hydrophillic, and has the ability to retain molecules 
above a specified molecular weight.  Aβ aggregation solution was pippeted into the 
sample reservoir without touching the membrane with the pipette tip.  The assembly was 
placed in Microfuge
R 
18 centrifuge, Beckman Coulter
TM 
and spun for 15
 
minutes at 
14,000 g.  After the run the vial containing the filtrate is seperated from the sample 
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reservoir.  The sample reservoir was turned upside down into a new vial and then spun 
for 3 minutes at 1000 x g to transfer the retentate into the vial. The supernatant and 
retentate were treated with THP-1 monocytes for 6 hours. The cell supernatants were 
tested for TNF-α response.  Simultaneously, an aliquot was diluted to 1µM concentration 
for AFM imaging. We also used centrifugal filter devices with 0.2µm pore size 
(Millipore Cat # UFC30LG25).  Aβ(1-42) was reconstituted in water and allowed to 
aggregate for 96 hours at 4C.  An aliquot was placed into the filter cup and centrifuged 
for 3 minutes at 12,000 x g, the filtrate was collected and treated with cells. AFM image 
analysis, Bradford assay was done with the filtrate and compared to that of the Total 
(unspun sample). 
 
2.14 Dynamic Light Scattering (DLS) 
 
Light scattering is useful in characterizing macromolecules and colloids.  This 
technique can be divided into two: Static light scattering and dynamic light scattering 
(DLS).  Static light scattering measures the time averaged intensities of the light scattered 
from a solution of particles and dynamic light scattering which measures the fluctuations 
of intensities of the scattered light.  Using these techniques one can obtain the weight 
average molecular weight and the radius of gyration from the total intensity (static light 
scattering) and the hydrodynamic (Stokes) radius (RH) from DLS (Bloomfield, 2000). 
In solution the macromolecules are buffered by the solvent molecules, and the 
molecules are in random motion called the Brownian motion.  As light scatters from the 
moving macromolecules, this motion imparts randomness to the phase of the scattered 
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light.  This leads to time-dependent fluctuations in the intensity of the scattered light.  In 
DLS the time-dependent fluctuations are measured by a fast photon counter.  The 
fluctuations are directly related to the rate of diffusion of the molecule through the 
solvent, and can be used to analyze the RH for the sample  
 DynaPro Titan Instrument (Wyatt Technology, Santa Barbara, CA) was used to 
make the RH measurements.  Aβ samples (30 µl) were spun at 18,000 x g for 10 minutes 
and supernatant was placed directly into a quartz cuvette.  The light scattering intensity 
was collected at 90 angle using a 10-second acquisition time.  Particle diffusion 
coefficients were calculated from auto-correlated light intensity data and converted into 
RH with Stokes-Einstein equation.  Histograms of percent mass vs. RH were generated 
using the Dynamics software (version 6.7.1).  The RH values were calculated from the 
histogram. 
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CHAPTER 3 
 
CORRELATION OF Aβ AGGREGATION STATE WITH ABILITY TO INDUCE 
PROINFLAMMATORY RESPONSE IN HUMAN THP-1 MONOCYTIC CELL 
MODEL SYSTEM 
 
3.1 Introduction 
AD is the most frequent form of senile dementia, and is characterized by 
extracellular senile plaques, and intracellular neurofibrillary tangles.  The extracellular 
plaques consist primarily of aggregated amyloid beta (Aβ), a 40-42 amino acid peptide 
derived by the proteolysis of amyloid precursor protein (APP).  Although only two amino 
acids longer, Aβ(1-42) polymerizes into amyloid fibrils more rapidly than the 
biologically abundant Aβ(1-40) form of the peptide (Jarrett et al., 1993b, Harper et al., 
1997a).  In addition to deposition of Aβ peptides into extracellular plaques, there is also 
evidence for the presence of intracellular Aβ that is believed to be initially involved in the 
disease process (LaFerla et al., 2007).  In vitro studies have shown that Aβ monomer will 
undergo non-covalent self-assembly to form a mixture of diverse Aβ assemblies that 
ultimately form insoluble fibrils (Harper et al., 1997b, Walsh et al., 1997, Harper et al., 
1999).  It is assumed that the same aggregation process occurs in vivo, and these wide 
ranges of morphologies appear to stimulate different types of biological responses in 
vivo.  Cell culture studies have demonstrated the neurotoxicity of Aβ fibrils (Pike et al., 
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1993, Lorenzo and Yankner, 1994, Seilheimer et al., 1997).  Recent studies now suggest 
that soluble oligomeric Aβ species may be more potent than the mature fibrils (Lambert 
et al., 1998, Hartley et al., 1999, Walsh et al., 2005).  Furthermore, a strong positive 
correlation has been demonstrated between soluble oligomeric Aβ and severity of 
dementia in humans (Lue et al., 1999). 
 One of the proposed mechanisms underlying progressive neurodegeneration in AD 
is a chronic inflammatory response to aggregated A involving production of toxic 
cytokines such as tumor necrosis factor alpha (TNF).  Pathology studies have shown the 
presence of inflammatory markers like activated microglia and proinflammatory 
cytokines surrounding the Aβ lesions in the human AD brain (McGeer et al., 1987).  
TNF is a crucial mediator of the inflammatory response.  Overexpression of TNF in 
the central nervous system of transgenic mouse models results in inflammation of the 
CNS and neurodegeneration (Probert et al., 1995).  In vitro studies have shown that 
TNF stimulation of neuronal cell lines leads to increased expression of inducible nitric 
oxide synthase that leads to apoptosis (Heneka et al., 1999).  TNF levels are elevated in 
the post mortem AD brain sections (Dickson et al., 1993) and micro vessels compared to 
non AD micro vessels (Grammas and Ovase, 2001).  TNFα levels are also significantly 
elevated in the cerebrospinal fluid (CSF) of clinically diagnosed AD patients (Tarkowski 
et al., 2003).  These findings suggest TNF levels as a valuable marker for 
proinflammatory response. 
 Though there are several A lesions, not all of them have surrounding 
inflammatory pathology (Walsh and Selkoe, 2007).  The exact mechanism by which A 
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causes neurodegeneration is still not clear.  Understanding the molecular structure of 
amyloid fibrils has attracted tremendous attraction over the past several years.  These 
studies have shed light on issues such as the nature of the intermolecular interactions that 
stabilize amyloid structures (Tycko, 2004).  Moreover, in vitro aggregation studies have 
provided useful information regarding fibrillogenesis mechanisms.  These studies have 
provided information about the various A species that are formed along the aggregation 
pathway, and how they vary in size, length, solubility and morphology (Harper et al., 
1997b, Walsh et al., 1997, Harper et al., 1999, Walsh et al., 1999, Stine et al., 2003).  
Further characterization of A aggregation species will therefore enable identification of 
the particular A assembly state that triggers the inflammatory mechanisms in AD. 
 Our objective in this study was to investigate the A structure-function relationship 
through modulation of Aβ aggregation conditions by varying several factors including 
peptide concentration, peptide length and temperature.  Synthetic Aβ peptides. were used, 
and characterization of the aggregation species were done using biophysical and 
biochemical techniques in an effort to identify the Aβ assembly state that induces 
maximum proinflammatory response in human THP-1 cell line.  Our data indicate that an 
intermediate fibrillar oligomeric aggregation species is optimal for inducing maximum 
proinflammatory response in THP-1 immune cell model system.  These data will provide 
additional information towards understanding the relationship between inflammation and 
AD.  The data from this study will subsequently provide clues to the development of 
therapeutic strategies to treat AD patients.  This work was done in collaboration with 
Maria Udan, University of Missouri, Saint Louis. 
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3.2 Cell Model System for Inflammatory Studies 
 
THP-1 human monocyte cells were used as a model system to study the 
proinflammatory response. THP-1 cells attain a microglia-like morphology when treated 
with lipopolysaccharide (LPS), a bacterial toxin (Yates et al., 2000), and hence, serves as 
a model of primary human microglial cells.  Human microglial cells are very difficult to 
obtain in large quantities, while the THP-1 cells are easy to grow and can be obtained in 
large quantities.  Previous studies have shown that both LPS and Aβ are capable of 
activating THP-1 cells, and stimulate cytokine production (Klegeris et al., 1997, Yates et 
al., 2000, Combs et al., 2001). 
 
3.3 Probing Aβ Aggregation State that Induces Maximum 
Proinflamamtory Response 
 
3.3.1  TNFα Production is Influenced by Aβ(1-42) Aggregation State 
 
Deposition of Aβ(1-40) and Aβ(1-42) peptides in the form of senile plaques is a 
neuropathological hallmark of AD.  Aβ(1-42) in the fibrillar form is abundant in the 
senile plaques.  Aβ(1-40) also has the tendency to form fibrils, but to a lesser extent 
(Iwatsubo et al., 1994).  We wanted to test the ability of Aβ(1-42) to stimulate the THP-1 
cells for proinflammatory response.  Aβ(1-42) forms aggregates very quickly and hence it 
was important to control the rate of aggregation in order to study the various species 
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along the fibril formation pathway.  The initial phase of Aβ(1-42) oligomerization 
involves the formation of pentamer units, hexamer units, and paranuclei.  These associate 
to form large oligomers and protofibrils that elongate to form mature fibrils (Bitan et al., 
2003)  
In our initial studies, Aβ(1-42) reconstituted in DMSO was used and aggregation 
reactions were followed by ThT fluorescence measurements.  Though ThT fluorescence 
values confirmed the progress of aggregation, there was inconsistency in the biological 
activity.  Some Aβ(1-42) preparations in DMSO were able to induce considerable activity 
while the others did not (data not shown).  A different protocol capable of generating 
monomeric starting material was employed.  The commercially available Aβ(1-42) 
peptide was treated with HFIP, vacuum centrifuged and stored as described in Methods.  
Aβ(1-42) aggregation reactions were set up by reconstituting the vacuum centrifuged 
peptide film in sterile water to a concentration of 100 µM and incubated at 4C.  Aliquots 
were removed periodically at 48, 72, 96, 120, 144, 168, 192 and 216 hours and treated 
with THP-1 monocytes with cell concentration of 1 x10
6
 cells/ml for 6 hours as described 
in Methods. The cell supernatants were tested for the ability to stimulate TNF 
production.  We observed that freshly reconstituted Aβ(1-42) induced secretion of very 
small amounts of TNF.  The TNF levels in the freshly reconstituted Aβ(1-42) varied 
amongst trials, but the levels were consistently low. However, we found a significant 
increase in TNF levels at the intermediate time points (48-72hours) of the aggregation 
reaction (Fig 3.1). Continued aggregation at 4C showed a decrease in the 
proinflammatory response after 96 hours, and the signal diminished by 216 hours (Fig 
3.1).  
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Figure 3.1 Proinflammatory activity of Aβ(1-42).  Aβ(1-42) was reconstitued in water 
to a concentration of 100 μM and stored at 4oC, as described in the Methods. THP-1 
monocytes were incubated with Aβ(1-42) to a final concentration of 15 μM.  Aliquots 
were removed immediately after reconstitution, and at 48, 96 and 216 hours of incubation 
at 4
o
C, treated with THP-1 cells, incubated for 6 hours at 37
o
C, 5% CO2. After 6 hours 
incubation, supernatants were collected and TNFα production was measured by ELISA.  
Each line in the figure corresponds to a separate experiment.  The peak response lies 
between 48-96 hours of aggregation at 4
o
C.  Courtesy Maria Udan, University of 
Missouri, Saint Louis. 
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The data from multiple experiments led us to hypothesize that an intermediate 
aggregation species may be responsible for inducing TNF production in THP-1 
monocytes. 
 
3.3.2 An Intermediate Aggregation State Induces Maximum 
Proinflammatory Response 
  The morphology of the aggregation species was studied using AFM.  Analysis of 
Aβ(1-42) aggregation time course was done in order to correlate the morphology with 
ability to induce TNF production in THP-1 cells.  As reported earlier (Udan et al., 
2008), we noticed small punctuate species with heights < 2 nm immediately upon 
reconstitution of Aβ(1-42) (Fig 3.2, zero hour). Dynamic light scattering (DLS) 
measurements of the freshly reconstituted Aβ(1-42) showed a major peak with an RH of 
1.0 nm.  This peak (95% mass) represents the monomeric Aβ and ensures that the starting 
material is monomeric.  AFM imaging of the aggregation reaction showed presence of 
flexible fibrillar structures by 48 hours (Fig 3.2).  These intermediate fibrillar structures 
correlated with maximal TNF production by THP-1 cells.  Height analyses of the fibers 
were done using the Nanoscope software as described in the Methods.  The fibers formed 
after 48 hours of aggregation have a mean height and standard deviation (SD) of 4.2 +/- 
1.4 nm.  The lengths of the fibers ranged from 1-3 µm.  Height analyses of the fibers 
made at corresponding time points of cell treatment indicate no significant change in the 
heights of the fibers as the aggregation proceeds from 48 hours to 216 hours.  The fibers 
formed at 216 hours time point had a mean height of 4.5 +/- 1.4 nm.  However, the length 
of the fibrils changed as the aggregation proceeds, especially fibers formed by 216 hours 
0 h 
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Figure 3.2. Morphology analyses of Aβ(1-42) aggregation species by AFM.  Aβ(1-
42) aggregation solutions (100 μM) in water was prepared as described in Methods, 
and allowed to aggregate at 4
o
C.  Aliquots were removed at 0, 48, 96 and 216 hours, 
diluted to 1 μM with water and applied on to mica grids as described in Methods, and 
imaged by AFM. Image panels are 5μm x 5μm and are shown in „height‟ mode.  The 
heights were measured using the Nanoscope III soft ware.  
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 of incubation (< 3 µm). There was a significant difference in the density of fibers.  The 
calculated values of the density of fibers are 1 fiber/µm
2 
at 48 hours of incubation and 6 
fibers/µm
2
 at 216 hours of incubation. ThT fluorescence measurements of the 
aggregation reactions were made in order to monitor the progression of the aggregation in 
the reactions as mentioned in Methods.  Measurements at the zero hour time point of  
Aβ(1-42) solution showed no ThT fluorescence, indicating absence of aggregated 
structures with β-sheet at the time of reconstitution.  ThT fluorescence intensity increased 
as the aggregation progressed indicating formation of β-sheet structures, and by 216 
hours of incubation there was nearly 25 fold increase in the fluorescence intensities 
compared to the values at start of the reaction (Fig 3.3). This correlates with the AFM 
images that show formation of increased fibrillar structures by 216 hours (Fig 3.2).  
 
3.4 Modulation of Aggregation Reaction Conditions 
 
 Aggregation of Aβ proceeds by a multistep, nucleation-dependent, process (Jarrett 
et al., 1993a).  In the absence of preformed fibril seed there is a significant lag period for 
the formation of Aβ fibrils.  Once the seeds are generated, there is rapid fibril elongation 
phase.  The lag time for the fibrils can be shortened by the addition of preformed fibril 
seeds to monomer solutions (Jarrett et al., 1993a).  The rate of Aβ fibril formation is 
controlled by both fibril seed concentration and monomer concentration (Naiki and 
Nakakuki, 1996).  Aβ aggregation is also dependent on temperature (Harper et al., 1999) 
and pH (Wood et al., 1996).  The calculated pI of Aβ is 5.5, and rapid aggregation of this 
peptide at pH 5.5-6.0 may be mediated by non-specific interactions of the highly 
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Figure 3.3.  ThT fluorescence scans of Aβ(1-42) aggregation time course. Each plot 
represents a separate 100 µM Aβ(1-42) aggregation reaction.  Aβ(1-42) aggregation 
reactions (100 µM) in sterile water, and incubated at 4C as described in Methods.  At 
specific time points aliquots of Aβ(1-42) aggregation solutions were removed and mixed 
with ThT diluted into water (5 µM) in a cuvette (final Aβ concentration 10 µM). ThT 
fluorescence was measured as described in Methods.  
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 hydrophobic neutral molecules (Wood et al., 1996).  In order to study the intermediates 
in the slow and controlled aggregation pathway, Aβ aggregation must occur outside of 
this rapid aggregation pH range.  Small changes in the organelle pH, or the peptide 
secretion rates might control the efficiency of fibril formation in vivo (Wood et al., 1996). 
 
3.4.1 Increased Peptide Concentration Diminishes the Proinflammatory Signal 
 
  In Fig 3.1, we have seen that Aβ(1-42) aggregation species formed at the later time 
points were not effective in inducing a proinflammatory response, suggesting that 
continued aggregation diminishes the response.  We increased the peptide concentration 
by 12 fold in order to increase the aggregation kinetics so that the lag time for nucleation 
is shortened.  This step will cause rapid polymerization and fibril formation.  The more 
concentrated solution of Aβ(1-42) (1.2 mM) was incubated at 25 C and the cells were 
treated with the same final concentration of 15µM of Aβ(1-42).  The Aβ(1-42) solution at 
zero hour was able to induce a very small level of TNF.  However, there was no 
induction of proinflammatory response at 24 hours and 48 hours even though the cells 
were treated with the same final concentration of 15 µM Aβ (Fig 3.4 A).  The results 
were very different from the 100 µM preparation wherein we were able to see the peak 
response at 48 hours.  AFM imaging of the concentrated samples showed the formation 
of small fibrillar structures at the time of reconstitution (Fig 3.4 B) and by 24 hours there 
was rapid fiber formation.  Height analyses of the concentrated Aβ(1-42) fibers were not 
possible due to severe overlapping of fibers.  However, the density was calculated to be 6  
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Figure 3.4. Increase in Aβ(1-42) peptide concentration decreases TNF-α signal 
Panel A. Two Aβ(1-42) aggregation reactions were set up.  Aβ(1-42), 100 µM (triangles) 
was incubated at 4
oC, and the concentrated Aβ(1-42) 1.2 mM (circles), was incubated at 
25
o
C.  At specific time points aliquots were removed from the two samples and treated 
with THP-1 cells with final Aβ concentration of 15 µM.  Courtesy Maria Udan.  Panel B-
C. Representative AFM images of the concentrated 1.2 mM Aβ(1-42) sample.  At 
specific time points aliquots were removed and diluted to final concentration of 1 µM and 
applied to grids as described in Methods. B. Aβ(1-42), 1.2 mM sample aliquot taken 
shortly after reconstitution and C, Aβ(1-42), 1.2 mM sample after 24 hours incubation at 
25
o
C. 
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Figure 3.5 Concentrated peptide solutions show high ThT fluorescence.  Two 
lyophilized aliquots of Aβ(1-42) were reconstituted to 0.1 mM incubated at 4C (circles) 
or 1.2 mM incubated at room temperature (diamonds).  ThT fluorescence was measured 
at different time points by mixing Aβ(1-42) (10 µM) with ThT (5 µM) as described in 
Methods. 
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 fibers per square micron after 24 hours incubation.  This was comparable to the fiber 
density at 216 hours aggregation of Aβ(1-42) (100 µM).  We have already seen from Fig 
3.1 that the 216 hour sample with the same density of fibers did not stimulate the cells for 
a response.  It is possible that an increase in the peptide concentration caused rapid 
aggregation so that the transient intermediate species were either not formed, or were 
immediately converted into the higher aggregated form. ThT fluorescence measurements 
were 10 times higher in the 1.2 mM solutions than in the 100 µM solutions indicating 
rapid formation of β-sheet structures in the 1.2 mM sample compared to the less 
concentrated peptide solution (Fig 3.5). 
 
3.4.2 Incubation of Aβ(1-42) at Higher Temperatures Diminishes  
Proinflammatory Response 
 
 Previous studies have shown that elongation rates of Aβ fibrils vary dramatically 
with temperature (Kusumoto et al., 1998).  The aggregation rate of 100 µM sample was 
accelerated by incubation at higher temperatures.  Three aggregation reactions of 100 µM 
Aβ(1-42) were prepared and incubated at 4C, 25C, or 37C.  Aliquots were taken from 
the reactions, treated with cells at final Aβ(1-42) concentration of 15 µM, and tested for 
ability to induce proinflammatory response.  Only the reaction set up at 4C stimulated 
the cells for a response, while the reactions set up at 25C or 37C significantly 
diminished the ability to stimulate THP-1 cells for TNFα production (Fig 3.6 A).  The 
aggregation reactions were monitored by ThT fluorescence measurements (Fig 3.6 B).  
ThT fluorescence values were high for the aggregation at 37C with a peak at 96 hour  
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Figure 3.6 Incubation at higher temperatures accelerates aggregation, but 
diminishes proinflammatory activity. Panel A.  A solution of Aβ(1-42), 100 µM was 
separated into three tubes and incubated at three different temperatures 4
o
C (circles), 
25
o
C (triangles) and 37
o
C (diamonds).  At various time points aliquots were removed for 
treatment with THP-1 monocytes. Secreted TNFα measurements for each time point were 
determined by ELISA.  Courtesy Maria Udan. Panel B. ThT fluorescence measurements 
were made at specific time points as described in Figure 3.3. 
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time point.  The ThT fluorescence values did not correlate with TNFα levels.  In Fig 3.6 
(Panel B) the highest ThT fluorescence intensities were recorded for the sample 
incubated at 37C.  However, the same sample did not stimulate the cells for high TNFα 
secretion.  AFM images of the aggregation time course showed differences in the extent 
of aggregation.  The peak TNFα response form the cells was at 96 hours, hence, we 
obtained the height analyses of the fibrils incubated at different temperature for this time 
point.  The images of Aβ(1-42) at 4C contained long flexible fiber structures with a 
mean height of 5.5 +/- 1.6 nm (SD) along with the globular species (Fig 3.7 E).  The 
sample at 25C displayed increased number of fibers with a mean height of 6.9 +/- 2.1 
nm.  There was disparity in the measured fibrils heights.  Also, there was an increase in 
fibers with height < 5 nm (Fig 3.7 F).  The AFM image of sample incubated at 37C 
showed less number of fibrils, and the average height of the fibrils were 6.1+/- 1.6 nm 
(Fig 3.7 G).  The heights were not very different from the 25C aggregation reaction.  
However, the striking feature was the absence of globular species.  The fibrils formed at 
37C had a twisted appearance, and shorter than the ones formed at the other two 
temperatures.  The decrease in the number of fibrils could possibly be due to decreased 
adsorption to the mica surface.  These data suggest that the proinflammatory response 
corresponded with the formation of the initial intermediate fibrillar structures of Aβ(1-42) 
solution that was incubated at 4C.  This finding was further strengthened by the 
observation that continued, accelerated, or increased fibril formation abolished the ability 
of Aβ(1-42) to stimulate the THP-1 monocytes to induce TNFα production. 
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Figure 3.7. Increasing the temperature of aggregation reactions failed to invoke 
TNFα response in THP-1 monocytes. 100 μM Aβ(1-42) was prepared in water (100 
µM), and incubated at 4
o
C, 25
o
C or 37
o
C. A-G. Representative AFM images of 
freshly prepared (A), 48 hours (B-D) or 96-hours (E-G) aggregation.  B and E are the 
images of Aβ(1-42) aggregation solution incubated at 4oC, (C and F) are images of 
25
o
C incubation, and (D and G) are images of 37
o
C incubation. Heights were 
determined using the Nanoscope software as described in Methods. 
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3.4.3 Proinflammatory Activity is Dependent on Peptide Length 
  
 Aβ is formed from APP by the action of α- β- γ- secretases.  The action of γ- 
secretases results in the formation of Aβ peptides of different fragments of 39-42 amino 
acids long (Selkoe, 2001).  Among the fragments formed, the most abundant is Aβ(1-40) 
fragment.  Among others, Aβ(25-35) fragment is the shortest peptide sequence that 
retains the biological activity comparable to Aβ(1-42) and exhibits β-sheet aggregated 
structures (Pike et al., 1995, D'Ursi et al., 2004).  Aβ-(25-35) is present in plaques and 
degenerating hippocampus neurons in the AD brains and not in age matched control 
subjects.  Aβ(25-35) has a high tendency to quickly assemble into insoluble aggregates 
(Clementi et al., 2005).  Our results so far indicate that Aβ(1-42) incubated at 4C formed 
a species that induces maximum proinflamamtory stimulus.  We wanted to test if length 
of the peptide is crucial for the proinflammatory stimulus.  Aβ(1-40), Aβ(25-35) peptide 
fragments were selected for the experiment and compared to the response from Aβ(1-42) 
under similar conditions.  Three separate reactions (100 µM) of these three peptides were 
set up and allowed to aggregate at 4C.  The aggregation reaction was monitored by 
making ThT fluorescence measurements at specific time points.  At specified time 
intervals the cells were treated separately with each of the three peptides and tested for  
TNFα production.  ThT measurements indicate that under similar conditions Aβ(1-40) 
and Aβ(25-35) did not aggregate as fast as the longer peptide Aβ(1-42) (Fig 3.8).  The 
supernatants from the THP-1 cells treatment indicated that only Aβ(1-42) aggregation 
solution incubated at 4C stimulated the cells and were consistent with our previous data. 
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Figure 3.8. Shorter Aβ peptide aggregates at a slower rate under similar 
conditions.  Three aggregation reactions were set up by reconstituting Aβ(1-42) 
(circles), Aβ(1-40) (squares) and Aβ-(25-35) (inverted triangles) in water to a 
concentration of 100 µM.  The aggregation reactions were allowed to incubate at 
4C.  At specific time points ThT fluorescence was measured by mixing Aβ (10 
µM) with ThT (5 µM) as described in Methods. 
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Aβ(1-40) and Aβ(25-35) aggregation reactions were not able to induce TNFα production 
in THP-1 cells under similar conditions (data not shown).  Therefore, to probe further we 
used Aβ(1-40) aggregation reactions set up at different temperatures.  Solutions of Aβ(1-
42) and Aβ(1-40) (100 µM) were prepared.  The Aβ(1-42) solution was incubated at 4C 
while Aβ(1-40) was incubated at 4C, 25C, or 37C.  THP-1 monocytes were treated 
with aliquots from the aggregation solutions with final Aβ concentration at 15 µM.  Only 
Aβ(1-42),aggregation reaction set up at 4C effectively stimulated the cells for TNFα 
production (Fig 3.9).  AFM (Fig 3.10) images indicate fibril formation by Aβ(1-40) 
sample incubated at the three different temperatures (Fig 3.10 A-C), but at a much slower 
rate compared to Aβ(1-42) (Fig 3.7 E-G).  Height analyses of these images indicate that 
fibrils were longer (> 5 µm) and only one or two fibrils could be located in a 5 µm x 5 
µm image panel.  The heights of these fibrils were slightly greater than Aβ(1-42) fibrils, 
measuring 5.9 +/- 1.7 nm (SD) at 96 hours (Fig 3.10 D).  There was very little change in 
the fibril heights from 96 hours to 216 hours, but they were slightly longer at 216 hours 
(Fig 3.10 G).  TEM images of the same Aβ(1-40) aggregation reactions also displayed 
fibril formation at the different temperatures (Fig 3.11).  Increased temperature resulted 
in the formation of large number of fibrils as seen in the AFM images, yet these 
aggregation species did not induce proinflammatory activity.  Aβ(1-40) and Aβ(1-42) 
oligomerize through different pathways (Bitan et al., 2003), and it is possible that Aβ(1-
42) with the extra two amino acids forms a distinct intermediate species that is able to 
stimulate a proinflammatory response.  AFM and TEM image analyses indicate the  
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Figure 3.9. Aβ(1-40) failed to induce proinflammatory activity on THP-1 cells.  
Aβ(1-40) (100 μM) was resuspended in sterile water, and incubated at 4oC (triangle), 
25
o
C (inverted triangle) and 37
o
C (diamond), as described in Methods. Aliquots from the 
respective aggregation solutions were used to treat the THP-1 monocytes to a final Aβ 
concentration of 15 μM for 6 hours; supernatants were collected and analyzed for TNFα 
production. Aβ(1-42) 100 μM incubated at 4oC was used as a control (circles).  Courtesy 
Maria Udan, Universit of Missouri, St-Louis. 
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Figure 3.10. Increased temperature induces formation of diverse fibrils, but fails to 
stimulate inflammatory response.  Aβ(1-40) (100 μM) was diluted to 1 μM and applied 
on the surface of freshly cleaved mica as described in Methods. The images shown above 
are representative AFM images of Aβ (1-40) samples. Panel 1 (A-C) are images after 48 
hours at 4
o
C (A), 25
o
C (B) and 37
o
C (C). Panel 2 (D-E) are images after 96 hours at 4
o
C 
(D), 25
o
C (E) and 37
o
C (F) and Panel 3 (G-H) images after 216 hours at 4
o
C (G), 25
o
C 
(H) AFM images panels are 5 μm x 5μm.  
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Figure 3.11. Aβ(1-40) forms diverse fibrils upon incubation at different 
temperatures. Representative TEM images of Aβ(1-40)) samples from the same 
experiment as mentioned in Figure 3.9.  Aβ(1-40) (100 µM) solutions were diluted to a 
concentration of 20 µM and applied to formvar coated copper grids as described in 
Methods. Panel 1 (A-C) are images after 48 hours at 4
o
C (A), 25
o
C (B) and 37
o
C (C). 
Panel 2 (D-E) are images after 96 hours incubation at 4
o
C (D), 25
o
C (E) and 37
o
C (F) 
and Panel 3 (G-E) images after 216 hours 4
o
C (G), 25
o
C (H) and 37
o
C (I). The scale 
bars represent 100 nm. 
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formation of different diverse fibrillar forms of Aβ(1-40), but none of these aggregation  
species were able to stimulate a proinflammatory response when treated with THP-1 
monocytes. 
 
3.4.4 Effect of pH, Ionic strength, and Buffer Type on Aβ(1-42) Aggregation and 
Proinflammatory Activity 
 
 The morphology of Aβ aggregation species alters under varying conditions of pH 
and ionic strength (Fraser et al., 1991, Harper et al., 1999).  Previous studies indicate that 
fibrillization of Aβ(1-40) in 0.1M HCl was highly reproducible, and was free from fibril-
fibril association (Lomakin et al., 1996).  The fibrils formed were also found to be 
morphologically indistinguishable from those formed in vivo (Lomakin et al., 1996).  In 
our experiments, pH measurements of Aβ(1-42) aqueous solutions in water were done 
using a microelectrode, and measured pH was 3.6.  Aggregation conditions were 
modulated by preparing Aβ(1-42) aggregation solution in the physiological pH 7.4.  We 
hypothesized that Aβ(1-42) at higher ionic strength and neutral pH will form different 
structures that may stimulate proinflammatory activity in a different way.  Aβ(1-42) was 
reconstituted in water (100 µM), and another preparation was made wherein Aβ(1-42) 
was reconstituted in 100 mM NaOH to a concentration of 2mM Aβ, followed by dilution 
into PBS to a final concentration of 100 µM.  The measured pH of the solution in PBS 
was 7.4.  The aggregation reactions were monitored by ThT fluorescence measurements.  
In all previous ThT fluorescence measurements, the aggregation of Aβ(1-42)/water 
solutions were monitored by ThT solution prepared in water which maintained the acidic 
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pH.  We followed this protocol inorder to rule out any change in Aβ morphology due to 
change in pH. The ThT values were very low and did not correlate with the 
corresponding AFM images of the same sample which showed formation of fibrils (data 
not shown).  However, we observed that the same Aβ(1-42)/water solution when mixed 
with ThT prepared in PBS (pH 7.4), or 50 mM Tris buffer (pH 8.0) had higher ThT 
fluorescence values compared to measurements made with ThT/water.  We analysed ThT 
fluorescence of an aggregated solution of Aβ(1-42)/water (100 µM), incubated at 4C for 
96 hours with ThT solutions prepared in water, 50 mM Tris buffer (pH 8.0) and 150 mM 
glycine buffer (pH 8.0) (Fig 3.12 ).  We observed that ThT prepared in glycine and Tris 
produced similar ThT fluorescence values that were significantly higher than ThT/water 
solution (Fig 3.12).  For subsequent experiments with Aβ(1-42)/water, ThT 
measurements were made with ThT prepared in Tris (pH 8.0) (Fig 3.13 A circles).  
Further investigations need to be done to probe the pH dependence of ThT fluorescence 
measurements.  The Aβ(1-42)/PBS solutions did not stimulate the THP-1 cells for TNFα 
production (Fig 3.13 B, triangles) compared to the aqueous Aβ(1-42) solution (Fig 3.13 B 
circles).  The PBS samples did not adhere to the mica discs for AFM imaging, 
therefore,TEM was used for morphology analyses.  TEM analyses of both preparations of 
Aβ(1-42) showed presence of fibrillar content (Fig 3.14). However, there were 
differences in the alignment of the fibrils.  The fibrils formed in the aqueous solutions 
were thin and were more or less isolated (Fig 3.14 A, C), while the fibrils formed by 
incubation in PBS showed lateral association (Fig 3.14 B, D).  Also, there was an 
increase in the number of fibrils in the PBS preparations.  This may be the reason for the 
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increase in ThT fluorescence values for the Aβ(1-42) solution in PBS (Fig 3.13, 
triangles). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 ThT fluorescence values were significantly higher at higher pH. Aβ(1-
42) was resuspended in water to a concentration of 100 µM and incubated at 4°C. After 
96 hours of incubation at 4°C, aliquots (7 µl) were removed from the aggregation 
solution and mixed  with (63µl) ThT solutions that were prepared in water, 50 mM Tris 
buffer (pH 8.0), and 150 mM Glycine buffer (pH 8.0). ThT fluorescence measurements 
were recorded as mentioned in the Methods 
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Figure 3.13. pH and ionic strength of aggregation solution influences rate of 
aggregation and Aβ(1-42) proinflammatory activity. Two lyophyllized Aβ(1-42) 
aliquots were reconstituted in either sterile water (circles) or 100 mM NaOH followed by 
dilution into sterile phosphate-buffered saline (PBS) (triangles) to a concentration of 100 
µM and incubated at 4°C.  (Panel A) ThT-fluorescence measurements for both Aβ(1-42) 
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solutions were made at specific time points as mentioned in the Methods.  (Panel B) At 
the above time points, aliquots from the two aggregation solutions were treated with 
THP-1 cells to a final concentration of 15 µM Aβ(1-42).  The secreted TNFα levels in 
cell supernatants were measured by ELISA.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14.  Modulation of pH and ionic strength results in formation of fibrils that 
diminish proinflammatory activity.  Two Aβ(1-42) aggregation solutions were 
prepared in either sterile water, or, in 100 mM NaOH followed by dilution into sterile 
phosphate-buffered saline (PBS) at a concentration of 100 µM and incubated at 4°C.  At 
specific time points aliquots were removed, diluted to 20 µM and applied on formvar 
coated grids as described in Methods. (Panel A) Aβ(1-42) in water after 48 hours and 
(Panel C) Aβ(1-42) 96 hours of incubation at 4C. (Panel B and D) Aβ(1-42) in PBS 
after 48 hours and 96 hours incubation at 4C.  The scale bar represents 100 nm. 
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3.5 Fibrils Formed in Aqueous Solutions are Soluble and Non Toxic to THP-1 Cells 
 
3.5.1 Test for Solubility of Proinflammatory Aggregation Species 
  
 The observations made from the aggregation modulation experiments confirm that 
Aβ(1-42) prepared in aqueous solutions and stored at 4C formed a species that 
stimulated the THP-1 monocytes for a proinflammatory response.  Our data also indicate 
that the proinflammatory activity diminished as the aggregation progressed (216 hours).  
The loss of stimulatory response was based on two assumptions.  One was the reasoning 
that the late stage fibrils precipitated out of the solution, and hence the loss of signal.  We 
tested the solubility of Aβ(1-42) aggregation species prepared in aqueous solutions at 
specified time points.  Aβ(1-42) was resuspended in water and an aliquot was separated 
and centrifuged at 18,000 x g for 10 minutes. The resultant supernatant and the unspun 
(total) sample were treated with cells to test for TNFα production as described in the 
Methods (Fig 3.15 A).  AFM images show that fibrils were present in the supernatant 
after centrifugation at 18,000 x g, indicating that fibrils do not precipitate out of solution 
even at the later time points of aggregation (Fig 3.15 B).  Insoluble fibrils will precipitate 
when spun at 18,000 x g.  Our findings confirm that fibrillar structures that stimulate the 
cells for proinflammatory response were soluble since the centrifugation supernatants 
were still able to activate the cells for a response (Fig 3.15 A). 
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Figure 3.15. Proinflammatory response is not affected by centrifugation of 
aggregation solutions at 18,000 x g.  (A) Aβ (1-42) solution (100 µM) were prepared in 
water and incubated at 4°C. At specific time points aliquots were removed, centrifuged at 
18,000 x g for 10 minutes at 4°C. The spun supernatant (inverted triangles) and unspun 
(total) (circles) were treated with THP-1 cells for 6 hours and TNFα measured in cell 
supernatants Courtesy Maria Udan.   At the same time points, aliquots were removed 
before and after centrifugation at 18,000 x g for 10 minutes, diluted to 1 μM, and imaged 
by AFM. Images are 5 μm x 5 μm. The AFM images above (B, C) correspond to total 
and spun supernatant sample after 96h, and (D, E) represent total and spun supernatant 
after 216 hour incubation at 4°C. 
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3.5.2 Test for Toxicity of Proinflammatory Aggregation Species 
  
 Toxicity of fibrils could be a reason for the loss of inflammatory response.  It was 
assumed that the fibrils, especially the ones formed in the later stages, were toxic to the 
cells.  We tested the toxicity of Aβ(1-42) prepared in aqueous solutions at the 
intermediate and the later time points using XTT assay.  The data indicates that the 
intermediate and the late stage fibrils are not toxic to the cells since the mitochondrial 
mediated reduction of XTT was not affected in both the samples (data not shown).   
 
3.6 Characterization of Aβ(1-42) Proinflammatory Species 
  
 The observations made from the above experiments indicate more clearly that 
when Aβ(1-42) prepared in aqueous solutions is incubated at 4C there is a specific time 
period for the formation of an aggregation species that is capable of inducing a 
proinflammatory response.  From the cumulative data it is clear that the time period for 
formation of the proinflammatory species ranges from 48-96 hours.  The shift in the peak 
response is attributed to variation in the Aβ(1-42) peptide lots that were purchased from 
r-Peptide.  These findings indicate that an intermediate Aβ(1-42) species was optimal for 
inducing proinflammatory response.  In order to characterize these species further we 
separated the samples by SDS PAGE followed by immunoblotting with Ab 9 antibody.  
Ab 9 binds to amino acid residues 1-16 of the Aβ peptide.  Aβ(1-42) prepared in aqueous 
solution was incubated at 4C, and aliquots of samples were snap frozen at specific time 
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points and separated by SDS PAGE.  The SDS PAGE resolved sample was subjected to 
immunoblotting.  There was no clear cut separation of aggregation species (data not 
shown). 
 Previous studies have shown that Aβ(1-42) aggregates were soluble after 
centrifugation at 16,000 x g and 100,000 x g for 30 minutes (Stine et al., 2003).  Our data 
clearly indicate that the fibrillar structures were soluble after centrifugation at 18,000 x g 
for 15 minutes.  We tested the solubility of Aβ(1-42) prepared in aqueous solutions by 
ultracentrifugation at higher speeds.  The peak proinflammatory response for the Aβ(1-
42) peptide lot was at 72 hours of incubation at 4C.  Hence, Aβ(1-42) solution was 
reconstituted in sterile water and allowed to aggregate for 72 hours, centrifuged at high 
speeds ranging from 50,000 x g to 150,000 x g for an hour at 4C.  The centrifugation 
supernatants were treated with THP-1 monocytes and evaluated for TNFα production.  
The centrifugation supernatants at 50,000 ( Fig 3.16 A) and 100,000 x g (Fig 3.16B) 
induced TNFα production in THP-1 cells and were almost similar to the unspun sample 
(total).  There was small decrease in the signal for 150,000 x g spin supernatant.  
Analyses of AFM images showed that high speed ultracentrifugation at 150,000 x g  was 
effective in removing some fibrils from the solution (Fig 13.17 D). Overall, the 
ultracentrifugation data further strengthened our hypothesis that intermediate fibrillar 
forms that elicited maximum proinflammatory response in THP-1 monocytes were 
soluble.  The data also suggests that the fibrils may spin down if spun at speeds higher 
than 150,000 x g.  Therefore spinning at 200-300 k for an hour could be done to confirm 
the above hypothesis. 
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Figure 3.16 Fibrillar structures are soluble after high speed ultracentrifugation.  (A) 
Aβ(1-42) was reconstituted in water (100 µM) and incubated at 4C. At specific time 
points two aliquots were removed, and one was centrifuged at 50,000 x g for 1 hour at 
4C. The centrifugation supernatant and total (circles) were treated with THP-1 cells as 
described in Methods.  (B) Aβ(1-42) was reconstituted in water (100 µM) and incubated 
at 4C for 72 hours.  Separate aliquots of the same solution were centrifuged for 1 hour at 
4C. at 10,000 x g and 150,000 x g.  The pre-centrifuge sample (Total) and the 
supernatants were incubated with THP-1 cells for 24 hours.  The secreted TNF α level 
was measured as described in Methods.  Courtesy Maria Udan 
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Figure 3.17  Fibrillar species are soluble even after high speed ultracentrifugation of 
Aβ(1-42) aggregation solutions. Aβ(1-42) was reconstituted in water (100 µM) and 
incubated at 4C for 72 hours as described in Fig 3.15.  Aliquots of the supernatant after 
centrifugation at 50,000 x g, (Panel B) 100,000 x g (Panel C), and 150,000 x g (Panel D) 
were diluted to 1 µM and applied onto mica grids as described in Methods.  (Panel A) 
Aβ(1-42), (total) after 72 hours at 4C.  The AFM image panels are 5µm x 5µm.  
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In order to confirm that proinflammatory response was due to intermediate fibrillar 
forms, it was necessary to remove fibrils from the aggregation solution, and test the 
ability of the solution without fibrils to evoke a response when treated with THP-1 cells.  
Centrifugal filter devices with 0.2 µm membrane pore have been reported to filter out Aβ 
(1-40) protofibrils from the aggregation solution (Lashuel and Grillo-Bosch, 2005).  We 
used centrifugal filter units with 0.2 µm PTFE membrane for our experiments.  Aβ (1-42) 
was reconstituted in water as described in Methods to a concentration of 100 µM and 
allowed to incubate at 4C for 72-96 hours.  An aliquot was centrifuged at 12,000 x g for 
3 minutes using 0.2 µm centrifugal filter devices.  The filtrate was tested for the ability to 
stimulate proinflammatory response and compared to the prefiltering sample (Fig 3.18 
A).  AFM images indicated that the filtrate was devoid of fibrils, but at the same time 
there were some globular species present (Fig 3.18 C).  The unfiltered sample had both 
fibrillar and globular species.  Bradford assay was done to determine the protein 
concentration in the pre and post filter samples.  The data showed about 35 % of Aβ 
remaining in the filtrate compared to the prefiltered sample.  In a separate experiment 
using the 0.2 µm filter, we collected the filtrate and the retentate.  The retentate was 
recovered from the filter cup and imaged by AFM.  The images showed the presence of 
both fibrillar and globular species (data not shown).  Treatment of THP-1 cells with the 
filtrate resulted in complete wipe out of proinflammatory response compared to unfiltered 
Aβ (1-42) solution.  ThT fluorescence of the filtrate was significantly reduced (75 A.U) 
in comparison to the unfiltered sample (870 A.U).  Results from this experiment suggest 
that the filter device is capable of removing fibrils from the aggregation solution and at 
the same time the filtrate does have some nonfibrilar Aβ.  The data also confirms that  
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Figure 3.18 Aβ(1-42) was reconstituted in water (100 µM) and incubated at 4C for 72 
or 96 hours as described in methods.  An aliquot was removed from the aggregation 
solution and centrifuged using 0.2 µm PTFE membrane filters at 12,000 x g for 3 
minutes. (Panel A). The unspun sample (Total) and the centrifugation filtrate were 
treated with THP-1 cells at a final concentration of 15 µM as described in Methods. The 
cell supernatants were tested for TNFα levels by ELISA. The same samples were diluted 
and applied on to mica grids at a final concentration of 1 µM for AFM imaging.C-D. 
AFM images of Total (C), and 0.2 µm centrifugation filtrate (D). The images are 5 µm x 
5 µm panels. 
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early fibrillar forms are required for  inducing a proinflammaotry response and these 
fibrillar species were soluble even after ultracentrifugation at high speed. 
 
3.7 Proinflammatory Aβ(1-42) Aggregation Species can be Recognized by Antibodies 
Specific for Fibrillar Conformation 
 At present not much is known about the high resolution oligomeric structural 
studies.  Conformation-dependent antibodies and antisera that specifically recognize 
amyloid fibrils (O'Nuallain and Wetzel, 2002, Kayed et al., 2007, Moretto et al., 2007) or 
prefibrillar oligomers (Kayed et al., 2003) have been reported.  These antibodies have the 
unusual property of recognizing generic epitopes that are associated with specific 
aggregation states regardless of their amino acid sequence (Glabe, 2008).  Fibrils have 
been defined as insoluble material that sediments at 100,000 x g. and data indicate 
existence of small soluble oligomers that can react with fibril-specific antibodies (Kayed 
et al., 2007).  These studies discuss the possibility of presence of oligomers with 
structural organization as that of insoluble fibrils (Glabe, 2008). These oligomers are 
termed fibrillar oligomers (Kayed et al., 2007).  Since fibril assembly is known to be 
nucleation dependent process, it is possible that small “seed” aggregates exist in which 
the peptide is organized in the same lattice structure as that of fibrils (Glabe, 2008).  
(Kayed et al., 2007) used fibrillar specific antibody (OC) to distinguish between fibrillar 
and the other oligomeric species.  We used OC immune serum to investigate if the 
aggregation species capable of inducing maximum proinflammatory response belong to 
fibrillar oligomer category.  Aβ(1-42) solution was allowed to age for 72 hours at 4C 
following which they were subjected to immunodepletion of OC positive material as 
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described in Methods.  The immunodepleted supernatant (OC sup) was simultaneously 
reprobed with OC immune serum and also with Ab 9 antibody, using dot blot assay.  Ab 
9 is a sequence specific antibody and is not dependent on the conformation.  Dot blot 
showed significant Aβ remaining in the supernatant probed by Ab 9.  There was very 
little reaction to OC immune serum (Fig 3.19 C & D). AFM image analyses showed a 
significant decrease in the fibrillar and diffuse material (Fig 3.19 B) compared to total 
(Fig 3.19A).  We wanted to probe the OC sensitivity of Aβ(1-42) aggregation species 
throughout the time course of our experiment.  Aβ(1-42) solution in water was prepared 
as described in Methods, and an aliquot was removed immediately upon reconstitution 
and snap frozen.  The remaining solution was incubated at 4C.  At specific time points 
aliquots were removed and probed for OC sensitivity.  The samples were also probed 
with Ab 9 antibody as control since it is sequence specific (Fig 3.19 E). Once we 
confirmed the presence of OC sensitive species in our Aβ(1-42) aggregation solutions, 
we performed immunodepletion experiment, and supernatants were treated with the cells 
as described in the Methods.  The ability of OC supernatant to stimulate TNFα 
production in THP-1 cells was assessed.  An aliquot of the same Aβ(1-42) solution 
(untreated) and Aβ(1-42) treated with rabbit IgG serum was used as control.  Rabbit IgG 
serum was used in order to rule out any non specific binding to fibrils.  Immunodepletion 
of OC-positive material in the Aβ(1-42) solution diminished the proinflammatory activity 
when compared to the untreated 18,000 x g spun sample or supernatants after IP with 
rabbit IgG and centrifugation at 18,000 x g (Fig 3.20 A).  The same samples were probed 
again with OC immune serum.  The dot blot showed a reduction in the OC positive 
material in the OC-immunodepleted material 
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Figure 3.19.  Immunoprecipitation with OC antisera depletes fibrillar oligomers and 
fibrils. Aβ(1-42) was reconstituted in sterile water (100 µM) and stored at 4C for 72 
hours. The solution was immunodepleted with OC antisera as described in the Methods.  
(A-B) AFM Images of the untreated (total) and the immunodepleted supernatant (OC 
Sup).  C-D. OC Supernatant probed again with OC antisera (C) and Ab-9 (D) by Dot blot 
assay. E-F Aβ(1-42) was reconstituted in sterile water (100 µM) and stored at 4C.  At 
the above mentioned time points aliquots were removed and probed with Ab 9 and OC 
antisera by Dot blot. 
.
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Figure 3.20. Immunoprecipitation with OC antisera reduces Aβ(1-42) induced  
proinflammatory response.  Aβ(1-42) was reconstituted in sterile water and incubated 
at 4C for 72 hours.  Aliquots of Aβ(1-42) solution were treated with OC antisera or 
rabbit IgG as described in Methods.  The immunodepleted Aβ(1-42) supernatants were 
reprobed with OC antisera to test for OC sensitivity by dot blot.  Simultaneously aliquots 
were also treated with THP-1 cells and tested for TNFα secretion.  (Panel A) Aβ(1-42) 
untreated solution (tot), Aβ(1-42) untreated, but centrifuged at 18,000 x g and supernatant 
collected (tot sup), OC immunodepletion supernatant (OC IP Sup) and rabbit IgG 
immunodepleted supernatant (IgG IP Sup) were incubated with THP-1 cells for 24 hours 
and the secreted TNFα was measured as described in Methods.  (Panel B) Dot blot of tot 
sup, OC/IP Sup and IgG IP Sup probed with OC antisera. 
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 compared to the 18,000 x g spun supernatants or the supernatants after IP treatment with 
the rabbit IgG (Fig 3.20 B). 
 
3.8 Size Exclusion Chromatography(SEC) of Aβ(1-42) Aggregation Species 
 
 The AFM images from ultracentrifugation experiments showed loss of fibrillar 
structures in the supernatant after centrifugation at both 100,000 x g and 150,000 x g.  
The loss of fibrils in the supernatants was higher in the case of centrifugation at 150,000 
x g.  In spite of this decrease in the fibrils, the cellular activity did not show a drastic 
decrease in the proinflammatory signal.  It has been discussed earlier that insoluble fibrils 
sediment when centrifuged at 100,000 x g (Stine et al., 2003).  Therefore, it is possible 
that during high speed centrifugation the insoluble fibrils were the ones that separated out 
of the solution, hence, there was no significant loss of cellular activity.  (Kayed et al., 
2007)) reported that SEC fractions of Aβ(1-42) showed a broad distribution of oligomer 
sizes from 8 kDa to 200 kDa, and they were recognized by OC.  In our experiments peak 
proinflammatory activity was around 72-96 hours of Aβ(1-42) incubation at 4C.  For 
further characterization, Aβ(1-42) solution was reconstituted in sterile water and allowed 
to incubate for 96 hours at 4C.  After 96 hours, the solution was centrifuged at 18,000 x 
g for 10 minutes and supernatant was loaded on to Superdex 75 column for separation of 
aggregation species as described in Methods.  The elution profile showed four peaks by 
UV absorbance one of them being the void volume peak, an included volume that 
comprised of peaks 2 and 3 and the monomer peak (Fig 3.21 A).  The peak fractions (11,  
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Figure 3.21 Characterization of aggregated Aβ(1-42) by SEC.  Aβ(1-42) reconstituted 
in sterile water was allowed to incubate at 4C for 96 hours.  The solution was 
centrifuged at 18,000 x g for 10 minutes and the supernatant was loaded on to Superdex 
75 column.  (Panel A) 280 nm absorbance elution profiles show four peaks indicated by 
arrows, (1) (Vo) Void Volume, and the peaks labeled 2, 3, and monomer are the peaks for 
the included volumes. The absorbance maximum for the peaks are 1.4 µM for the void, 
and 5.7 µM, 3.7 µM , 18.3 µM, for the included volume. (Panel B) Select peak fractions 
were probed for OC sensitivity by Dot Blot.  Fractions were used for dot blot without 
dilution. (Panel C) The OC positive fractions were treated with THP-1 monocytes for 6 
hours, and TNFα was measured as described in Methods. (Panel D) AFM image analysis 
of the peak fraction that gave maximum proinflammatory response. The image panels are 
3 µm x 3 µm. 
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13, 16, 19 and 21) were assessed for OC reactivity by dot-blot analysis (3.21 B).  All of 
the selected fractions, with the exception of the monomer, showed OC-positive material. 
Selected peak fractions were treated with THP-1 monocytes to test their ability to induce 
proiflammatory response.  The included peak 2 (Frac 13) showed the highest levels of 
TNFα secretion (Fig 3.21 C).  The peak fraction that gave maximum proinflammatory 
signal was analysed by AFM.  Images showed the presence of large number of short 
fibrillar structures which were in the range of 100-200 nm in length, and average height 
(diameter) of 5.4 nm +/- 1.6 SD for n= 116 measurements. 
 
3.9 Discussion 
 
 AD accounts for about two-thirds of the cases of progressive dementia in elderly 
people (Golde, 2002).  The exact sequence of events that lead to AD is still debated.  
However, there is lot of evidence that supports the hypothesis that accumulation of Aβ in 
the brain triggers a complex pathological cascade leading to neuronal damage and 
ultimately dementia (Selkoe, 2001).  One of the events within this pathological cascade is 
an inflammatory response.  A key finding that signals the presence of neuroinflammation 
is the accumulation of reactive microglia in the degenerating areas of the brain (McGeer 
and McGeer, 2004, McGeer et al., 2005).  Clumps of activated microglia appear on the 
senile plaques found in AD brains and also in the surrounding tissue (McGeer and 
McGeer, 2004).  However, very few, if any, were found in similar regions of control 
brains.  AD-relevant inflammation has been investigated by studying the interactions of 
human brain microglia with synthetic or brain derived Aβ peptides.  These studies were 
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based on the pathological observations that activated microglia in the AD-affected brains 
are associated with aggregated, thioflavin S-reactive, Aβ plaques (Walker and Lue, 
2005).  These studies indicate that microglia upon interaction with fibrillar amyloid 
plaques become activated.  Fibrillar Aβ aggregates cause a limitation in the phagocytosis 
that leads to cell activation in a proinflammatory manner (Walker and Lue, 2005).  
Studies also indicate the involvement of cytokines (Dickson et al., 1993) in signaling for 
activation.  Dystrophic neurites, activated microglia and proinflammatory cytokines are 
the inflammatory markers that are found surrounding the Aβ lesions in the human brain.  
An array of different aggregate morphologies ranging from dense core neuritic plaques to 
granular diffuse wispy Aβ deposits are observed in the human brain.  However, only the 
plaques seem to provoke the inflammatory response (Selkoe, 2004), and microglia were 
observed surrounding only the dense core plaques and not diffuse plaques. 
 
 In this study we used THP-1 monocytes to investigate the Aβ-induced 
proinflammatory response.  These cells have been used extensively in such studies since 
they display a similar pattern of activation to that of microglial cells (Klegeris et al., 
1997, Yates et al., 2000, Combs et al., 2001).  Aβ solution was allowed to aggregate over 
a time period and monitored for the ability to induce a proinflammatory response from 
THP-1 monocytes.  Earlier studies have used Aβ(1-40) preparations in acidic pH to 
monitor the fibrillization of Aβ and also to quantitate the nucleation and elongation rate 
constants (Lomakin et al., 1996).  The fibrils formed were morphologically identical to 
the ones formed in vivo (Lomakin et al., 1996).  We observed that an intermediate Aβ(1-
42) species formed in aqueous solutions (pH 3.6-4) was optimal in inducing a 
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proinflammatory response.  The peak activity correlated with the formation of short 
fibrillar structures that appeared early on in the time course.  There was slight shift in the 
peak cellular response due to the variation in the Aβ lots but nevertheless the peak was in 
the intermediate time points (48-96 hours) during the course of aggregation (Fig 3.1).  
The proinflammatory activity diminished with the appearance of fibril structures (216 
hour).  Modulation of aggregation of Aβ(1-42) and Aβ(1-40), by increasing the 
temperature of the reaction conditions, resulted in the formation of different types of 
aggregates (Fig 3.9-11), but they did not provoke a proinflammatory response.  Aβ(1-42) 
fibrils formed at neutral pH in PBS were also not effective in inducing a proinflammatory 
response (Fig 3.13).  In fact, the aggregation at neutral pH, and increased ionic strength 
promotes aggregation as shown in the TEM images and ThT fluorescence data (Fig 3.13-
3.14).  The data indicates that acceleration in the aggregation process may have by-
passed the formation of the transient fibrillar structures that induces the maximum 
proinflammatory response.  The OC-immunodepletion studies suggest that the active 
Aβ(1-42) aggregation species is reminiscent of fibrillar oligomers previously reported 
(Kayed et al., 2007).  There is evidence for the formation of Aβ in acidic conditions.  The 
build up of intracellular Aβ may be an early event in the pathogenesis of AD and Downs 
Syndrome (LaFerla et al., 2007).  Accumulation of intracellular Aβ precedes formation of 
extracellular deposits (Mori et al., 2002).  AD and Downs syndrome brains were analyzed 
along with the control brains and the data indicates that most of the intracellular Aβ ends 
at residue 42 (Takahashi et al., 2002).  Further, it is suggested that endosomes are the 
likely sites of Aβ generation due to their acidic nature, and the enzymes BACE-1 and β-
secretase have optimal activity at the acidic pH.  There is also evidence showing the 
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interaction of BACE-1 and APP by FRET (Kinoshita et al., 2003).  The link between 
extracellular and intracellular Aβ is still under investigation.  However, immunotherapy 
studies show that removal of extracellular plaques are slowly followed by the removal of 
intracellular plaques (Oddo et al., 2004).  These findings suggest that extracellular Aβ 
may be formed from the intraneuronal pools and there exists a dynamic equilibrium 
between the pools, such that when the extracellular pools are removed the intraneuronal 
pools are forced out of the cell. At present not much is known about the morphology of 
the intraneuronal Aβ.  We have seen that Aβ(1-42) in aqueous solution (pH 3.6-4) form 
short fibrillar structures that are capable of inducing proinflammatory response (Fig 3.2).  
It is possible that these fibrillar precursors may form intraneuronally and when secreted 
lead to the activation of the microglial cells that in turn induces the proinflammatory 
response.  Freshly reconstituted Aβ solutions have punctuate species <2 nm, and DLS 
measurements of freshly reconstituted Aβ showed a predominant peak of 1nm species 
that corresponds to monomer.  AFM image analyses have shown that the 
proinflamamtory species have a mean height and standard deviation (SD) of 4.2 +/- 1.4 
nm respectively.  AFM imaging of Aβ aggregation species over time was helpful in 
providing information regarding the dimensions and morphology of the aggregated Aβ. 
 
 Modulation of aggregation conditions like change in pH, temperature and mode of 
aggregation (quiescent/agitation) have indicated a change in the fibril structure and 
neuronal toxicity.  Solid state structural studies indicate the presence of in register-
parallel β-sheets for full length Aβ(1-40), Aβ(1-42) and shorter fragment Aβ-(10-35) 
(Benzinger et al., 2000, Tycko, 2003).  Our studies show that changing the pH and ionic 
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strength of aggregation solutions altered the fibril morphology and diminished the 
proinflammatory response (Fig 3.13).  Aβ(1-40) and the shorter peptide Aβ-25-35 failed 
to stimulate the THP-1 monocytes for a proinflammatory response under similar 
aggregation conditions.  This may perhaps be due to the slow nucleation propensity of 
Aβ(1-40) thereby resulting in the formation of a very low concentration of fibrillar 
oligomers.  Aβ-25-35 is supposed to aggregate fast and the biological activity can be 
compared to that of Aβ(1-42), but in our studies this shorter peptide failed to stimulate 
the proinflammatory response.  It is possible that the last two amino acids in Aβ(1-42) are 
very important for the formation of the active proinflammatory species. 
 
 The intermediate fibrillar species in Aβ(1-42) aqueous solution was the most active 
in inducing a proinflammatory response.  We tried to further characterize the aggregation 
species by separating out fibrils from solution by ultracentrifugation (100,000 x g and 
150,000 x g).  Our results indicate that fibrillar structures are soluble and centrifugation 
supernatants are able to stimulate the cells for TNFα production (Fig 3.16-17).  AFM 
image analysis showed a decrease in fibrils in the supernatant.  But this decrease did not 
cause a drastic change in the proinflammatory signal.  In order to characterize the 
aggregation species further, we used conformation-specific antibodies.  These 
conformation-specific antibodies have the ability to distinguish between fibrillar and 
oligomeric species (Kayed et al., 2007).  OC antisera can bind fibrillar species and 
precursors to fibrils that have already formed a fibrillar core structure.  In fact, (Kayed et 
al., 2007) reported the existence of prefibrillar oligomers that were found to be different 
from fibrillar oligomers.  Since the OC sera can detect any fibrillar species, we chose the 
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time point of aggregation that gave the maximum proinflamamtory activity to conduct 
immunodepletion studies.  The data indicate that the selective removal of fibrillar 
oligomers from the aggregation solution resulted in lowering the proinflammatory signal 
(Fig 3.20).  AFM imaging of the SEC fraction that eilicited the maximum 
proinflammatory response showed the presence of short rod like fibrillar structures (Fig 
3.21D).  These findings substantiate our hypothesis that small units of the intermediate 
fibrillar precursors are optimal for inducing proinflammatory response.  The small units 
are crucial since we have observed that continued aggregation, and accelerated 
aggregation resulted in fibrils that failed to stimulate the cells.  These active 
proinflammatory species seem to be transient and appear simultaneously with the fibrils.  
From the time course of aggregation it is evident that these transient small units disappear 
to form bigger units mostly due to elongation.  The intermediate species bound well to 
OC sera indicating presence of fibrillar species.  These fibrillar oligomers may be similar 
to “seed” aggregates in which the peptide is organized in the same lattice structure as that 
of the fibrils (Glabe, 2008).  Further investigations will help decipher if these fibrillar 
oligomers are precursors to protofibrils. 
 Soluble Aβ(1-42) oligomeric species have been implicated as primary toxic species 
in many neurodegenerative diseases.  In fact, large fibrillar plaques provide much less Aβ 
surface area to neuronal membranes compared to a number of small oligomers.  It is 
possible that a group of small oligomers can diffuse into synaptic clefts and these 
assemblies are better candidates for inducing synaptic dysfunction (Haass and Selkoe, 
2007).  Amongst the several unresolved questions, one question raised is the possible role 
of soluble oligomers in triggering a proinflammatory cascade.  It is possible that these 
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species could activate the local microglia and astrocytes either directly or indirectly that 
could lead to synaptic dysfunction (Haass and Selkoe, 2007).  Our findings indicate that 
the soluble prefibrillar oligomeric species formed during the intermediate stage of the 
aggregation pathway are optimal for inducing a proinflammatory response.  This could be 
the partial answer to the question raised above, although a thorough characterization of 
the proinflammatory aggregation species will answer the question completely.  The 
plaque core contains fibrillar Aβ, and there are reports that indicate plaques to be a 
reservoir of bioactive molecules (Meyer-Luehmann et al., 2008).  These studies also 
discuss about the presence of soluble oligomeric Aβ around the plaques. These 
oligomeric Aβ contribute to synapse loss in a mouse model of AD (Koffie et al., 2009).  
Their studies indicate presence of polymorphic Aβ species not only in the brain 
parenchyma, but also within the plaque area.  According to our findings, the soluble pre-
fibrillar Aβ(1-42) species are optimal for triggering a proinflammatory response in 
human THP-1 monocytes.  These studies provide additional information into the 
complexities of Aβ aggregation morphology and may help in deciphering treatment 
strategies.  Identification of the favorable conformation of Aβ(1-42) that triggers a 
proinflammatory response opens up avenues to further probe into the interaction of Aβ 
with cell surface receptors. 
 
 
 
 
 
 
 
 145 
 
3.10 Bibliography 
 
Benzinger, T. L., Gregory, D. M., Burkoth, T. S., Miller-Auer, H., Lynn, D. G., Botto, R. 
E. and Meredith, S. C., 2000. Two-dimensional structure of beta-amyloid(10-35) 
fibrils. Biochemistry. 39, 3491-3499. 
 
Bitan, G., Kirkitadze, M. D., Lomakin, A., Vollers, S. S., Benedek, G. B. and Teplow, D. 
B., 2003. Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 
oligomerize through distinct pathways. Proc Natl Acad Sci U S A. 100, 330-335. 
 
Clementi, M. E., Marini, S., Coletta, M., Orsini, F., Giardina, B. and Misiti, F., 2005. 
Abeta(31-35) and Abeta(25-35) fragments of amyloid beta-protein induce cellular 
death through apoptotic signals: Role of the redox state of methionine-35. FEBS 
Lett. 579, 2913-2918. 
 
Combs, C. K., Karlo, J. C., Kao, S. C. and Landreth, G. E., 2001. beta-Amyloid 
stimulation of microglia and monocytes results in TNFalpha-dependent 
expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci. 
21, 1179-1188. 
 
D'Ursi, A. M., Armenante, M. R., Guerrini, R., Salvadori, S., Sorrentino, G. and Picone, 
D., 2004. Solution structure of amyloid beta-peptide (25-35) in different media. J 
Med Chem. 47, 4231-4238. 
 
Dickson, D. W., Lee, S. C., Mattiace, L. A., Yen, S. H. and Brosnan, C., 1993. Microglia 
and cytokines in neurological disease, with special reference to AIDS and 
Alzheimer's disease. Glia. 7, 75-83. 
 
Fraser, P. E., Nguyen, J. T., Surewicz, W. K. and Kirschner, D. A., 1991. pH-dependent 
structural transitions of Alzheimer amyloid peptides. Biophys J. 60, 1190-1201. 
 
Glabe, C. G., 2008. Structural classification of toxic amyloid oligomers. J Biol Chem. 
283, 29639-29643. 
 
Golde, T. E., 2002. Inflammation takes on Alzheimer disease. Nat Med. 8, 936-938. 
 
Grammas, P. and Ovase, R., 2001. Inflammatory factors are elevated in brain 
microvessels in Alzheimer's disease. Neurobiol Aging. 22, 837-842. 
 
Haass, C. and Selkoe, D. J., 2007. Soluble protein oligomers in neurodegeneration: 
lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 8, 
101-112. 
 146 
Harper, J. D., Lieber, C. M. and Lansbury, P. T., Jr., 1997a. Atomic force microscopic 
imaging of seeded fibril formation and fibril branching by the Alzheimer's disease 
amyloid-beta protein. Chem Biol. 4, 951-959. 
 
Harper, J. D., Wong, S. S., Lieber, C. M. and Lansbury, P. T., 1997b. Observation of 
metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol. 4, 
119-125. 
 
Harper, J. D., Wong, S. S., Lieber, C. M. and Lansbury, P. T., Jr., 1999. Assembly of A 
beta amyloid protofibrils: an in vitro model for a possible early event in 
Alzheimer's disease. Biochemistry. 38, 8972-8980. 
 
Hartley, D. M., Walsh, D. M., Ye, C. P., Diehl, T., Vasquez, S., Vassilev, P. M., Teplow, 
D. B. and Selkoe, D. J., 1999. Protofibrillar intermediates of amyloid beta-protein 
induce acute electrophysiological changes and progressive neurotoxicity in 
cortical neurons. J Neurosci. 19, 8876-8884. 
 
Heneka, M. T., Feinstein, D. L., Galea, E., Gleichmann, M., Wullner, U. and 
Klockgether, T., 1999. Peroxisome proliferator-activated receptor gamma 
agonists protect cerebellar granule cells from cytokine-induced apoptotic cell 
death by inhibition of inducible nitric oxide synthase. J Neuroimmunol. 100, 156-
168. 
 
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N. and Ihara, Y., 1994. 
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific 
A beta monoclonals: evidence that an initially deposited species is A beta 42(43). 
Neuron. 13, 45-53. 
 
Jarrett, J. T., Berger, E. P. and Lansbury, P. T., Jr., 1993a. The C-terminus of the beta 
protein is critical in amyloidogenesis. Ann N Y Acad Sci. 695, 144-148. 
 
Jarrett, J. T., Berger, E. P. and Lansbury, P. T., Jr., 1993b. The carboxy terminus of the 
beta amyloid protein is critical for the seeding of amyloid formation: implications 
for the pathogenesis of Alzheimer's disease. Biochemistry. 32, 4693-4697. 
 
Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., Margol, L., Wu, 
J., Breydo, L., Thompson, J. L., Rasool, S., Gurlo, T., Butler, P. and Glabe, C. G., 
2007. Fibril specific, conformation dependent antibodies recognize a generic 
epitope common to amyloid fibrils and fibrillar oligomers that is absent in 
prefibrillar oligomers. Mol Neurodegener. 2, 18. 
 
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W. and 
Glabe, C. G., 2003. Common structure of soluble amyloid oligomers implies 
common mechanism of pathogenesis. Science. 300, 486-489. 
 147 
Kinoshita, A., Fukumoto, H., Shah, T., Whelan, C. M., Irizarry, M. C. and Hyman, B. T., 
2003. Demonstration by FRET of BACE interaction with the amyloid precursor 
protein at the cell surface and in early endosomes. J Cell Sci. 116, 3339-3346. 
 
Klegeris, A., Walker, D. G. and McGeer, P. L., 1997. Interaction of Alzheimer beta-
amyloid peptide with the human monocytic cell line THP-1 results in a protein 
kinase C-dependent secretion of tumor necrosis factor-alpha. Brain Res. 747, 114-
121. 
 
Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., 
Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., Hyman, 
B. T. and Spires-Jones, T. L., 2009. Oligomeric amyloid beta associates with 
postsynaptic densities and correlates with excitatory synapse loss near senile 
plaques. Proc Natl Acad Sci U S A. 106, 4012-4017. 
 
Kusumoto, Y., Lomakin, A., Teplow, D. B. and Benedek, G. B., 1998. Temperature 
dependence of amyloid beta-protein fibrillization. Proc Natl Acad Sci U S A. 95, 
12277-12282. 
 
LaFerla, F. M., Green, K. N. and Oddo, S., 2007. Intracellular amyloid-beta in 
Alzheimer's disease. Nat Rev Neurosci. 8, 499-509. 
 
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., 
Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., 
Finch, C. E., Krafft, G. A. and Klein, W. L., 1998. Diffusible, nonfibrillar ligands 
derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl 
Acad Sci U S A. 95, 6448-6453. 
 
Lashuel, H. A. and Grillo-Bosch, D., 2005. In vitro preparation of prefibrillar 
intermediates of amyloid-beta and alpha-synuclein. Methods Mol Biol. 299, 19-
33. 
 
Lomakin, A., Chung, D. S., Benedek, G. B., Kirschner, D. A. and Teplow, D. B., 1996. 
On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei 
and quantitation of rate constants. Proc Natl Acad Sci U S A. 93, 1125-1129. 
 
Lorenzo, A. and Yankner, B. A., 1994. Beta-amyloid neurotoxicity requires fibril 
formation and is inhibited by congo red. Proc Natl Acad Sci U S A. 91, 12243-
12247. 
 
Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. 
H., Rydel, R. E. and Rogers, J., 1999. Soluble amyloid beta peptide concentration 
as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 155, 853-
862. 
 148 
McGeer, E. G., Klegeris, A. and McGeer, P. L., 2005. Inflammation, the complement 
system and the diseases of aging. Neurobiol Aging. 26 Suppl 1, 94-97. 
 
McGeer, P. L., Itagaki, S., Tago, H. and McGeer, E. G., 1987. Reactive microglia in 
patients with senile dementia of the Alzheimer type are positive for the 
histocompatibility glycoprotein HLA-DR. Neurosci Lett. 79, 195-200. 
 
McGeer, P. L. and McGeer, E. G., 2004. Inflammation and the degenerative diseases of 
aging. Ann N Y Acad Sci. 1035, 104-116. 
 
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., 
Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J. and 
Hyman, B. T., 2008. Rapid appearance and local toxicity of amyloid-beta plaques 
in a mouse model of Alzheimer's disease. Nature. 451, 720-724. 
 
Moretto, N., Bolchi, A., Rivetti, C., Imbimbo, B. P., Villetti, G., Pietrini, V., Polonelli, 
L., Del Signore, S., Smith, K. M., Ferrante, R. J. and Ottonello, S., 2007. 
Conformation-sensitive antibodies against alzheimer amyloid-beta by 
immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem. 
282, 11436-11445. 
 
Mori, C., Spooner, E. T., Wisniewsk, K. E., Wisniewski, T. M., Yamaguch, H., Saido, T. 
C., Tolan, D. R., Selkoe, D. J. and Lemere, C. A., 2002. Intraneuronal Abeta42 
accumulation in Down syndrome brain. Amyloid. 9, 88-102. 
 
Naiki, H. and Nakakuki, K., 1996. First-order kinetic model of Alzheimer's beta-amyloid 
fibril extension in vitro. Lab Invest. 74, 374-383. 
 
O'Nuallain, B. and Wetzel, R., 2002. Conformational Abs recognizing a generic amyloid 
fibril epitope. Proc Natl Acad Sci U S A. 99, 1485-1490. 
 
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H. and LaFerla, F. M., 2004. Abeta 
immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau 
aggregates via the proteasome. Neuron. 43, 321-332. 
 
Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G. and Cotman, C. W., 1993. 
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide 
assembly state. J Neurosci. 13, 1676-1687. 
 
Pike, C. J., Walencewicz-Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G. 
and Cotman, C. W., 1995. Structure-activity analyses of beta-amyloid peptides: 
contributions of the beta 25-35 region to aggregation and neurotoxicity. J 
Neurochem. 64, 253-265. 
 
 149 
Probert, L., Akassoglou, K., Pasparakis, M., Kontogeorgos, G. and Kollias, G., 1995. 
Spontaneous inflammatory demyelinating disease in transgenic mice showing 
central nervous system-specific expression of tumor necrosis factor alpha. Proc 
Natl Acad Sci U S A. 92, 11294-11298. 
 
Seilheimer, B., Bohrmann, B., Bondolfi, L., Muller, F., Stuber, D. and Dobeli, H., 1997. 
The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct 
fiber morphology. J Struct Biol. 119, 59-71. 
 
Selkoe, D. J., 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 81, 
741-766. 
 
Selkoe, D. J., 2004. Cell biology of protein misfolding: the examples of Alzheimer's and 
Parkinson's diseases. Nat Cell Biol. 6, 1054-1061. 
 
Stine, W. B., Jr., Dahlgren, K. N., Krafft, G. A. and LaDu, M. J., 2003. In vitro 
characterization of conditions for amyloid-beta peptide oligomerization and 
fibrillogenesis. J Biol Chem. 278, 11612-11622. 
 
Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, 
M. F., Xu, H., Greengard, P. and Gouras, G. K., 2002. Intraneuronal Alzheimer 
abeta42 accumulates in multivesicular bodies and is associated with synaptic 
pathology. Am J Pathol. 161, 1869-1879. 
 
Tarkowski, E., Andreasen, N., Tarkowski, A. and Blennow, K., 2003. Intrathecal 
inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg 
Psychiatry. 74, 1200-1205. 
 
Tycko, R., 2003. Insights into the amyloid folding problem from solid-state NMR. 
Biochemistry. 42, 3151-3159. 
 
Tycko, R., 2004. Progress towards a molecular-level structural understanding of amyloid 
fibrils. Curr Opin Struct Biol. 14, 96-103. 
 
Udan, M. L., Ajit, D., Crouse, N. R. and Nichols, M. R., 2008. Toll-like receptors 2 and 4 
mediate Abeta(1-42) activation of the innate immune response in a human 
monocytic cell line. J Neurochem. 104, 524-533. 
 
Walker, D. G. and Lue, L. F., 2005. Investigations with cultured human microglia on 
pathogenic mechanisms of Alzheimer's disease and other neurodegenerative 
diseases. J Neurosci Res. 81, 412-425. 
 
Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., 
Benedek, G. B., Selkoe, D. J. and Teplow, D. B., 1999. Amyloid beta-protein 
 150 
fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J 
Biol Chem. 274, 25945-25952. 
 
Walsh, D. M., Klyubin, I., Shankar, G. M., Townsend, M., Fadeeva, J. V., Betts, V., 
Podlisny, M. B., Cleary, J. P., Ashe, K. H., Rowan, M. J. and Selkoe, D. J., 2005. 
The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues 
for therapeutic intervention. Biochem Soc Trans. 33, 1087-1090. 
 
Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M. and Teplow, D. B., 1997. 
Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J 
Biol Chem. 272, 22364-22372. 
 
Walsh, D. M. and Selkoe, D. J., 2007. Abeta Oligomers - a decade of discovery. J 
Neurochem. 
 
Wood, S. J., Maleeff, B., Hart, T. and Wetzel, R., 1996. Physical, morphological and 
functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's 
amyloid peptide Abeta. J Mol Biol. 256, 870-877. 
 
Yates, S. L., Burgess, L. H., Kocsis-Angle, J., Antal, J. M., Dority, M. D., Embury, P. B., 
Piotrkowski, A. M. and Brunden, K. R., 2000. Amyloid beta and amylin fibrils 
induce increases in proinflammatory cytokine and chemokine production by THP-
1 cells and murine microglia. J Neurochem. 74, 1017-1025. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 151 
 
 
 
CHAPTER 4 
 
DIVERSE Aβ AGGREGATION ASSEMBLIES AND THEIR ROLE IN ACTIVATION 
OF DIFFERENT BIOCHEMICAL PATHWAYS 
 
4.1 Introduction 
 The neuropathological features of AD include amyloid deposits, neurofibrillary 
tangles and selective neuronal loss (Selkoe, 1991).  Amyloid deposits contain Aβ, a 40-
42 residue peptide produced by the endoproteolytic cleavage of amyloid precursor 
protein (APP) (Selkoe, 1993).  Microglia are the immune cells of the brain.  Aβ deposits 
attract the microglia and activate them to produce inflammatory mediators, some of 
which will act as a feed back to induce further chemotaxis and activation.  Once at the 
site of Aβ deposition, the activated microglia attempt to phagocytose and clear the 
substance, thereby leading to more activation (Rogers and Lue, 2001).  The plaques in 
AD brain are surrounded by activated microglial cells (Heneka and O'Banion, 2007).  
Microglia may be responsible for the phagocytosis and removal of Aβ under normal 
conditions (Wisniewski et al., 1991).  In AD, it is argued that the microglia clustered 
around Aβ deposits become dysfunctional and incapable of removing Aβ (Rogers et al., 
2002).   
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The limbic and association cortices of AD brain are surrounded by dead or dying 
neurons, activated microglial cells and reactive astrocytes (Selkoe, 1989, Mrak and 
Griffinbc, 2001).  Aβ induced neurotoxicity has been demonstrated in numerous cell 
culture studies (Pike et al., 1993, Lorenzo and Yankner, 1994, Simmons et al., 1994).  
Transgenic mice expressing mutant human APP develop neuropathological lesions 
similar to those found in AD patients.  Immunization of these mice with Aβ(1-42) 
aggregates reverses the neuropathology significantly (Janus et al., 2000, Morgan et al., 
2000).  This effect could be due to two possibilities.  One is that the antibodies generated 
by the host will neutralize Aβ in a restricted compartment, or it may deplete some soluble 
form of Aβ.  The other possibility could be that the microglia get activated due to the 
immunization and this clears the deposited Aβ.  These lead to reversal of cognitive 
imbalance (Janus et al., 2000, Morgan et al., 2000).  The proposed hypothesis is that the 
immune system acts as a peripheral sink, traps Aβ, and depletes it from CNS (Matsuoka 
et al., 2003, Heneka and O'Banion, 2007).  When there is an overwhelming production of 
Aβ(1-42), the levels exceed the rate at which the macrophage machinery clears the 
amyloid deposits resulting in the plaque core found within the AD brain.  Also, the 
clearance mechanisms become less efficient as one ages and this causes severe deposition 
of Aβ aggregates.  These data indicate the significant contribution of Aβ(1-42) to 
neurotoxicity in AD. 
 
Extensive biophysical studies reveal that full length and fragments of Aβ peptides 
form intermolecular parallel β-sheet structures in amyloid fibrils (Serpell, 2000, 
Antzutkin et al., 2002, Balbach et al., 2002).  In addition to β-sheets, turn structures or 
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bend structures were also present at positions 24-27 in Aβ(1-40) aggregates (Whittemore 
et al., 2005), and positions 26-27 in Aβ(1-42) aggregates (Olofsson et al., 2006).  
However, the precise positions of these turn or bend structures in Aβ aggregates are still 
under investigation.  The relationship between the turn position and its impact on 
inflammatory response is not known.  A detailed investigation into Aβ aggregation 
profile may provide clues into the structure-function relationship. 
We investigated the relationship between Aβ aggregation state and its role in the 
activation of monocytes and their maturation into macrophages.  We identified that a 
rapidly formed oligomeric aggregation species is responsible for the maturation of 
monocytes into macrophages, and an intermediate fibrillar oligomer elicits 
proinflammatory response via TLR2 and TLR4 receptors. 
  
4.2 Role of Aβ Aggregation State in Monocyte Recruitment 
 
 
 This study was done in collaboration with Nikkilina Crouse, and the work is 
published in (Crouse et al., 2009).  The cell surface represents the first site of interaction 
between extracellular Aβ and neurons.  Therefore the cell surface may be the location 
where the neurotoxic cascade is initiated (Bateman et al., 2007).  Neurotoxicity studies of 
Aβ indicate that  aggregated Aβ is generally more toxic than monomeric Aβ (Pike et al., 
1993, Simmons et al., 1994, Podlisny et al., 1998, Walsh et al., 1999, Walsh et al., 2002). 
Blood monocytes represent a large pool of scavenger and potential effector cells 
inside blood vessels both in homeostasis, as well as, during inflammatory processes 
(Auffray et al., 2007).  In mammals, monocytes also represent the accessory cells that 
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link inflammation and innate defense against microorganisms to adaptive immune 
responses (Auffray et al., 2009).  Aβ is believed to play roles in monocyte migration (Yan 
et al., 1996, Giri et al., 2000, Le et al., 2001), adhesion and differentiation into 
macrophages (Yan et al., 1996).  Aβ assemblies exhibit a wide range of morphologies 
that appear to stimulate different types of biologic responses in vivo.  The type of 
aggregation species or the receptor mechanisms that causes the monocyte/microglia 
recruitment, monocyte differentiation, and microglial activation are not fully understood.  
We investigated the ability of Aβ aggregation species to induce monocyte maturation into 
an adherent form. 
 
4.3. Aβ(1-42) Induces THP-1 Monocyte Adhesion and Maturation 
 
THP-1 monocytes cell model system was used for studying the monocyte 
recruitment and differentiation process since they are non-adherent and have a round 
morphology (Tsuchiya et al., 1980).  They normally circulate in the blood.  In the event 
of a proinflammatory, or immune stimuli in the periphery, the monocytes are recruited to 
the site and are differentiated into macrophages.  The differentiation process is an attempt 
to round up and destroy the foreign pathogen, and prevent further damage to the body.  
THP-1 monocytes can be induced to differentiate along the monocytic pathway.  These 
cells can be converted into mature cells with functions of macrophages by treatment with 
phorbol diesters (Tsuchiya et al., 1982).  Phorbol-12-myristate-13-acetate (PMA) is 
known to induce cell differentiation. (Schwende et al., 1996) have reported that PMA  
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Fig 4.1 Aβ(1-42) induces monocyte adherence comparable to PMA. THP-1 
monocytes were treated with 10 ng/ml PMA or 15 µM Aβ(1-42) from a freshly 
reconstituted 100 μM water solution and incubated for 6 hours at 37°C. Percent 
adherence was determined by direct cell counting as described in the methods. Standard 
error bars were calculated from n=17 trials for PMA and n=22 trials for Aβ(1-42). Water 
(n=15) controls induced 5 ± 1% adherence. Courtesy Nikkilina Crouse 
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induces adherence, and their reports also show a decrease in cell proliferation when 
treated with PMA.  We used PMA as a control to monitor the differentiation in cells.   
When THP-1 cells were incubated with PMA for 6, 24 and 48 hours respectively,there 
was monocyte differentiation.  The ability to differentiate the monocytes was evaluated 
by measuring monocyte adhesion, a marker for cell maturation.  Freshly reconstituted 
Aβ(1-42) in water (100 µM) induced 41.85 +/- 4.14 % adherence, and it was comparable 
to the 43.11+/- 3.65 % induction by PMA (10 ng/ml) (Fig. 4.1).  The monocyte adhesion 
ability was dependent on the concentration of Aβ.  When cells were treated with different 
Aβ(1-42) concentrations (5, 10, 15 µM), the 15 µM Aβ(1-42) induced maximum 
adherence. (data not shown).  We used this concentration for further experiments. 
 
4.4 Freshly solubilized Aβ(1-42) Induces Maximum Monocyte Maturation Compared to 
Aggregated Aβ(1-42). 
 The influence of Aβ(1-42) aggregated state in inducing the monocyte maturation 
was tested by incubating Aβ(1-42) for longer incubation time.  Aβ(1-42) was 
reconstituted in water, an aliquot was treated with the cells immediately, and the 
remaining solution was allowed to aggregate at 4C.  At specific time points of 
aggregation (0, 48, 72, 96, 120, 144, 216 hours), aliquots of Aβ(1-42) aggregation 
solution were treated with cells, and the ability to induce the monocyte adhesion was 
monitored.  The maximum adhesion occurred at zero and 48 hours of aggregation, and 
the ability to induce adhesion was lost with increase in the duration of aggregation.  AFM 
images of samples at the correlating time points showed presence of small globular 
species for the freshly reconstituted solution of Aβ(1-42).  Small fibrillar structures were  
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Fig. 4.2 Aβ(1-42) aggregates in freshly reconstituted solution induce monocyte 
adherence. Aβ(1-42)) was reconstituted in sterile water to 100 µM and incubated at 4°C. 
(A) At the given times, cells were treated with 15 µM Aβ for 6 hours and adherence was 
measured by direct counting as described in the Methods. Error bars represent standard 
error for n trials of 19 (0 h), 17 (48 h), 4 (72 h), 5 (96 h), 7 (120 h), 3 (144 h), and 7 (216 
h) Courtesy Nikkilina Crouse. (B-E) Representative AFM images of Aβ(1-42) 
aggregation at 4°C taken at 0, 48, 96 and 216 hours respectively. Aβ(1-42) was diluted a 
concentration of 1 µM and applied on mica grids as described in Methods. Images are 5 
µm x 5µm panels.  
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observed after 48 hours along with the small globular species, and by 96 hours, there was 
an increase in the number of fibrils, and a significant loss of ability to induce cell 
adherence.  The data clearly suggest that aggregation species present in the freshly 
reconstituted Aβ(1-42) was the most effective in inducing monocyte maturation.  Height 
analysis of the AFM images showed presence of diffuse material < 1nm in height in the 
freshly reconstituted Aβ(1-42).  Short rod like structures averaging 4-5 nm appeared by 
48 hours and these were able to induce monocyte adhesion but was slightly less than the 
zero hour sample.  As the aggregation progressed there was an increase in the number of 
fibrils.  The heights of the fibrils averaged between 5-6 nm.  There was significant 
increase in the fibril numbers with heights greater than 6 nm after 216 hours aggregation.  
We observed the disappearance of the diffuse aggregation species as the aggregation 
progressed.  The data from this experiment suggests that fibrillar aggregates were unable 
to induce maturation of THP-1 monocytes to an adherent form.  Several trials of the 
experiment showed consistency in this trend although the percent adhesion levels showed 
a variation depending on the Aβ(1-42) lot numbers. 
 
4.5 Increase in Peptide Concentration Affects the Ability to Induce Monocyte Maturation 
 
 Data from section 4.3 suggests that increased Aβ(1-42) aggregation decreases the 
monocyte maturation process.  The maximum activity was exhibited by Aβ(1-42) species 
present at the time of reconstitution.  We modulated the aggregation conditions by 
increasing the starting concentration of the monomer.  We hypothesized that, there will 
be an increase in the rate of the species that forms immediately after reconstitution.  Aβ 
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aggregation proceeds by multistep, nucleation-dependent process (Jarrett and Lansbury, 
1993).  Formation of the nucleation seed is the rate limiting step, so that, in the absence 
of preformed seeds, there is a significant lag time for the formation of fibrils.  The rate of 
monomer incorporation to form fibrils increases as concentrations of monomer and seed 
increases (Naiki and Nakakuki, 1996). 
We increased the monomer concentration by 10 fold (1 mM) and compared 
activity to the 100 µM Aβ(1-42) solution that was used for the experiment in Fig 4.2. 
Increased monomer concentration will alter the rate of formation of the early species.  
The cells were however treated with the same final concentration of 15µM Aβ(1-42).  
The more concentrated 1 mM Aβ(1-42) solution showed a decrease in the ability to 
induce monocyte adhesion (Fig 4.3 A).  AFM images showed presence of fibers with 
heights ranging 2-3 nm immediately upon reconstitution in the 1 mM Aβ(1-42) solution.  
Aliquots of the same preparation was analysed by TEM, and the fibril widths were 6-10 
nm.  Further incubation of 1mM Aβ(1-42) solution for 24 hours resulted in increased 
fibril formation compared to Aβ(1-42) 100 µM sample.  The fibrils were longer and the 
heights were 4-5nm, but the monocyte adhesion inducing activity was diminished (Fig 
4.3).  The treatment of 1 mM Aβ(1-42) with the cells produced 67 % of monocyte 
maturation induced by the 100 µM sample.  It is possible that accelerated aggregation 
depleted the Aβ species capable of inducing monocyte maturation.  The depletion is due 
to the rapid aggregation into the fibrillar forms as seen in the AFM images (Fig 4.3 B-C).  
These findings suggest that the maturation of monocytes was induced by either a 
monomeric, or, oligomeric species that was formed early in the aggregation reaction of 
100 µM Aβ(1-42) that was reconstituted in water. 
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Fig 4.3. Increased peptide concentration decreases monocyte adherence. Two 
aggregations were set up by reconstituting Aβ(1-42) in sterile water to 100 µM and 1 mM 
and incubated at 4°C. A. Cells were treated with 15 µM Aβ for 6 hours and adherence 
was measured by direct counting as described in the Methods (Courtesy Nikkilina 
Crouse).  B-E. Representative AFM images of Aβ(1-42) aggregation. B and D) Aβ(1-42), 
100 µM, at zero and 24 hours incubation at 4°C, C and E) Aβ(1-42), 1 mM at zero and 24 
hours incubation at 4C respectively. Images are 5 µm x 5µm panels. 
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4.6 Monocyte Maturation is Induced by Aβ(1-42) and not Aβ(1-40) 
The maximum monocyte adherence was found when THP-1 cells were treated 
with freshly reconstituted Aβ(1-42).  We hypothesized that the monomeric species may 
be potent.  Studies of the kinetics of Aβ fibril formation have shown that Aβ(1-42) forms 
fibrils significantly faster than Aβ(1-40) (Jarrett et al., 1993).  The initial oligomerization 
and assembly of Aβ(1-40) and Aβ(1-42) indicate that these peptides have distinct 
behaviors at the earlier stages in the assembly, monomer oligomerization (Bitan et al., 
2003). The shorter peptide, Aβ(1-40), is believed to remain in the monomer state for a 
longer time than Aβ(1-42) (Walsh et al., 1997).  In order to further clarify the Aβ 
aggregation species responsible for monocyte maturation, we compared the reactions 
between Aβ(1-40) and Aβ(1-42).  We tested the ability of Aβ(1-40) to induce monocyte 
maturation.  Since the aggregation propensity of Aβ(1-40) is much slower we reasoned 
that the monomer would remain the solution longer, and  we could test our hypothesis to 
see if monomer species, or, early oligomeric species was actually inducing the maturation 
of monocytes.  We investigated the time-dependent aggregation of Aβ(1-40) (100 µM) 
reconstituted in sterile water and incubated at three temperatures 4C, 25C, 37C.  The 
activity was compared to Aβ(1-42) (100 µM) incubated at 4C.  Significant difference 
was observed in the two peptide solutions immediately after reconstitution.  Aβ(1-42) 
(100 µM) was able to induce 57% monocyte adhesion while Aβ(1-40) under similar 
conditions did not (Fig 4.4 A).  Accelerating the Aβ(1-40) kinetics by increasing the 
temperature did not induce any monocyte adherence.  Continued aggregation of Aβ(1-40) 
showed fibrils formation by 216 hours, but none of the intermediates formed had  
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Fig.4.4 Aβ(1-40) aggregated at different temperatures does not induce THP-1 
adherence. Aβ(1-40) was reconstituted in sterile water to 100 µM and incubated at 4C, 
25 or 37°C.  Panel A. At the given times, cells were treated with 15 µM Aβ(1-40) for 6 
hours and adherence was measured by direct counting as described in the Methods. Aβ(1-
42) incubated at 4C was used as the control, Panel A (circles). Error bars represent 
standard error for n trials of 3. Courtesy Nikkilina Crouse. B-D. Representative AFM 
images of Aβ(1-40) aggregation taken at 0 hours at the three different temperatures. E-G. 
AFM images of Aβ(1-40) aggregation taken at 216 hours at 4, 25 or 37°C, respectively. 
Images are 5 µm x 5 µm. The images are in the height mode. 
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 the ability to induce monocyte maturation.  The results suggest that adhesion-inducing 
activity was mediated by an aggregation species that was formed in the Aβ(1-42) 
pathway, but was not formed by any of the aggregation species formed by Aβ(1-40).  
These data led us to hypothesize that the two extra amino acids in Aβ(1-42) may be 
important in the formation of species responsible for monocyte maturation process. 
 
 
4.7 Oligomeric Aβ(1-42) Induces Monocyte Maturation 
 
From the results discussed above, we hypothesized that monomer could still be 
the active species, but the activity was dependent on the two additional amino acids in 
Aβ(1-42).  The extra two amino acids may be crucial for the monomer induced monocyte 
adhesion.  We have seen in Section 4.5 that the lag phase in nucleation–dependent 
polymerization process can be altered by a change in concentration of monomer.  Two 
Aβ(1-42) aggregation solutions were initiated, one at 50 µM concentration and the other  
at a concentration of 100 µM.  We were of the opinion that in the 50 µM aggregation 
solution the available starting monomer concentration is low and therefore the 
aggregation reaction will be slower.  Also, there would be availability of high monomer 
compared to oligomers due to slower aggregation.  On the other hand the 100 µM Aβ(1-
42) solution has more concentration of the monomer thereby driving the reaction towards 
oligomer formation.  We assumed that this would result in a decrease in the monomer 
compared to oligomer.  The cells were treated with the same final concentration of 15µM 
Aβ(1-42).  Cells treated with freshly reconstituted 100 µM Aβ(1-42) induced 58+/- 4% 
adhesion while there was only 16+/- adhesion for the cells treated with 50 µM Aβ(1-42) 
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(Fig 4.5 A).  If monomer was responsible for inducing adhesion then the 50 µM Aβ(1-42) 
aggregation solution with a high monomer:oligomer ratio should have induced a high 
monocyte adhesion property.  Upon additional incubation for 24 hours the activity 
reduced in both aggregation reactions to 41+/- 5 and 12+/-3% adhesion for 100 µM and 
50 µM Aβ(1-42) respectively.  There was further decrease in the adhesion levels as the 
aggregation progressed to 48 hours.  AFM images of the freshly reconstituted solutions of 
50 µM and 100 µM solutions did not show any distinct morphological species that could 
differentiate between the two preparations (Fig 4.5 B).  However, the 48 hour images 
showed a difference in the extent of aggregation (Fig 4.5 C and D).  The images showed 
the formation of fibrillar species in the 100 µM preparation that correlated with a drop in 
the cell adhesion.  The 50 µM sample at the same time did not have any fibrillar 
aggregates, but was not able to stimulate cell adhesion.  Though AFM images could not 
provide additional information regarding the morphology of the species that induces 
adherence in the cells, it was evident that the monomer was not involved in inducing 
adherence in the THP-1 cells. 
 
4.8 Mutated Aβ(1-42) (L34P) Does not Induce Monocyte Maturation  
The data so far indicated that an active Aβ(1-42) aggregation species was capable of 
inducing cell adherence.  These active species were formed in freshly reconstituted 
solutions of Aβ(1-42) indicating that the species is formed early in the aggregation, and 
the role of monomer in the maturation process was ruled out at this point. We wanted to 
try a mutational approach to get further clarification of the species that was active in the  
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Fig 4.5 Lowering the initial Aβ(1-42) concentration decreases monocyte adherence. 
Aβ(1-42) was reconstituted in sterile water to either 100 µM or 50 µM and aggregated at 
4°C. (Panel A) At the times indicated, THP-1 cells were treated with 15 µM of either 
solution for 6 hours at 37°C. The percent adherence was determined as described in the 
Methods. SE was determined for n trials of 3 (0 hours) and 2 (24 hours and 48 hours, 50 
µM). Only 1 trial was done for 100 µM at 48 hours. Water-induced adherence controls 
(2.8 ± 0.4 %) were subtracted from final percent adherence presented. Differences 
between 100 µM and 50 µM treatments were significant at 0 (* p<0.0005) and 24 hours 
(** p<0.005) of aggregation. Courtesy Nikkilina Crouse. (Panel B-D) Representative 
AFM images of the same experiment B) 50 µM sample after 24 h, D) 100 µM sample 
after 24 hours. 
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maturation of monocytes.  Single mutations in proteins can cause aggregation to switch 
from one pathway to the other.  Systematic replacement with proline in peptides is a 
reliable method for predicting the secondary structure (Wood et al., 1995).  Proline 
residues are rarely present in the β- sheets, but can easily be accommodated in the turns 
and bends (Chou and Fasman, 1978, Lifson and Sander, 1979).  Hence, proline residues 
can be introduced into peptides to slow down the aggregation process. Liu et al., (2004) 
investigated the aggregation of Aβ using different Aβ fragments and concluded that 
residues 17-20 and 30-35 are the important regions for aggregation.  Introduction of 
proline into Aβ peptide sequence can improve the solubility and also block or reduce 
aggregation (Wood et al., 1995)  We tried a mutated Aβ(1-42) L34P peptide for further 
probing.  If the last two amino acids in Aβ(1-42) were responsible for transformation of 
monocytes into macrophages, the Aβ(1-42) L34P should also be able to form the active 
species.  The leucine to proline mutation at residue 34 slows down aggregation and 
destabilizes the fibrils (Williams et al., 2004).  This mutation enables the peptide to 
remain in the non fibrillar form for a longer time.  However, Aβ(1-42) L34P prepared 
under similar conditions failed to induce monocyte adhesion after reconstitution in sterile 
water.  The cells responded to differentiation by PMA in these experiments (data not 
shown).  Even prolonged incubation up to 168 hours failed to induce monocyte adhesion. 
Aβ(1-42) L34P did not produce any fibrillar structures as seen in the AFM images.  
These data suggest that a rapidly forming Aβ(1-42) oligomeric species was active in 
inducing monocyte cell adhesion.  These results clearly indicated the monomer was not 
involved in inducing differentiation in monocytes. 
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Fig. 4.6 Aβ(1-42) L34P does not induce THP-1 monocyte adherence  
Aβ(1-42) (L34P) was reconstituted in sterile water to 100 µM and incubated at 4°C. A. 
At the given times, cells were treated with 15 µM Aβ L34P (triangles) for 6 hours and 
adherence was measured by direct counting as described in the Methods. Error bars 
represent standard error for n trials of 5 for Aβ(1-42) L34P. The time course for Aβ(1-42) 
(circles) from Fig 4.2 is shown for comparison. Courtesy Nikkilina Crouse.  B-C. 
Representative AFM images of Aβ(1-42) L34P aggregation at 4°C taken at 0 (B) and 168 
hours (C), respectively. Images are 5 µm x 5 µm and taken as described in Methods.  
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However, there was rapid aggregation when Aβ(1-42) (L34P) was reconstituted in water 
and incubated at 37C.  The measured pH of Aβ(1-42) (L34P) solution was 3.4.  This pH 
was close to the measured pH of Aβ(1-42) solutions reconstituted in water.  Dense fibrils 
formed upon incubation at 37C for 24 hours. The fibril density increased as the 
aggregation progressed (Fig 4.7).  We also noticed less diffuse structures at the start of 
the aggregation reaction (Fig 4.7 A).  Upon prolonged incubation at 37C, fibrils were 
sheared (Fig 4.7 F-G).  It is clear that these morphologies failed to induce maturation in 
THP-1 monocytes.  However, the ability of these aggregates to induce a proinflammatory 
response is yet to be probed.  Aβ(1-42) (17-35) fragment contained a high ratio of β-sheet 
structure, and was comparable to full length Aβ(1-42) (45% and 41%) (Liao et al., 2007).  
The mutation at position 34 may alter the β-sheet structure and may have a different 
effect on the proinflammatory-stimulating activity.  These findings may provide 
important information towards the correlation of structure and biological activity. 
 
4.9 Amyloid Derived Diffusible Ligands (ADDLs) Not Effective Inducers of 
Monocyte Adhesion 
 
We wanted to investigate the effect of oligomers on monocyte maturation process.  
Lambert et al., (1998), reported the detection of small globular structures ~ 5-6 nm in 
diameter which they referred to as ADDLs.  These structures were free of large 
protofibrils or fibrils (Walsh et al., 1997, Harper et al., 1999).  Also, Aβ(1-42) appear to 
populate these structures to a higher degree than Aβ(1-40) (Walsh et al., 1997, Stine et 
al., 2003).  ADDLs cause neuronal cell death, block LTP (Lambert et al., 1998) and  
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Fig 4.7. Aβ(1-42) (L34P) aggregates rapidly at high temperatures.  Aβ(1-42)(L34P) 
was reconstituted to 100 µM in water and allowed to aggregate at 37C.  At specific time 
points an aliquot was removed, diluted to 1µM and grids were prepared for AFM imaging 
as described in Methods. A-G. AFM images at zero (A), 24 hours (B), 48 hours (C), 72 
hours (D), 96 hours (E), 168 hours (F), and 216 hours (G).  The image panels are 5µm x 
5µm and are in the “height” mode 
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inhibit reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
in neural cell lines, which is an indication of cell death (Dahlgren et al., 2002, Wang et 
al., 2002, Kim et al., 2003)  When low concentrations of ADDLs (5 nM) were incubated 
with organo typic mouse brain culture slices for 24 hours there was a 20 % loss in cell 
number.  However, at higher concentrations (500 nM), and incubation for shorter periods 
resulted in complete loss of LTP (Lambert et al., 1998, Wang et al., 2002).  Since our 
data indicates that Aβ(1-42) oligomeric species was causing monocyte adhesion, we 
wanted to see if ADDLs had any effect on THP-1 monocyte adhesion.  The preparation 
of ADDLs was different from the regular Aβ(1-42) aggregation reactions.  The protocol 
includes an incubation step for 24 hours, and the centrifugation supernatant after 24 hours 
was called ADDLs.  For our experiments, we tested the pre-centrifugation solution (total) 
and the ADDLs.  The pre-centrifugation solution induced 6+/-3% and ADDLs induced 7 
+/- 2% adhesion respectively (Fig 4.8 A). 
AFM images showed the presence of small oligomeric species ranging from 1-6 
nm ( mean = 3.0 +/- 1.3 nm  SD) respectively (Fig 4.8 C).  The morphological aspects of 
the spherical aggregates correlated with earlier reports of ADDLs (Dahlgren et al., 2002).  
However, the cellular data suggest that Aβ(1-42) oligomeric species that induces cell 
adhesion was different from ADDLs.  Moreover, ADDLs are prepared in a different 
solution, and we have seen in Chapter 3 that change in solution conditions alter the 
aggregation morphology, and biologic activity.  It is possible that the active Aβ(1-42) 
species are different and are generated before the ADDLs-like conformation is formed. 
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Fig 4.8 ADDLs failed to induce monocyte adherence. ADDLs were prepared in 
DMSO/ice cold Ham‟s F12 medium with phenol red as described in Methods. Panel A 
Cells were treated with the Aβ(1-42) aggregation solution prior to centrifugation (Total) 
or ADDLs at a final concentration of 15 µM Aβ(1-42). PMA (10 ng/ml was included as 
control. Adherence is presented as the average ± SE for n=2 trials for PMA and n=4 trials 
for Total and ADDLs over two separate experiments. Courtesy Nikkilina Crouse, 
University of  Missouri, St Louis. Panel B-C. AFM images of Total (Panel B), and 
ADDLs preparation (Panel C) that were used to treat THP-1 cells. The images are 5 µm x 
5 µm panels and are shown in the “height” mode. 
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4.10 Intermediate fibrillar Aβ(1-42) Aggregation Species Activate Innate Immune 
Response in THP-1 Cells via Toll-like Receptors (TLRs) 2 and 4 
 
This work was done in collaboration with Maria Udan and is published in (Udan 
et al., 2008).  TLRs are known to comprise a family of 10 proteins (Akira, 2003).  TLRs 
are often considered to be the staring point of immunity.  They function in continuous 
sampling of extracellular environment, and informing the cell to respond to infection.  
These cellular responses are facilitated via signaling pathways (Parker et al., 2007).  One 
of the earliest phagocytes to respond to infection is the tissue macrophage.  These 
originate as monocytes in the peripheral blood system.  TLR stimulation activates 
numerous genes in the human monocytes, leading to the release of cytokines, chemokines 
and growth factors that exert potent autocrine and paracrine inflammatory responses. 
(Kopydlowski et al., 1999, Wang et al., 2000, Ritter et al., 2005). 
Human THP-1 monocytes produce significant proinflammatory response when 
treated with aggregated Aβ (Klegeris et al., 1997, Yates et al., 2000).  Aβ(1-42) peptides 
were prepared by reconstitution in water and incubated at 4C as described in Methods, 
and the aggregation was monitored by AFM.  The freshly reconstituted Aβ(1-42) solution 
showed a dense population of punctuate species that had very little stimulatory effect on 
the cells for a proinflammatory response. Continued aggregation produced thin flexible 
fiber like structures.  Over the time course of aggregation, we identified that the fibers 
formed at 48 hours was able to induce maximum proinflammatory response. AFM height 
analysis indicated the presence of fibrils that fell into two populations.  One was the most 
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populated peak that had a mean height of 4.4 nm +/- 0.1 nm and the other was a 
population of fibers that had a mean height of 7.9 +/- 0.6 nm respectively.  Prolonged 
incubation beyond 96 hours incubation at 4C resulted in the loss of cell stimulation.  
From Chapter 3 we have seen that fibrillar oligomers were optimal to stimulate maximum 
response.  The objective of the study was to determine which transmembrane TLR plays 
a functional role in transducing the Aβ-induced innate immune signal through the 
membrane. 
A TLR neutralization assay was developed to probe the TLRs that mediate the 
Aβ(1-42) induced proinflammatory response.  The assay was initially tested on the TLR 
agonists LPS and Pam3CSk4 in order to determine the sensitivity of the assay (Udan et al., 
2008) (data not included).  Once we determined the sensitivity of the assay, we conducted 
the neutralization studies against the Aβ(1-42) proinflammatory response.  In Chapter 3, 
we have already seen that aggregated Aβ(1-42) that has been incubated at 4C for 48 
hours or 72 hours stimulated maximum proinflammatory response.  Hence, we used 
Aβ(1-42) that has been aggregated for 48-72 hours for the neutralization assays.  Both 
TLR2 and TLR4 neutralizaton resulted in the attenuation of the Aβ(1-42) induced 
proinflammatory signal, with the TLR2 showing a greater degree of blocking activity.  
The antibody neutralization experiments indicated that multiple TLRs mediate the Aβ-
induced activity. When the cells were neutralized by a combination of TLR2 and TLR4 
antibodies, there was increased blocking of the Aβ(1-42) induced proinflammatory signal 
(Fig 4.9).  These data indicate that both TLR2 and TLR4 have active roles in mediating 
the Aβ(1-42) induced innate immune response. 
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The interaction between Aβ- aggregates, TLRs and innate immunity will provide 
some more details into the complexities of the AD etiology.  From chapter 3 we have  
identified that small intermediate Aβ(1-42) fibrillar oligomers are optimal for inducing 
proinflammatory response.  We will be extending the studies to get more information 
regarding the interaction of Aβ with the cells.  We have done preliminary studies to label 
the Aβ(1-42) with immunogold label antibodies (Fig 4.10).  We will be extending the 
investigations to study the interaction between Aβ and the cell membranes using the 
immunogold label studies 
 
4.11 Discussion 
 
The role of macrophages in the innate immune system has gained lot of 
importance, and it has been established that they are crucial for defense against microbes 
and removal of cellular debris (Fiala et al., 2007).  Brain amyloidosis is hypothesized as a 
very crucial mechanism in the AD brain.  Accumulation of Aβ either in fibrillar, soluble 
or oligomeric conformations, is toxic to neurons. (Lambert et al., 1998, Hardy and 
Selkoe, 2002, Oddo et al., 2006).  Neuropahological study of AD and control brains 
showed penetration of blood derived monocytes across brain microvessels, excessive 
engorgement of macrophages with Aβ.  Also, there was  retention of these macrophages 
in the wall of congophillic vessels (Fiala et al., 2002).  Despite data suggesting the 
recruitment of non resident cells into the CNS, there is still no clear picture of how the 
transformation from monocytes to macrophages occurs.  Human monocytes from 
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Fig 4.9 TLR2, TLR4 play an active role in Aβ-induced innate immune response 
activation. Aβ(1-42) 100 μM was prepared in sterile water and incubated at 4C for 48-72 
hours depending on the peptide lot as described in Methods. THP-1 monocytes were pre-
incubated with 10 μg/ml of TLR2, TLR4 CD14(InvivoGen) antibodies, or IgG isotype 
controls, as described in Methods. Isotype controls were rat IgG (Sigma) for TLR2 and TLR4 
and IgG1 for CD14. After incubation, THP-1 cells were stimulated with 15 μM of Aβ(1-42) 
for 6 hours. TNFα was measured using ELISA.Courtesy Maria Udan.  
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Fig 4.10.  Immugold labeling of Aβ(1-42) fibrils. Aggregated Aβ(1-42) (100 µM) was 
diluted  to concentration of 20 µM and applied on to formvar coated copper grids as 
described in Methods.  The grids were incubated with Aβ sequence specific antibody Ab 
9 for an hour, followed by incubation with secondary antibody conjugated to 10 nm gold 
particles.  The grids are stained with 2% uranyl acetate and imaged using JOEL TEM 
microscope.  (Panel A) TEM image with a magnification of 10 k.The scale bar represents 
200 nm.  (Panel B) TEM image with a magnification of 25 k. Scale bar represents 100 
nm.  
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different donors were tested for their ability to differentiate into macrophages.  These 
studies have shown that in the presence of Aβ(1-42), the monocytes differentiate into 
macrophages and also have the ability to secrete cytokines and chemokines (Fiala et al., 
1998).  The aggregation state of Aβ plays a crucial role in the ability to interact with 
cells.  Structural polymorphism is a prominent feature in Aβ aggregation.  Aβ that is 
found in the parenchyma of the brain have been shown to be a continuum of structures, 
and is not limited to a specific aggregation species.(Selkoe, 2004).  We have identified 
that an early oligomeric form of Aβ(1-42) can transform the monocytes into an adherent 
form.  The adherence induced by this oligomeric Aβ(1-42) is comparable to a known 
differentiating agent, PMA (Fig 4.1).  We also observed that the ability to induce 
monocyte maturation is lost as Aβ(1-42) aggregates into fibrils.  The AFM images 
indicate that small globular species were predominant at the time of reconstitution (Fig 
4.6 B).  As aggregation proceeds, fibrillar structures are formed that led to a decrease in 
the ability to convert the monocytes into the adherent form.  The shorter peptide Aβ(1-
40) did not induce cell adherence in spite of increasing the aggregation temperature (Fig 
4.4).  This confirms that the active species was formed in the Aβ(1-42) aggregation 
pathway.  The mutational study with Aβ(1-42)(L34P) was done since this peptide does 
aggregate well due to the presence of proline at residue 34 (Williams et al., 2004).  We 
hypothesized that there would be high monomer to oligomer ratio due to the reduced 
potential to aggregate.  AFM images confirmed that the aggregation was not rapid, but 
could not specifically identify the specific species (Fig 4.6).  Decreasing the amount of 
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starting monomer concentration, could increase the possibility of a large monomer to 
oligomer ratio.  Decreasing the monomer concentration to 50 µM extended the lag phase 
of aggregation compared to 100 µM Aβ(1-42) (Fig 4.5).  The fact that the 50 µM Aβ(1-
42) preparation induced less cell adherence than the 100 µM sample clearly rules out the 
role of monomer in monocyte maturation.  Therefore it is clear that specific Aβ(1-42) 
oligomeric species stimulates the monocyte adherence.  ADDLs are oligomeric species, 
yet, were not able to induce monocyte adhesion (Fig 4.8).  ADDLs are species that are 
formed after 24 hours incubation.  The active species in our experiments are formed at 
the time of reconstitution of Aβ(1-42) solution.  It is possible that the active Aβ(1-42) 
oligomeric species are smaller than ADDLs .  The data from this part of the study 
indicate that Aβ(1-42) is able to induce adherence in the non adherent THP-1 monocytes.  
These data may provide further information in understanding the recruitment and 
transformation of non-resident monocytes into the CNS in AD. 
  We have seen that an early oligomeric species induces adherence in monocytes 
(Crouse et al., 2009).  The data clearly indicates that the Aβ(1-42) aggregation progresses 
to form fibrillar structures that diminished the ability to induce cell adhesion, but induces 
a proinflammatory response in THP-1 cells.  Here we see the influence of Aβ aggregation 
state in eliciting a biological response.  It is possible that the early oligomeric species 
induces the recruitment of monocytes from blood.  The activation of microglia may be 
separate process from that of monocyte recruitment or differentiation.  From our data we 
see that as the aggregation progresses into formation of the intermediate fibrillar species 
it triggers the proinflammatory response.  These fibrillar forms triggers the microglial 
activation.  Our data also shows that an intermediate fibrillar oligomeric species of Aβ(1-
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42) triggers the proinflammatory response that is mediated via receptors  TLR2 and 
TLR4 (Udan et al., 2008).  We have also seen that neutralization of TLR2 and TR4 
results in attenuating the fibrillar oligomeric Aβ(1-42) induced signal (Fig 4.9).  
However, blocking the TLR2 and TLR4 did not attenuate the oligomeric Aβ(1-42) 
induced monocyte adherence (data not shown).  These data further clarify the 
significance of Aβ aggregation state and its involvement in different biochemical 
pathways.  These data may provide important clues into the different stages in the 
inflammatory pathway. 
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CHAPTER 5 
 
 
Conclusion 
 
Data from our studies indicate that Aβ(1-42) has the ability to stimulate the THP-
1 monocytes for a proinflammatory response.  We have also shown the significance of 
the Aβ(1-42) aggregation state in eliciting this response from the cells.  By using a 
combination of biophysical and cellular assays we have identified that an intermediate 
fibrillar species in Aβ(1-42) aggregation pathway is capable of eliciting maximum 
proinflammatory response.  Our data also indicate that only intermediate species formed 
from Aβ(1-42) aggregation solution incubated at 4C could activate the cells for a 
response.  Aggregation of Aβ(1-40) under similar conditions did not elicit stimulatory 
activity.  Furthermore, high speed centrifugation of Aβ(1-42) aggregation solution 
established the solubility of the proinflammatory species. The centrifugation supernatant 
was active in stimulating the cells.  Using conformation-specific antibodies, we were able 
to categorize the proinflammatory species as fibrillar oligomers.  Our 
immunoprecipitation (IP) protocol, using fibril-specific antibody (OC immune serum), 
depleted the active species from aggregation solution, which was confirmed by depletion 
of proinflammatory response by the IP supernatant.  Characterization of Aβ(1-42) 
aggregation solution by SEC enabled isolation of the peak fraction that gave maximum 
proinflammatory response.  These studies strengthen our earlier findings (Udan et al., 
2008) where we had shown the involvement of toll-like receptors, particularly TLR4 and 
TLR2, in Aβ-induced response.  We have also shown that an early oligomeric species in 
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the Aβ(1-42) aggregation pathway has the ability to transform monocytes into an 
adherent form that look like macrophage cells.  Here again we were able to display the 
exclusive property of Aβ(1-42) to form an early oligomeric assembly that was not formed 
by the oligomeric Aβ(1-42) ADDLs and the mutated Aβ(1-42) (L34P) (Crouse et al., 
2009).  Overall, our data displays the correlation between Aβ and the human immune 
response, and also pinpoints the assembly state that is involved in activating the different 
stages of inflammatory pathway.  This study provides further clues into understanding the 
mechanism of Aβ induced inflammatory response and may be useful in designing 
therapeutic strategies towards the treatment of AD. 
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